

# CURRICULUM VITAE

*Teaching, Scientific, and Management activities*

## ***Professor Fabrizio Schifano***

**MD, FRCPsych, Dip Psychiatry, Dip Clin Pharmacology**

### **Summary of current duties**

- *Full Professor of Clinical Pharmacology and Therapeutics; Head of the ‘Psychopharmacology, Drugs of Misuse and Novel Psychoactive Substances’ Research Unit* Department of Clinical Pharmaceutical and Biological Sciences, University of Hertfordshire (UK)
- *World Health Organization (WHO) member of the Expert Committee on Drug Dependence (ECDD; 2023)*
- *‘Future Pharmacology’ journal; Editor-in-Chief*
- *Lead Consultant Psychiatrist (drug and alcohol; locum); West Sussex*
- *Honorary Consultant Psychiatrist; Hertfordshire Partnership University NHS Foundation Trust (HPFT)*

School of Life and Medical Sciences,  
College Lane Campus, University of Hertfordshire  
Hatfield, Herts, AL10 9AB, UK

### **Qualifications, academic and professional**

- Doctorate in Medicine and Surgery, University of Padova (I)
- Postgraduate Specialist Diploma in Psychiatry, University of Padova (I)
- Postgraduate Specialist Diploma in Clinical Pharmacology, University of Padova (I)
- **Fellowship Royal College of Psychiatrists (FRCPsych; UK)**
- **Approved as a Full Professor of Pharmacology (MIUR; Italy)**  
<https://abilitazione.cineca.it/ministero.php/public/esitoAbilitati/settore/05%252FGI/fascia/1>
- **Approved as a Full Professor of Psychiatry (MIUR; Italy)**  
<https://abilitazione.cineca.it/ministero.php/public/esitoAbilitati/settore/06%252FD5/fascia/1>

### **Transferable skills; Contributions to knowledge**

I am one of the very few physicians in Europe with training and specialist qualifications in both (clinical) pharmacology and psychiatry. Outstanding contribution has been made to several (e.g. mainly clinical) areas, including the identification of those physiopathological alterations which are making the individuals prone to developing either a substance or a behavioural addiction. This knowledge is of crucial relevance in identifying possible treatment and management approaches which are properly tailored to these very vulnerable clients’ needs. Over the years, I have developed skills in a range of areas, including: Treatment and management of substance-based and non-substance-based addiction in both clinical and neurobiological terms.

### **Record of outputs; record of support through grants for research**

I have published: **207 either research or systematic reviews; 16 editorials; 93 review papers in peer-reviewed journals; 1 book; 22 research monographs; and 68 contributions to edited works. Scopus indicators: H-index: 51; number of documents: 301; total number of citations: 9,533 (@ 12<sup>th</sup> January 2024).**

According to SagePolicyProfiles (December 2023), my research work has received 270 citations across 175 policy documents worldwide. My expertise ranks in the **top 0.83%** of 6,234 published authors worldwide on hallucinogens from 2011 through 2021; and the **top 3% of all scientists worldwide** according to the 2024 AD Scientific Index.

I have been the Principal Investigator/co-PI of **6 consecutive EU Commission-funded, multi-centre (i.e.: up to 12 EU countries involved) research programmes.** Reported a significant and sustained success in obtaining research grants; **I have been able to secure in excess of 5 million euros** over the last 15 years or so.

The **research grants obtained** have included:

- University of Hertfordshire; Misusing with novel antidiabetics to achieve a size 0? A pilot, qualitative and quantitative, research project. £12,256; April-July 2023; ***Principal Investigator***
- Welsh Government (WG); evaluation of the rapid implementation of Injectable Buprenorphine (Buvidal) which forms part of the range of interventions within opioid substitution treatment (OST) services. March 2023-March 2025; Total value: £25,000; PI: University South Wales; Co-PI and Clinical Lead
- Sardinia (I) Regional Government, Agency for Public Health. *Research project:* Addressing the substance misuse issues in Sardinia (I) inmates; a pre- vs post-training assessment of clinicians' experience, practices, and attitudes. June-December 2023; Total value: £20,000; ***Principal Investigator and Grant Holder.***
- Impact grant to support evidence gathering relating to the Research Excellence Framework (REF 2021); February-July 2019. Total value: £1,200.50 ***Principal Investigator and Grant Holder.***
- European Commission, total amount dedicated for the Univ Hertfordshire: 304.311,70 Euros; Project EPS/NPS – Enhancing Police Skills concerning Novel Psychoactive Substances (NPS); ***Co- Principal Investigator*** (2015-2016). Targeted call on cross border law enforcement cooperation in the field of drug trafficking - DG Justice/DG Migrations and Home Affairs (JUST/2013/ISEC/DRUGS/AG/6429)
- European Commission, total amount: 635,000 Euros. “EU-MADNESS (European-wide, Monitoring, Analysis and knowledge Dissemination on Novel/Emerging pSychoactiveS): integrated EU NPS monitoring & profiling to prevent health harms and update professionals “. ***Principal Investigator and Grant Holder.*** (2014-2016). EU Commission Directorate General Justice:

‘Drug prevention and information’ (2007-2013). Action grants  
JUST/2013/DPIP/AG

- Society for the Study of Addiction. ‘Support on developing and updating teaching and learning resources for the substance misuse in the undergraduate Medical Curriculum project Development’. £40,000; **Principal Investigator and Grant Holder**. (2013-2014)
- European Commission/EC; European Health Award to ReDNet (Schifano PI) for best EC-funded project. Euros 10,000; **Principal Investigator and Grant Holder**. (2013)
- National Treatment Agency, Department of Health (UK). ‘Sustainability transition phase of the substance misuse in the undergraduate medical curriculum project’. £39,000. **Principal Investigator and Grant Holder**. (2013-2014)
- Department AntiDrug Policies/Dipartimento Politiche Antidroga; Italian Government: 'Analysis of drugs available on the web and better description of web users'; Roma, Italy; euros 15,000. **Principal Investigator and Grant Holder**. (2013)
- European Commission: Supervisor/Trainer for the EU’s Leonardo da Vinci programme providing opportunities of academic training for 26 weeks (2012-2013). Trainee: Dr Carla Gimeno; **Principal Investigator**
- European Commission, total amount: 833,333 Euros. “Recreational Drugs’ European Network: an ICT prevention service addressing the use of novel compounds in vulnerable individuals. ReDNet “. **Principal Investigator and Grant Holder**. (2010-2012). EU Health programme (2008-2013); Second Health Programme - Call for proposals 2009. Executive Agency for Health and Consumers.
- University of Hertfordshire, QR small competitive grant fundings: ‘Monitoring the ever-changing world of novel psychoactive substances through the analysis of related information made available online and from coroners’ reports’. **Co-Principal Investigator**; £4,993 (2012-2013)
- European Commission: Supervisor/Trainer for the EU’s Lifelong Learning program providing opportunities of vocational training under GRUNDTVIG ASSISTANTSHIP for 13-45 weeks during August 2010 to July 2011 ([http://www.programmallp.it/home.php?id\\_cnt=68](http://www.programmallp.it/home.php?id_cnt=68)). Trainee: Dr Daniela Zummo **Principal Investigator**
- (Different funders, including the Dept of Health, the MS&D and the University of Hertfordshire). £70,000. Impact of Manor community pharmacy monitoring programme on diabetes-related outcomes in primary care: a pilot study. This project has been selected as finalist in the 2009 RPSGB competition. **Principal Investigator**

- European Commission, total amount: 706,000 Euros. “Psychonaut web mapping system“. **Principal Investigator and Grant Holder**. Number of research assistants, 2. (2008-2009). Executive Agency for Public Health; Call for proposals ‘Public Health’ 2006.
- (University of Hertfordshire and MedPharma). £50,666. Development of Novel Topical Sprays; Formulation development of a benzodiazepine for absorption through buccal mucosa in vitro. **Co-Principal Investigator**. Number of research assistants, 1. (2007-2008)
- Department of Health, England. £800,000. Provision of a data collection, analysis and reporting system for drug-related deaths. 2004-2012; npSAD; in collaboration with St George’s University of London. **Co-Principal Investigator/Co-Applicant and Grant Holder**. Number of research assistants, 2.
- Department of Health, England. £17,816. Project to identify trends in drug related deaths in England and Wales (1999- 2004). 2005-2006. **Co-Principal Investigator /Co-Applicant and Grant Holder**. Number of research assistants, 2.
- European Monitoring Centre for Drugs and Drug Abuse (EMCDDA). 24,995 Euros. Organization of an intensive course on ‘Analysis, interpretation and reporting of drug-related data’; external advice to the EMCDDA for the implementation and development of National Data Collection Systems on Drugs. 2004. **Principal Investigator and Grant Holder**.
- European Commission, total amount 494,000 Euros. “Psychonaut 2002. Internet and drugs”. 2002-2004. **Principal Investigator and Grant Holder**. Grant number: SPC 416; 2002 306 (2002–2004) of the EU Directorate General—Public Health and Risk Assessment.
- European Commission, total amount: 660,000 Euros (contribution to St George’s, University of London, Division of Mental Health-Addictive Behaviour: £79,000). “Treatment systems Research on European Addiction Treatment; An European six-centre joint medico-social health care systems research venture on opioid addiction. TREAT 2000”. 2000-2003. **Co-Principal Investigator/Co-Applicant and Grant Holder**. European Commission Directorate General for Research; grant no: QLRT 199900873.
- Buckinghamshire Mental Health NHS Trust, £ 2,178. “Serious untoward incident panel”. 2004. **Principal Investigator and Grant Holder**. Research Miscellaneous account
- St George’s Hospital Medical School, £700. Support running of the Psychonaut 2002 project. 2002. **Principal Investigator and Grant Holder**.

- European Commission. “Methadone prescription and its impact on HIV status”. 1992-1994. **Co-Principal Investigator/Co-Applicant and Grant Holder**. Number of research assistants, 1.
- European Commission. £500,000. “Drugs and Mental Health”. 2002-2005. *Collaborator; Steering Group member*. Number of research assistants, 5.
- Department of Health, England. £171,000. “The efficacy of enhanced counselling in the primary prevention of hepatitis C among injecting drug users: A randomised controlled trial. 2000-2002. *Collaborator; Steering Group member*. Number of research assistants, 2.

### **Teaching activities; Supervision of research students and research staff**

- 1989-1999: Hon Professor of Clinical Psychopharmacology, Postgraduate School of Clinical Pharmacology, University of Padova (I) School of Medicine
- 2000-2006: Senior Lecturer/Associate Professor; St George’s, University of London MBBS/Medical School; regularly involved in course lecturing;
- 2001-2006: Research and Critical Skills Module leader, MSc/PG Dip Addictive Behaviour, St George’s, University of London
- 2004-2006: PhD examiner; University of East London and University of London
- Supervision for the final dissertation preparation of: a) 5 PhD and 1 MD students (UK; all successful); b) 15 doctorate students from the University of Padova, Bologna and Rome Schools of Medicine, Pharmacy, Psychology and Political Sciences (all successful); c) 20 students from the MSc course in Addictive Behaviour, St George’s, University of London (all successful; 2000-2005); d) 2 MSc students from the University of London (both successful); e) 25 MPharm students from the University of Hertfordshire (all successful).
- *Currently supervising 4 PhD students; University of Hertfordshire*

### **Invitations to participate as keynote speaker/discussant at international meetings; international collaborations**

I am invited to participate as a *keynote speaker* to some 25 national/international conferences per year, whilst having been instrumental in organizing 19 major international conferences (UK/abroad; see below).

### **Consultancy and commissioned reports**

- European Expert for the European Medicines’ Agency (EMA; 2010-2022)
- Member of the Advisory Council on the Misuse of Drugs (ACMD) (2011-2019)
- I have previously served as advisor to: Member of the National Institute of Health and Clinical Excellence (NICE) Mental Health Consideration Panel (2006-2011); the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA; 2005); the UK Advisory Council on the Misuse of Drugs (ACMD; 2008); the UK All Parliamentary Drug Misuse Group (2008; 2023); the Italian Government (2008; on issues related to substance misuse); the Executive Board of the Royal College of Psychiatrists, Faculty of Substance Misuse (2008-2010).

- In my Principal Investigator role of the UK National Programme Substance Abuse Deaths I have contributed to a large number of national reports on drug related deaths.

### **Creation of intellectual properties and its subsequent development and application in the wider community**

- Developed/implemented a methodology for assessing the web with respect to the issues related to trafficking, consumption, synthesis of licit and illicit compounds with the support of several EU Commission grants: ‘Psychonaut 2002’ (2002-2004); ‘Psychonaut Web Mapping system’ (2008-2009); and ‘EU-ReDNet/Recreational Drug Network’ (2010-2012); EU-MADNESS (2014-2016); and EPS/NPS (2015-2016) projects
- Implemented and analysed the largest database ever of amphetamines and ecstasy (MDMA; MDA)-related fatalities and published these results in learned journals

### **Membership of peer review bodies/committees**

- *Research proposal referee*: a) Medical Research Council/UK; Neurosciences and Mental Health Board (since 2004); b) EU Commission; 6<sup>th</sup> and 7<sup>th</sup> Research Framework Programme (since 2004); c) National Treatment Agency/UK (2005); d) Research for Patient Benefit/UK (2007); e) Economic & Social Research Council/UK (2009); f) **ANVUR/Italy (2014; 2016)**
- *Peer reviewed journals referee*: served on this role for a range of international journals, including: **The Lancet; British Medical Journal; Neuropsychopharmacology; Psychopharmacology (Berlin); Journal of Psychopharmacology; Addiction; Drug and Alcohol Dependence; International Psychiatry; Psychotherapy and Psychosomatics; BMC Psychiatry; Human Psychopharmacology (Clin Exp); Neuroscience and Biobehavioral Reviews; Canadian Medical Association Journal**
- *Editorship*; currently Associate Editor of: **Frontiers in Psychiatry; Brain Sciences; and Minerva Psichiatrica**. Previously collaborated with: ‘International Psychiatry’ (Section Editor); ‘Current Drug Abuse Reviews’; ‘ISRN Addictions’; ‘Journal of Maintenance in the Addictions’; ‘Current Psychopharmacology’; ‘Open Neuropsychopharmacology Journal’; ‘Clinical and Experimental Gastroenterology’; ‘Substance Misuse and Rehabilitation’; ‘Frontiers in Addictive Disorders’

### **Awards:**

- June 2006: ‘START’ prize; given by the Italian Cabinet Ministers’ Presidency for my addiction research;
- 2009-2017: National Award (9 points) from the highly competitive/prestigious Clinical Excellence Awards NHS Consultants’ scheme
- February 2013: awarded the Royal College of Psychiatrists’ Fellowship
- October 2013: European Commission/EC; European Health Award to the ReDNet (Schifano as PI) for best EC-funded project
- 2013 certificate of excellence in reviewing for the ‘Neuroscience and Biobehavioral Reviews’ journal.

- **June 2015: University of Hertfordshire ‘Excellence in Research’ category winner**

## *CV extended version*

### *A. PERSONAL DETAILS AND CAREER HISTORY*

#### **1. Name and Surname: Fabrizio SCHIFANO**

#### **2. DoB: June 22nd, 1956**

#### **3. Education** – Schools and Universities attended, with dates

- Scientific Lyceum (European equivalent of the A levels): completed in 1975, July, in Padova, Italy
- **Doctorate** in Medicine and Surgery, MD (‘Laurea in Medicina e Chirurgia’; obtained in 1981, July, in the University of Padova, Italy; quoted as 110/110; i.e.: top marks)
- Postgraduate Specialist Diploma in **Psychiatry** (completed in 1985, December, in the University of Padova, Italy; quoted as 70/70 “magna cum laude”; i.e.: obtained honours with distinction)
- Postgraduate Specialist Diploma in **Clinical Pharmacology** (completed in 1989, July, in the University of Padova, Italy; quoted as 70/70 “magna cum laude”; i.e.: obtained honours with distinction)
- Membership of the Royal College of Psychiatrists (**MRCPsych**; UK; March 2002; obtained with distinction); fellowship/**FRCPsych** since 2013

#### **4. Qualifications** – Academic and professional – membership of bodies

- **GMC** Full Registration (UK; September 1988) and inclusion in the GMC Specialist Register Section (**General Psychiatry, Adult**, since March 2000)
- **FRCPsych**; since 2013
- Membership of the Royal College of Psychiatrists/Substance Misuse Faculty (2003-2006)
- Section 12 (2) Mental Health Act approval (UK; March 2004-present)
- Approved clinician (since 2009, November)
- Inclusion in the List of Psychotherapists, General Medical Council of Padova, Italy (since 1990)

#### **5. Previous employments and appointments held**

##### **a. Previous clinical/academic appointments**

- April-May 2023: Visiting Professor; University of Chieti (I)

- Consultant Psychiatrist (Addictions), Hertfordshire CGL Recovery Drug and Alcohol Team (April 2012- April 2023)
- September 2006-March 2012: Consultant Psychiatrist (*Primario Psichiatra*; Addictions); Hertfordshire Partnership NHS Foundation Trust
- June 2000-August 2006: Senior Lecturer in Addictive Behaviour, Division of Mental Health (Addictive Behaviour); St George's, University of London and Honorary Consultant Psychiatrist (*Primario Psichiatra*) in the Richmond, Roehampton and Kingston Drug and Alcohol Teams, SW London and St George's Mental Health Trust (June 2000-August 2006)
- Consultant/*Primario* of the NHS Addiction Treatment Unit/SerT no.1, Local Health Unit no. 16, Padova, Italy (1996-2000)
- Specialist in Psychiatry, NHS Addiction Treatment Unit of Padova, Italy (1991–1996)
- Head of the NHS Drug and Alcohol Unit, Conegliano General Hospital, Conegliano, Italy (1987-1990)
- Senior House Officer in the Department of Psychiatry, NHS Dolo General Hospital, Dolo, Italy (1984-1987)
- Lieutenant Medical in the Department of Neuropsychiatry, Military Hospital of Padova, Italy (1983-1984)

#### **b. Previous teaching appointments**

- **Visiting Lecturer** in the Department of Addictive Behaviour, MSc and PGDip in Addictive Behaviour, **St George's**, University of London, UK (1994-2000)
- **Hon Professor of Clinical Psychopharmacology**, Postgraduate School of Clinical Pharmacology, University of Padova School of Medicine, Padova, Italy (1989-1999)
- Lecturer in the Master's School of Addictive Behaviour, University of Padova School of Psychology, Italy (1994 – 2000)
- Lecturer in the Postgraduate Diploma School of Psychodynamic Psychotherapies, Padova, Italy (1991–1994)
- Lecturer of “Neuropsychiatry and Mental Hygiene” in the Nurses' School of the Local Health Unit of the Veneto Region, Vittorio Veneto, Italy (1987–1988)
- Lecturer of “Neuropsychiatry and Mental Hygiene” in the Nurses' School of the Padova Military Hospital (1983)

#### **c. Previous managerial and research appointments**

- Advisory Council on the Misuse of Drugs (ACMD; UK), Core Member (2011-2019) and Chair of the Image- and Performance-Enhancing Drugs/IPED working group (2017-2019)
- Member of the Drugs and Therapeutics Committee, South West London and St George's Mental Health NHS Trust (2003-2006)
- Member of the Drugs and Therapeutics Committee of the Local Health Unit no.16, Padova, Italy (1999 - 2000)
- Member of the Ethics Committee of the Local Health Unit no.16, Padova, Italy (1997 – 2000)

- Member of the Steering Committee (as Membership Officer) of the European Collaborating Centres in Addiction Studies, ECCAS (1997–1999)
- Chairman of the Steering Committee of the European Collaborating Centres in Addiction Studies, ECCAS (1995–1997)
- Visiting Research Worker in the Institute of Psychiatry, Section of Clinical Psychopharmacology, University of London, UK (September 1988-March 1989)

## 6. Present appointments

- **Chair in Clinical Pharmacology and Therapeutics**, School of Life and Medical Sciences, University of Hertfordshire (UK)

## 7. Visiting appointments/secondments

- April 2003-December 2008; Honorary Consultant Psychiatrist in the St Peter's Project Charity, London
- July 2006- June 2010 Member of the Executive Board of the Royal College of Psychiatrists, Faculty of Substance Misuse
- Hon Consultant Psychiatrist, Hertfordshire Partnership NHS Foundation Trust (2012-2013)

## *B*      *TEACHING*

### 1.      **Current teaching duties; undergraduate and postgraduate**

#### a. MPharm, Undergraduate

- Development of Level 3 and Level M clinical options including teaching materials and assessment framework.
- Developing and implementing use of simulation in MPharm degree
- Teaching and design of case studies on MPP2 Pharmacology & Therapeutics
- Writing exam questions for modules Levels 1 and 2
- Reviewing Clinical Pharmacology & Therapeutics in MPharm and map against the General Pharmaceutical Council UK syllabus

#### b. MD/PhD

(2005) PhD examiner; University of East London, London  
 (2006) PhD examiner; SOAS University of London, London  
 (2009-2011) PhD supervisor, University of Hertfordshire, successful  
 (2010-2013) MD supervisor, University of Hertfordshire, successful  
 (2011-2013) PhD supervisor, University of Rome, successful

#### c. MRCPsych/overseas academic attachments

UK: Supervisor of some 30 trainees in Psychiatry (since 2002)

UK: Supervision of some 50 overseas academic attachments over the last 16 years. In all cases, under my supervision, they have either completed their own postgraduate training and/or have published results of their research in peer-reviewed journals

## **2. Other teaching; internal and external**

- (2012-2017): Visiting Professor in the University of Padova (I) Medical School, Dept of Psychiatry
- (2006): Hon Lecturer in the Master's School on Dual Diagnosis, Middlesex University, UK
- (2004- 2006): Hon Lecturer in the Master's School of Addictive Behaviour, Catholic University of Rome School of Medicine, Italy
- (2005): Hon Lecturer in the Region of Sicily CEFPAS School, Addictive Behaviour, Caltanissetta, Italy
- (2006): Hon Lecturer to the 'Amministrazione Penitenziaria' Personnel, Padova, Italy
- (2004) Hon Lecturer in the Master's School of Criminology, University of Parma School of Psychology, Italy
- (2005-2012): Consultant Supervisor, Nurse Prescribing Course; Faculty of Healthcare Sciences; St George's, University of London; University of Chichester and University of Hertfordshire (UK).

## **3. Innovative work and contributions to curriculum reform and development**

Previously, whilst employed by St George's, University of London: Full reorganization of the Research and Critical Skills Module, MSc and PGDip in Addictive Behaviour, St George's, University of London, Division of Addictive Behaviour, University of London, UK

## **4. Examination responsibilities**

Previously, whilst employed by St George's, University of London: *Responsible term 5* (i.e.: Neurosciences; Psychiatry; Psychology and Sociology applied to Health) Examiner; Examiner *MBBS Special Study Module*, St George's Medical School, University of London; Examiner *MBBS final exam*; Examiner *MBBS OSCE*; Examiner *MBBS long papers*; Examiner *MBBS admission panel*; *Chair MBBS admission panel*; Examiner *MSc Addictive Behaviour*; Examiner *PG Diploma in Addictive Behaviour*: St George's Medical School, University of London

## **5. Results of assessment of teaching ability**

- As part of my academic appraisals since 2001 my teaching ability has always been considered as satisfactory/very satisfactory.

## **6. Appointments held as Course Director, Module Co-ordinator, PBL tutor, etc**

2003-2006: CBL tutor; St George's Medical School, University of London  
2001-2006: Research and Critical Skills Module leader, MSc and PG Diploma Addictive Behaviour; St George's Medical School, University of London

2000 – 2006: Postgraduate Students' Tutor and Research Supervisor (MSc Addictive Behaviour, Postgraduate Diploma in Addictive Behaviour and Distance Learning Certificate in Substance Misuse); St George's Medical School, University of London

Previously; 1989-99: Honorary Professor of Clinical Psychopharmacology, Postgraduate Residency School in Clinical Pharmacology, University of Padova School of Medicine, Padova, Italy

C. *RESEARCH AND ACADEMIC/PROFESSIONAL STANDING*

**1. Publications**

Publications related to teaching; refereed

1. SCHIFANO F. CPD; Test your knowledge on cannabinoids in clinical practice. Medscape; February 13, 2021. Available from: [https://www.medscape.org/viewarticle/944143?src=mkmemr\\_driv\\_cust\\_mscpe\\_educns\\_210213-944143-ous-psyc](https://www.medscape.org/viewarticle/944143?src=mkmemr_driv_cust_mscpe_educns_210213-944143-ous-psyc)
2. SCHIFANO F. Distance Learning initiative (FAD) for the Italian Federation of Pharmacists (FOFI). Theme: Abuse of recreational and prescribing drugs (Abuso farmaci e sostanze stupefacenti; identification number: 3836-308346); 2020-2021. Number of Pharmacist professionals to be targeted: 12,000. Available from: <https://www.fadfofi.com/web/fadinfo.asp>
3. SCHIFANO F. Distance Learning initiative (FAD) for the Italian Federation of Pharmacists (FOFI). Theme: The patient suffering from a major depressive disorder; the role of the pharmacist (Il paziente con disturbo depressivo maggiore ed il farmacista; identification number: 3836-246251; 2018-2019). Number of Pharmacist professionals to be targeted: 12,000. Available from: <https://www.fadfofi.com/fofi-prev/ita/fadinfo.asp>
4. Guirguis A, Gittins R, Corkery JM, SCHIFANO F. Substance use and misuse. Second edition 2012. A CPPE open learning programme. Update September 2016. Legal highs. Section 1.8. Centre for Pharmacy Post Graduate Education (CPPE). Access restricted to registered users only.
5. SCHIFANO F, Albanese A: Stimulants: treatment approaches and organizing services. Online Continuing Professional Development/CPD module; Royal College of Psychiatrists, published online on 22/07/2013; available from: <http://www.psychiatrycpd.co.uk>
6. SCHIFANO F, Albanese A: Stimulants: current epidemiology and impact on mental health. Online Continuing Professional Development/CPD module; Royal College of Psychiatrists, published online on 27/10/2011; available from: <http://www.psychiatrycpd.co.uk/default.aspx?page=14160>
7. Serpelloni G, SCHIFANO F: Linee guida per la prevenzione ed il trattamento dell'overdose da eroina e degli effetti acuti

dell'ecstasy. Regione del Veneto, Linee Guida ed Altri Contributi, Verona, Italy, 2000

8. SCHIFANO F: Designer Drugs. Manual of the Training Course for Addiction Professionals, Emilia Romagna Region (I), November 2002
9. SCHIFANO F: Pharmacological and toxicological issues related to stimulant misuse. Manual of the Training Course for Addiction Professionals, Emilia Romagna Region (I), February 2003

#### Conference contributions; refereed

Catalani V, SCHIFANO F, Botha M, Corkery J, Guirguis A. NPSfinder® designer benzodiazepines: QSAR and Docking studies. Poster presented at the 7<sup>th</sup> international (online) conference on novel psychoactive substances; 18-19 November 2020.

Chiappini S, SCHIFANO F, Corkery JM, Guirguis A. Beyond the purple drank. Study of promethazine abuse according to the eudravigialnce dataset. University of Hertfordshire, United Kingdom. Poster presented at the 7<sup>th</sup> international (online) conference on novel psychoactive substances; 18-19 November 2020.

Napoletano F, SCHIFANO F, Corkery JM, Guirguis A, Arillotta D, Zangani C, Vento A. NPSfinder: a systematic tool to identify novel psychoactive substances (NPS) by crawling the pro drug/'psychonaut' websites. Presentation made at the 7<sup>th</sup> international (online) conference on novel psychoactive substances; 18-19 November 2020.

Guirguis A, Gittins R, SCHIFANO F. The UK's First Home Office-Licensed and Pharmacist-Led Community Drug Checking Service. Presentation made at the 7<sup>th</sup> international (online) conference on novel psychoactive substances; 18-19 November 2020.

Ramos, C., Guirguis, A., Smeeton, N., Zaman, H., Felice, AM, Bancroft, S., Gittins, R., Corkery, J., Hawksworth, G., Schifano, F. Exploring the baseline knowledge and experience of NPS of healthcare professionals in the United Kingdom. 10th Annual CMHP Psychiatric Pharmacy Conference 2019, Loughborough 11 - 13 October 2019. Poster; **Highly commended for CMHP poster Award.**

Ramos, C., Guirguis, A., Smeeton, N., Zaman, H., Felice, AM, Bancroft, S., Gittins, R., Corkery, J., Hawksworth, G., Schifano, F. Exploring the baseline knowledge and experience of NPS of healthcare professionals in the United Kingdom. Medicines Safety, RPS, London, Nov 17th, 2019; Poster

Chiappini S, SCHIFANO F, Guirguis A, Corkery JM. Loperamide diversion and abuse: assessment of its non-medical use through the analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports. Abstract presented at the Sixth NPS international conference,

Maastricht (NL); April 8-9, 2019

Napoletano F, Vento A, Corkery JM, Guirguis A, Arillotta D, Zangani C, Berritta D, Gilgar L, SCHIFANO F. NPSfinder: uno strumento sistematico per identificare nuove sostanze psicoattive (NPS) attraverso la scansione dei siti degli psiconauti. Conference: “Le Nuove sfide in psichiatria”, Rome (I), 17-19 June 2019; winner of the poster competition

Napoletano F, Vento A, Corkery JM, Guirguis A, Arillotta D, Zangani C, Berritta D, Gilgar L, SCHIFANO F. NPSfinder: a systematic tool to identify novel psychoactive substances (NPS) by crawling the pro drug/’psychonaut’ websites. Conference: Society for the study of addiction annual conference 2019, 7th-8th Nov 2019, Newcastle. Link: <https://www.addiction-ssa.org/annual-conference/695/>

Chiappini, S., Schifano, F., Corkery, J.M., Guirguis, A. The uncontrollable rise of opioids. Study of the European situation from the Eudravigilance adverse drug reactions database of fentanyl abuse/misuse/ dependence cases. Abstract being presented to the UH LMS conference, April 2019

Chiappini S, Guirguis A, Corkery JM, SCHIFANO F. Prescription and over-the-counter drug misuse in the context of the NPS scenario; considering the pharmacovigilance approach to evaluate the abuse and misuse of medications. Abstract accepted for presentation at the Sixth NPS international conference, Maastricht (NL); April 8-9, 2019

Bonaccorso S, Metastasio A, Ricciardi A, Stewart N, Jamal L, Rujully NUD, Theleritis C, Ferracuti S, Ducci G, SCHIFANO F. Synthetic cannabinoid use in a case series of patients with psychosis presenting to acute psychiatric settings: clinical presentation and management issues. Presentation made at the sixth International Conference on Novel Psychoactive Substances; 8–9 April 2019 Maastricht, The Netherlands

Lione LA, Deligianni E, Daniel OJ, Corkery JM, SCHIFANO F. NPS awareness, use, preference and health perception following the United Kingdom Psychoactive Substances Act 2016. Presentation made at the sixth International Conference on Novel Psychoactive Substances; 8–9 April 2019 Maastricht, The Netherlands

Schifano F. Pregabalin friend or foe? Its use in psychiatric disorders and its potential of misuse. Royal College of Psychiatrists; Faculty of General Adult Psychiatry Conference 2018 11-12 London, 11<sup>th</sup> October 2018. Abstracts’ book page 2-3.

Loi B, De Luca M, Margiani G, Pintori N, Miliano C, Di Chiara G, SCHIFANO F. Neurochemical characterization of the synthetic stimulants 2-DPMP and D2PM. Conference on: NPS: New frontiers in addiction? Pula (I), October 10-13, 2017; Abstracts’ book, page 3

Orsolini L, Ciccarese M, Papanti GD, De Berardis D, Guirguis A, Corkery

JM, SCHIFANO F. Psychedelic fauna for psychonaut hunters. Poster presented at the European College of Neuropsychopharmacology, ECNP, 2018, Barcelona, Abstracts' book

Chiappini S, Corkery JM, Guirguis A, SCHIFANO F. Prescription drug diversion and misuse. Assessment of the non-medical use of a range of molecules through pharmacovigilance databases. UH 2018 Annual Research Conference School of Health & Social Work

Loi B, Zloh M, De Luca M, Pintori N, Corkery JM, SCHIFANO F. Schifano. 4,4'-dimethylaminorex ('4,4'-DMAR'; 'serotoni') misuse; a web-based study. Conference on: NPS: New frontiers in addiction? Pula (I), October 10-13, 2017; Abstracts' book, page 4

Deligianni E, Daniel OJ, Corkery JM, SCHIFANO F, Lione L. Novel Psychoactive Substance (NPS) awareness, use and health perception following the UK Psychoactive Substances Act 2016. Research Advances in Psychiatry 2017, 4: 61

SCHIFANO F. Over a decade of clinical experience and research on NPS: lessons learned and next steps. Research Advances in Psychiatry 2017, 4: 28

Orsolini L, Papanti GD, Corkery JM, SCHIFANO F. the role of the deep web/dark net in the NPS spread and market chain. Research Advances in Psychiatry 2017, 4: 75

Di Chiara G, De Luca MA, Castelli P, SCHIFANO F. Third generation synthetic cannabinoids. Research Advances in Psychiatry 2017, 4: 41

Papanti GD, Orsolini L, Corkery JM, SCHIFANO F. Synthetic cannabinoids and synthetic cannabinoid-induced psychotic disorders. Research Advances in Psychiatry 2017, 4: 42

Corkery JM, Guriguis A, Orsolini L, Papanti GD, SCHIFANO F. An investigation into the relationship(s) between the different chemical classes of synthetic cathinones and their effects: desired, adverse and toxic. Research Advances in Psychiatry 2017, 4: 53

Orsolini L, Valchera A, Papanti GD, De Berardis D, Vecchiotti R, Tomasetti C, Iasevoli F, Martinotti G, Di Giannantonio M, SCHIFANO F. The endless trip: psychopathology and psychopharmacology of HPPD. Research Advances in Psychiatry, 2016 (suppl 1): 24

Papanti GD, Bonavigo T, Sandri F, Pascolo-Fabrizi E, Bertossi F, Tirone G, Orsolini L, SCHIFANO F. LAI and substance use disorders: a look into the future. Research Advances in Psychiatry, 2016 (suppl 1): 30

Santacroce R, Ruiz Benassar C, Sancho Jaraiz JR, Merino del Villar C, Corkery JM, SCHIFANO F, Di Giannantonio M, Carenti ML, Catalano C, Cinosi E, Papanti GD, Angelini F, Cialone L, Pasquini A, Mancini V, Corbo

M, Fiori F, Sarchione F, Martinotti G. Parties to die for: drug related and drug caused fatalities in Ibiza in 2015. *Research Advances in Psychiatry*, 216 (suppl 1): 37.

Simonato P, Bersani FS, Martinotti G, SCHIFANO F, Corazza O. Can we exploit mobile phone technology to disseminate rapid information on Novel Psychoactive Substances (NPS) to health professionals? Presented at the European Health Forum Gastein, Gastein (Austria), September 2016.

Loi B, De Luca MA, Miliano C, Davidson C, Castelli MP, SCHIFANO F, Di Chiara G. Effect of BB-22 on dopamine release: Comparison between in vivo microdialysis studies and ex vivo fast scan cyclic voltammetry studies. LMS research conference, University of Hertfordshire, Hatfield, (UK), April 5th, 2016.

Loi B, De Luca MA, Miliano C, Porcu A, Martorelli M, Davidson C, Castelli MP, SCHIFANO F, Di Chiara G. Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation spice/K2: BB-22, 5F-PB-22, 5F-AKB-48 AND STS-135. Poster presented at the XVIth Congress of the Italian Society of Neuroscience; Cagliari-Sardinia-Italy, October 8-11, 2015.

Corkery JM, Claridge H, Goodair C, Papanti D, Orsolini L, Körber S, SCHIFANO F. The characteristics of deaths involving kratom in the United Kingdom and elsewhere. Presented at the Fourth International Conference on Novel Psychoactive Substances; 30-31 May 2016; Budapest (H). *Research and Advances in Psychiatry* 2:103, 2015.

Orsolini L, Papanti GD, Francesconi G, SCHIFANO F. Navigating in the Virtual Mind of the Web': the E-psychonauts' Profiling. *European Psychiatry*. [Volume 30, Supplement 1](#), 28–31 March 2015, Page 1045

De Luca MA, Castelli MP, Loi B, Porcu A, Martorelli M, Miliano C, Kellett K, Davidson C, Stair JL, Schifano F, Di Chiara G. Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135. Presented at the Fourth International Conference on Novel Psychoactive Substances; 30-31 May 2016; Budapest (H). *Research and Advances in Psychiatry* 2:132, 2015.

Aldhwaihi K, Pezzolesi, Umaru, SCHIFANO F. An evaluation of the types and contributing factors of dispensing errors in Luton and Dunstable hospital pharmacy. 21st Congress of the EAHP "Hospital pharmacists taking the lead - partnerships and technologies", Vienna (Austria), 16-18th March 2016

Orsolini L, Papanti GD, Valchera A, Corkery J, SCHIFANO F. Novel psychoactive substances. *European Psychiatry*, 33 (suppl): S59-60; 2016

Orsolini L, Papanti GD, Valchera A, Vecchiott R, Corkery J, SCHIFANO F.

Is addiction medicine part of psychiatry? *European Psychiatry* 2016; 33:S15

Aldhwaihi, Pezzolesi, SCHIFANO F., Umaru. An evaluation of the types and contributing factors of dispensing errors in King Saud Medicine City pharmacies. 9th Saudi Students Conference, Birmingham (UK), 13-14th February 2016

SCHIFANO F. New psychoactive substances. Abstracts' Book of the UNODC and WHO Scientific Consultation on Prevention of Drug Use and Treatment of Drug Use Disorders. Vienna (A), 08-10 December 2015, page 78.

Ciccarese, M., Orsolini<sup>1</sup>, L., Papanti<sup>1</sup>, D., Pini, L.A., SCHIFANO F. (2015). Abstract for oral presentation. Psychoactive animals and new usage patterns. AAP 2015. 24th International Meeting on Forensic Medicine. Alpe-Adria-Pannonia. Semmelweis University, Budapest, Hungary. 1-3 July 2015. Available at: [http://www.aap2015.com/view\\_abstract/?id=11](http://www.aap2015.com/view_abstract/?id=11).

Orsolini L, Papanti GD, Ciccarese M, Corkery JM, SCHIFANO F. Methoxphenidine (1-(1-(2-methoxyphenyl)-2-phenylethyl) piperidine; 2-MeO-Diphenidine): preliminary data on chemical, pharmacological and clinical effects. Poster accepted for presentation at 23rd European Congress of Psychiatry (EPA 2015); Wien, Austria, 28-31 March 2015

Alghannam A, Aslanpour Z, Evans S, SCHIFANO F. Evaluation of glibenclamide quality in Saudi Arabia. *Hospital Pharmacy; FIPSUB-1982*

Papanti GD, Orsolini L, Bonavigo T, Sandri F, Pascolo-Fabrici E, SCHIFANO F. Synthetic cannabinoids and the serotonin syndrome; an unforeseen association? Poster presented at the IV International Congress Dual Disorders. Addictions and other mental disorders. Barcelona, April 17-20, 2015; *Revista de Patología Dual* 2015; 2:117.

Orsolini L, Papanti GD, Francesconi G, SCHIFANO F. "Navigating in the virtual mind of the web": The e-psychonauts' profiling. Poster accepted for presentation at 23rd European Congress of Psychiatry (EPA 2015); Wien, Austria, 28-31 March 2015

Loi B, De Luca MA, Miliano C, Corkery J, Zloh M, SCHIFANO F, Di Chiara G. Microdialysis study of dopamine transmission in the nucleus accumbens shell and caudate putamen after 2,4-DNP administration in adult rats. *Life and Medical Sciences Hatfield Conference*, April 14th, 2015

Papanti GD, Orsolini L, Bonavigo T, Sandri F, Pascolo-Fabrici E, SCHIFANO F. Synthetic cannabinoids and the serotonin syndrome: an unforeseen association. Poster presented at the IV International Congress on Dual Disorders, 17-20 April 2015, Barcelona, Spain.

Baresse V, Dutta N, Miliano C, Loi B, Cadoni C, Ambrosio E, Opacka-Juffry J, SCHIFANO F, Di Chiara G, Davidson C. Potential Psychoactive Effects of the weight loss drug 2,4-Dinitrophenol (DNP). Poster presented at the British

Association of Pharmacology conference, London December 18<sup>th</sup>, 2014;  
Abstract available at: [https://bps.conference-services.net/resources/344/3811/pdf/PHARM14\\_0344.pdf](https://bps.conference-services.net/resources/344/3811/pdf/PHARM14_0344.pdf)

SCHIFANO F. Novel psychoactive substances. Proceedings of the South Eastern Division Autumn meeting of the Royal College of Psychiatrists, Winchester (UK), November 13<sup>th</sup>, 2014

St John-Smith P, Orsolini L, SCHIFANO F. Rethinking drug addiction from an evolutionary psychiatric perspective: the Novel Psychoactive Substances and the new sub-culture of the e-Psychonauts. Presented at the 16<sup>th</sup> Annual meeting of the Society for Evolutionary Studies, Osaka (Japan), August 21-24, 2014. Proceedings of the Symposium on 'Evolutionary Psychiatry: reconsiderations of biological mechanisms of psychiatric disorders with evolutionary perspective', page 105, Abstract book

Alghannam A, Evans S, SCHIFANO F, Aslanpour Z. Focus group with postgraduate pharmacy students in the UK regarding medicine quality in Saudi Arabia. Poster presented at the University of Hertfordshire Research Conference, Hatfield (UK), April 9-10, 2014.

Simonato P, Corazza O, SCHIFANO F. Dazed and confused: a brief overview of novel psychoactive substances as new challenge for healthcare professionals. Poster presented at the University of Hertfordshire Research Conference, Hatfield (UK), April 9-10, 2014.

Aldhwaihi K, Umaru N, SCHIFANO F, Pezzolesi C. An evaluation of dispensing errors at King Saud Medical City pharmacies. Poster presented at the University of Hertfordshire Research Conference, Hatfield (UK), April 9-10, 2014.

Francesconi G, Corkery J, Orsolini L, Papanti D, SCHIFANO F. Venlafaxine as a 'trip bomb': review of the relevant peer-reviewed literature and pro drug websites. Poster presented at the University of Hertfordshire Research Conference, Hatfield (UK), April 9-10, 2014.

Orsolini L, Papanti D, Francesconi G, Corkery J, SCHIFANO F. "Navigating in the virtual mind of the web": the e-psychonauts' profiling. Poster presented at the University of Hertfordshire Research Conference, Hatfield (UK), April 9-10, 2014.

Papanti D, Francesconi G, Orsolini L, Corkery J, SCHIFANO F. Are 'spice-drugs' hallucinogenic? Poster presented at the University of Hertfordshire Research Conference, Hatfield (UK), April 9-10, 2014.

Simonato PL, Santacroce R, Corazza O, Martinotti G, Cinosi E, Di Giannantonio M, SCHIFANO F. New cannabinoids and stimulants for sale on the internet: the case of psyclone. Poster presented at the University of Hertfordshire Research Conference, Hatfield (UK), April 9-10, 2014.

Alghannam A, Evans S, SCHIFANO F, Aslanpour Z. Focus group with postgraduate pharmacy students in the UK regarding medicine quality in Saudi Arabia. Poster presented at the University of Hertfordshire Research Conference, Hatfield (UK), April 9-10, 2014.

Goodair C, Corkery J, Claridge H, SCHIFANO F. Deaths in the UK from drugs and volatile substances Faculty of Public Health Conference; Warwick, July 3rd 2013; Poster

Aldhwaihi K, Umaru N, SCHIFANO F, Pezzolesi C. An Evaluation of Dispensing Errors at King Saud Medical City Pharmacies. 4th International Conference on Healthcare Ergonomics and Patient Safety (HEPS 2014) in Taipei, Taiwan June 23-26, 2014

Santacroce R, Corazza O, Chillemi E, Janiri L, SCHIFANO F, Di Giannantonio M. Sexual enhancement products for sale online: raising awareness of the psychoactive effects of yohimbine, maca, horny goat weed and ginkgo biloba. Poster accepted for presentation at the American Psychiatric Association annual meeting, New York (USA), May 3-7 2014

Santacroce R, Corazza O, Chillemi E, Martinotti G, SCHIFANO F, Di Giannantonio M. Sexual enhancers and psychoactive effects: analysis of on-line reports and review about the main components, II International Congress on Dual Disorders, Barcelona, 23-26 October 2013.

Cinosi E, Santacroce R, Martinotti G, Lupi M, Chillemi E, Fiori F, Sarchione F, Acciavatti T, Marini S, Corazza O, SCHIFANO F, Di Giannantonio M. Epidemiology of New Psychoactive Substances in a Sample of Adolescents and Young Adults: a Cross Sectional Study. 2° International Conference on Novel Psychoactive Substances, Swansea (UK), 12-13 Sept 2013.

Cinosi E, Santacroce R, Martinotti G, Lupi M, Chillemi E, Fiori F, Sarchione F, Acciavatti T, Marini S, Corazza O, SCHIFANO F, Di Giannantonio M. Sexual enhancers and psychoactive effects: analysis and review of on-line reports. International Conference on Novel Psychoactive Substances, Swansea (UK), 12-13 Sept 2013.

Papanti D, SCHIFANO F, Bonavigo T, Moressa V, Carrus D, Martinotti G, Pascolo-Fabrizi E. Spice and the “Eternal Recurrence” of Synthetic Cannabimimetics. Presentation made at the Nights2013 Conference; September 2013, Padova (I)

Corazza O, Assi S, Simonato P, SCHIFANO F. The SMAIL service: exploiting mobile phone technology for promoting international information exchange, 3 International Multidisciplinary Forum on New Psychoactive Drugs, EMCDDA, Lisbon, 27 June 2013.

Papanti F, SCHIFANO F, Martinez-Luna N, Martinotti G. From cannabis psychosis to ‘spiceophrenia’. Presented at the 3<sup>rd</sup> International Congress on

Dual Disorders; Barcelona, 23-26 October, 2013

SCHIFANO F. 'Bubble Troubles'; Clinical and Pharmacological Issues. *Current Drug Abuse Reviews*, 6: 263, 2013.

Bonavigo T, Papanti D, Sandri F, Bertossi F, Pascolo-Fabrici E, SCHIFANO F. Synthetic Cannabimimetics and Psychosis: A Review of the Recent Literature. *Current Drug Abuse Reviews*, 6: 265, 2013.

Corkery JM, SCHIFANO F. Factors Impacting on the Evolution and Characteristics of UK Deaths Involving 'Traditional' and 'New' Stimulants. *Current Drug Abuse Reviews*, 6: 266, 2013.

Bersani FS, Corazza O, Simonato P, Mylokosta A, Levari E, Lovaste R, SCHIFANO F. Drops of Madness? Recreational Misuse of Tropicamide Collyrium; Early Warning Alerts from Russia and Italy. *Current Drug Abuse Reviews*, 6: 281, 2013.

Bonavigo T, Papanti D, SCHIFANO F. Fake Pot Art. *Current Drug Abuse Reviews*, 6: 282, 2013.

Chiappini S, Claridge H, Corkery J, Gimeno Clemente C, Goodair C, Loi B, SCHIFANO F. Methoxetamine: An Analogue of Ketamine. *Current Drug Abuse Reviews*, 6: 84-5, 2013.

Gimeno Clemente C, Chiappini S, Claridge H, Corkery J, Goodair C, Loi B, SCHIFANO F. The Unregulated Psychoactive Compound: 'Benzo Fury'. *Current Drug Abuse Reviews*, 6: 286, 2013.

Loi B, Chiappini S, Claridge H, Corkery J, Gimeno Clemente C, Goodair C, SCHIFANO F. Fatalities Associated with Mephedrone in Combination with Other Stimulant Drugs in Young People Aged 16-24 Years. *Current Drug Abuse Reviews*, 6: 292-3, 2013.

Papanti D, SCHIFANO F, Bonavigo T, Purgato M, Zhabenko O, Carrus D, Pascolo-Fabrici E. Novel Psychoactive Substances' Epidemic as a 'Glocal' Phenomenon. *Current Drug Abuse Reviews*, 6: 296-7, 2013.

Papanti D, SCHIFANO F, Bonavigo T, Purgato M, Girlanda F, Zhabenko O, Bertossi F, Sandri F, Carrus D, Pascolo-Fabrici E. Post-Hoc Considerations and Analysis from "Spiceophrenia": A Systematic Review. *Current Drug Abuse Reviews*, 6: 297-8, 2013.

Valeriani G, Corazza O, Robiony M, Bersani FS, Bersani G, SCHIFANO F. 'Spice', 'Meow Meow', 'Pink Cham-pagne', 'Black Mamba': An International Challenge? An Overview of the Brand Names of Novel Psychoactive Substances. *Current Drug Abuse Reviews*, 6: 303-4, 2013

Santacroce R, Martinotti G, Lupi M, Chillemi M, Fiori F, Sarchioni F, Acciavatti T, Cinosi E, Marini S, Corazza O, SCHIFANO F, Di Giannantonio

M. Epidemiology of new psychoactive substances in a sample of adolescents and young adults: a cross sectional study. Poster presented at the International Conference 'Changes in Psychiatry'; Rome, 9-10 May 2013

Foulsham R, Ali M, SCHIFANO F, Dhillon S. Information requirements of community pharmacy patients with long term chronic conditions. Presented at the Health Services Research and Pharmacy Practice conference, Cork (Ireland), April 23-24, 2012

Robinson P, Ali M, Schifano F, Phillips G, Dhillon S. Improvement in cardiovascular risk factors in patients with diabetes by a community pharmacy education and monitoring project'. Oral presentation at British Hypertensive Society Annual Scientific Meeting, September 10-12, 2012, Cambridge, UK

Di Melchiorre G, Corazza O, Assi S, SCHIFANO F on behalf of the ReDNet Research group. The Emergence of Novel Psychoactive Substances (NPS): the role of the Recreational Drugs European Network. 11th World Association for Psychosocial Rehabilitation (WAPR) Congress, Milan (I), November 2012

Jebadurai J, SCHIFANO F, Deluca P. The characteristics of a new 'Legal High', 25I NBOMe: Also known as NBOMe-2C-I/ BOM-CI/ CIMBI-5. Poster presented at the Faculty of Addictions Conference, 3-4 May 2012, Cardiff (UK)

Ali M, SCHIFANO F, Robinson P, Phillips G, Doherty L, Melnick P, Sinclair A, Dhillon S Improvement in cardiovascular risk factors in patients with diabetes by a community pharmacy education and monitoring project. British Hypertension Society Annual Meeting 2012 - Abstract for oral presentation, Cambridge (UK), 11th Sep 2012

Corazza O, Assi S, Di Melchiorre G, SCHIFANO F. (2012) The Emergence of Novel Psychoactive Substances (NPS): the role of the Recreational Drugs European Network. Abstract for poster presentation at XI International Congress of the World Association for Psychosocial Rehabilitation, Milan, Italy, 10-13 November 2012.

Assi, S., Corazza, O., Schifano, F., on behalf of the ReDNet project (2012) Anticipating the Future and Adapting to Change: the Role of the Recreational Drugs European Network, The 2012 NIDA International Forum and the College on Problems of Drug Dependence (CPDD) conference, Palm Springs, California, USA, 9-14 June 2012

SCHIFANO F: The ever-changing world of psychoactive drugs: clinical and pharmacological challenges. The First International Conference on Novel Psychoactive Substances (NPS), "The Ever-Changing World of Psychoactive Drugs", Budapest, Hungary, 12-13 March 2012

Naveed A, SCHIFANO F: Searching the web for psychoactive compounds, an extreme case. The First International Conference on Novel Psychoactive Substances (NPS), "The Ever-Changing World of Psychoactive Drugs",

Budapest, Hungary, 12–13 March 2012

Corazza O, SCHIFANO F, on behalf of the ReDNet research group.  
Anticipating the future and adapting to change: the role of the ReDNet project.  
Jornadas Nacionales de Socidroga-alcohol, Tarragona, Spain, 29-31 March  
2012

Ali M, SCHIFANO F, Robinson P, Phillips G, Sinclair A, Dhillon S. Impact  
of community pharmacy diabetes monitoring and education programme on  
diabetes management: a randomised controlled study. Poster presented at  
EuroPrevent 2012 (European Society of Cardiology Congress), May 03-05,  
2012, Dublin, UK

Ali, M., SCHIFANO F., Robinson, P., Phillips, G., Melnick, P., Laming, L.,  
Sinclair, A. & Dhillon, S. (2011). 'Impact of community pharmacy diabetes  
monitoring and education programme on diabetes management: a randomised  
controlled study'. Poster presented at 7<sup>th</sup> National Conference of the Primary  
Care Diabetes Society, November 18-19, 2011, Birmingham, UK

Pezzolesi C, Dhillon S, SCHIFANO F, Kostrzewski A, Pickles J, Manser T.  
Development and evaluation of a Handover Performance Tool (HPT) for  
medical shift handovers. Presented at the 5th International Workshop on  
Behavioural Science Applied to Acute Care Teams, Zurich, Switzerland, 20-  
21 October 2011

SCHIFANO F. 'Legal highs'. Royal College of Psychiatrists, South Eastern  
Division, Autumn Academic meeting, Leeds Castle, Kent, November 3<sup>rd</sup>, 2011

Jebadurai J, SCHIFANO F, Deluca P. The characteristics of a new 'Legal  
High', Benzofury: Also known as 6 APB which is 6-(2-aminopropyl)  
benzofuran and 6 APDB which is 6-(2-aminopropyl)-2,3-dihydrobenzofuran.  
Poster presented at the Royal College of Psychiatrists Faculty of Addictions  
Psychiatry Annual Conference. Bristol, May 12-13, 2011

Scherbaum N, Deluca P, SCHIFANO F, Siemann H. Das PSYCHONAUT-  
Projekt – Das Internet und die Diversifizierung des Drogenkonsums.  
Deutscher Suchtkongress 2011, in press

SCHIFANO F. La psichiatria e gli psichedelici degli psiconauti (Psychiatry  
and the psychonauts' psychedelics). Rome, 15-19 February 2011. Italian  
Journal of Psychopathology, S1: 22-23, 2011

SCHIFANO F: Substance misuse: epidemiology and trends. Talk given at the  
Royal Society of Medicine, London, 25<sup>th</sup> May 2010

SCHIFANO F: Psychiatry and the psychonauts' psychedelics. Talk given at  
the Royal College of Psychiatrists (Addictions) conference, Bristol, 29-30<sup>th</sup>  
April 2010, Bristol (UK)

Schmidt M, Sharma A, SCHIFANO F, Feinmann C: Legal highs on the net. Poster presented at the Royal College of Psychiatrists (Addictions) conference, Bristol, 29-30<sup>th</sup> April 2010, Bristol (UK)

Corazza O, SCHIFANO F, Deluca P, Davey Z, on behalf of the Psychonaut Web Mapping Group. Cultura telematica, trascendenza corporea e nuove droghe: come gli internauti diventano psiconauti. In: La Barbera, D. (ed) Proceedings of III International Congress of the Italian Society of Psychotechnologies, Palermo (I), 23-25 November 2009

Pezzolesi C, Dhillon S, Muir H, Pickles J, Arshad M, Ghaleb M, SCHIFANO F. Clinical audit of handover practice in one UK General District Hospital. Poster presented at the Implementation Science and Patient Safety - NPSA 3rd Annual UK Patient Safety Research Workshop, London, December 16, 2009.

SCHIFANO F. The addiction-prone personality. Presented at the 7<sup>th</sup> Summer School of Neuroscience, Catania (I), July 11-17 2009

Davey Z, Corazza O, Deluca P, SCHIFANO F. Can novel compounds induce psychosis? Poster presented at the Substance Misuse and Psychosis Conference, Birmingham (UK), July 9-10, 2009

Corazza O, SCHIFANO F, Davey Z, Deluca P: Consciousness, drugs and the internet. Paper presented at the Conference: 'Toward a science of consciousness 2009', Hong Kong (China), June 11-14. Journal of Consciousness Studies, pp 95, 2009

SCHIFANO F, Dhillon S, Phillips G, Ali M, Jagessar V, Robinson P: Impact of community pharmacy monitoring programme on diabetes-related outcomes in primary care. Poster presented at the NHS National Institute for Health Research Conference: 'Delivering better health services', Birmingham (UK), June 3-4, 2009

SCHIFANO F: Recreational drugs; clinical pharmacology and psychopathology issues related to their use. Presented at 13<sup>th</sup> Congress of the Italian Society of Psychopathology, Rome (I), February 10-14, 2009. Italian Journal of Psychopathology, 15:S1, 19, 2009

SCHIFANO F, Dhillon S, Phillips G, Ali M, Jagessar V, Robinson P. Impact of community pharmacy monitoring programme on diabetes-related outcomes in primary care. Presented at the NHS National Institute for Health Research, Delivering Better Health Services, Birmingham, 2009

SCHIFANO F, Ali M, Phillips G, Dhillon S. 'Manor Pharmacy diabetes monitoring programme. Presented at the Health & Human Sciences Research Institute Showcase, Hatfield, UK, University of Hertfordshire, 2008.

SCHIFANO F, Ali M, Phillips G, Dhillon S. Manor Pharmacy diabetes monitoring programme. Poster presented at the Health and Human Sciences Research Institute Showcase, October 21-24 2008, Hatfield (UK)

Deluca P, SCHIFANO F: Illicit drugs available online; building up the Psychonaut, European-wide, Monitoring System. Presented at the Mednet 2008, World Congress on Internet in Medicine, Toronto (Canada) October 2008

Reissner V, Kokkevi A, Di Furia L, SCHIFANO F, Room R, Stohler R, Scherbaum N. Drug Consumption, Health service use and outcome in opiate Addicts in Europe: An 18-Month Follow-up from Athens to Zurich. Presented at the 16th European Congress of Psychiatry, Nice (France), 05 – 09<sup>th</sup> April, 2008. *European Psychiatry*, Vol. 23, p. S74 Suppl. 2, 2008 (abstract)

Reissner V, Kokkevi A, Di Furia L, SCHIFANO F, Room R, Stohler R, Scherbaum N. Drogenkonsum, Inanspruchnahmeverhalten und Outcome im Verlauf in Europa: Von Athen bis Zürich. Presented at the Congress of the Deutschen Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde, Berlin (Germany), 21 – 24th November 2007. *Der Nervenarzt*, Supplement 2, p. 161, 2007 (abstract)

Deluca P, SCHIFANO F: MDMA: Searching the Internet for drug related websites; analysis of online available information on ecstasy. Presented at the Mednet 2006, 11th World Congress on Internet in Medicine, Toronto (Canada) October 2006

SCHIFANO F: Urgenze psichiatriche e trattamento farmacologico delle nuove droghe. *Psichiatria e Psicoterapia*, 25, suppl 2: 45, 2006 (abstract)

SCHIFANO F: Ecstasy and polydrug abuse: clinical aspects, pharmacological issues and post-mortem findings. *Journal of Psychopharmacology*, 18 (Suppl): S27, 2004 (abstract)

Zangara A, Rovetto F, Forza G, Goford J, SCHIFANO F: Smart drugs, Eco drugs: an European Prospective Survey on a Population of Dutch Smartshop Customers. *Journal of Psychopharmacology* 18 (Suppl): A37, 2004 (abstract)

Parrott AC, Milani RM, Turner JJD, SCHIFANO F: Recreational ecstasy (MDMA) polydrug use: The psychiatric symptoms and psychobiological problems associated with cigarette smoking and other psychoactive drugs. *Journal of Psychopharmacology*, 16 (3): G5 Suppl. S, 2002 (abstract)

Milani R, SCHIFANO F: Neuropsychological problems associated with ecstasy use. *Journal of Psychopharmacology*, 4: A14, 2000 (abstract)

Forza G, Levarta E. SCHIFANO F: Use, abuse and dependence from benzodiazepines in methadone-maintained patients; theoretical and practical issues. *European Psychiatry*, 15 (suppl 2): S14.03: 238s, 2000 (abstract)

Di Furia L, Forcella MC, Savani N, Picello S, SCHIFANO F: Drug addiction and sexuality. *European Psychiatry*, 15 (suppl 2): P01.175: 367s, 2000 (abstract)

Di Furia L, Scivittaro F, Rizzo M, SCHIFANO F, Sgro' M: Psychiatric comorbidity among drug addicts. Evaluation of prevalence rate and creation of a network of intervention. *European Psychiatry*, 15: 440S-440S Suppl. 2, 2000 (abstract)

Forza G, Levarta E, Da Ros D, Gentile N, SCHIFANO F: Benzodiazepines consumption in a sample of methadone-maintained patients: Characteristics of use and psychopathological profile. *European Psychiatry*, 13 (suppl. 4): s15, 1998 (abstract)

Levarta E, Forza G, Da Ros D, SCHIFANO F: Benzodiazepines consumption in the context of poly-substance abuse and of impulse dyscontrol. *European Neuropsychopharmacology*, 8 (suppl. 2): s283-4, 1998 (abstract)

SCHIFANO F, Garofoli F: Dothiepin vs S-adenosylmethionine for the treatment of major depression in weaned alcoholics: a pilot study. *European Neuropsychopharmacology*, 3: 330, 1993 (abstract)

Gallimberti L, SCHIFANO F, Ferri M, Ferrara SD, Gessa GL: The treatment of alcohol dependence; a double-blind pilot study with gamma-hydroxybutyric acid. *Biological Psychiatry*, 29: 500s, 1991 (abstract)

SCHIFANO F, Gallimberti L, Ferrara SD: The treatment of rapid cycling bipolar affective disorder; lithium versus lithium plus carbamazepine. *Biological Psychiatry*, 29: 378s, 1991 (abstract)

#### Conference contributions: Other

(please note that this list is not exhaustive and is meant to give only an indication of the range of conference contributions given)

Naveed A, SCHIFANO F: Searching the web for psychoactive compounds: an extreme case. 11<sup>th</sup> British Pakistani Psychiatric Association Conference; Birmingham (UK), October 13-14, 2012

Di Melchiorre G, SCHIFANO F, Corazza O. Le nuove potenzialita' in materia di nuove droghe: risultati ad un anno del Recreational Drug European Network (Novel potential relating to the misuse of novel psychoactive drugs; 1-year results of the Recreational Drug European Network). WAPR Conference, October 2011

Pezzolesi C, Dhillon S, Muir H, Pickles J, SCHIFANO F, Randell W, Hussain Z: Prevalence and types of reported handover incidents in one UK general hospital. 7<sup>th</sup> Annual Research Day, Hatfield (UK), 22<sup>nd</sup> April 2009

SCHIFANO F: Drug and Alcohol Misuse issues and Clinical Practice in the EU. The Royal College of Psychiatrists; Eastern Division Spring Academic Meeting, Cambridge May 13<sup>th</sup>, 2008

Reissner V, Kokkevi A, Di Furia L, SCHIFANO F, Room R, Stohler R, Scherbaum N. TREAT – Opioidabhängige Patienten und ihr Behandlungssystem

in sechs europäischen Großstädten – eine vergleichende Studie. Presented at the wissenschaftlichen Jahrestagung des Bundesverbandes für stationäre Suchtkrankenhilfe e.V., Berlin (Germany), 12 – 13th March, 2008.

SCHIFANO F: New trends in drug addiction; implications for psychiatric disorders. Proceedings of the International Meeting on ‘ Fattori di rischio dei disturbi psichici/Risk factors for psychiatric disorders’, Rome (I), 7-9<sup>th</sup> November 2007

SCHIFANO F: A critical overview of the Medline, peer reviewed, literature on the use of Herbal Medicine in the treatment of addiction. Proceedings of the International Meeting on ‘Herbal Medicine in the Treatment of Addictions’, London February 12-16, 2006

SCHIFANO F: Dual diagnosis clients; an emerging issue in metropolitan areas. Proceedings of the bilateral UK/I Meeting on ‘Psychiatric Emergencies in metropolitan areas; Rome and London’, Rome (I), January 13-14, 2005

SCHIFANO F: Impulsivity/aggressive behaviour and substance abuse. Proceedings of the Fourth National Congress of the Italian Society of Psychiatry, Substance Misuse Section, Rimini (I), December 2-4, 2004

Deluca P, SCHIFANO F: Searching the Internet for drug related websites; methodological issues. International Council on Alcohol and Addictions (ICAA) Conference, Venice, November 2<sup>nd</sup>, 2004.

SCHIFANO F: Cocaine misuse and dependence. Proceedings of the Meeting on ‘Psychiatric Comorbidity and Drug Abuse’, Parco dei Tigli, Teolo, Padova (I), May 28<sup>th</sup>, 2004

SCHIFANO F: The National Programme on Substance Abuse Deaths (np-SAD): data capture system and reporting. SW London & St George’s MH NHS Trust Research & Development Conference, May 24<sup>th</sup>, London, 2004

Zangara A, Rovetto F, Forza G, SCHIFANO F: Smart drugs, eco drugs; an European perspective. Survey on a population of Dutch smartshop customers. British Association of Psychopharmacology Annual meeting, poster presentation, Harrogate (UK), July 26-28, 2004

Zangara A, Rovetto F, Forza G, SCHIFANO F: The Dutch smartshop as a model for Europe in the sale of smart and eco drug. Proceedings of the Clubhealth 2004 International Conference, Australia, May 2004

SCHIFANO F: Ecstasy, morbidity and mortality. Abstracts’ Boook of the Royal College of Psychiatrists Faculty of Substance Misuse Annual Conference, Glasgow (UK), 6-7 May, p. 4, 2004

SCHIFANO F, Oyefeso A, Pollard M, Corkery J, Ghodse AH: Ecstasy and polydrug abuse: Clinical aspects, pharmacological issues and post-mortem findings. Proceedings of the British Psychological

Society Annual Conference, Bournemouth (UK), 13-15 March, p. 11, 2003

SCHIFANO F, Leoni M, Rawaf S, Rovetto F, Ghodse, A H Psychonaut 2002: the importance of the virtual market and the modification of drug scenarios. Paper presented at the CyberTherapy Conference 2003, San Diego (CA).

SCHIFANO F, Leoni M, Deluca P, Rovetto F. Surfing the net whilst wandering around for drugs: the Psychonaut 2002 Project preliminary results. Paper presented at the European Association for Behaviour Analysis Conference 2003, Parma (Italy).

SCHIFANO F: Cocaina: dipendenza e trattamento. Proceedings' Book of the Third National Congress of Addiction Medicine, Verona (I), September 27, pp. 17-18, 2002

Rawaf S, SCHIFANO F: Internet and the Psychonauts. European Seminar Euridice Project 'Using Internet in Preventing Drug Addiction', November 2000, Mantova (I)

SCHIFANO F: Eccitanti e psichedelici del sabato sera. Proceedings' Book of the National Meeting on 'Risk and Pleasure', Rapallo (I), November 1999

SCHIFANO F, Di Furia L, Bricolo R: Ecstasy: aspetti epidemiologici e clinici. Proceedings of the 2<sup>nd</sup> Congress of the Società Italiana Comportamenti di Abuso e Dipendenza (SICAD), Acireale, Catania (I), June 16-19, pp. 250-62, 1996

SCHIFANO F, Di Furia L, Bricolo R: Affective disturbances and MDMA (ecstasy) abuse. Proceedings of the 40<sup>th</sup> International Institute on the Prevention and Treatment of Dependencies, Amsterdam (NL), June 30-July 5, p. 24, 1996

SCHIFANO F, De Leo D: Suicide prevention and psychotropic drugs. Proceedings of the 18th International Association for Suicide Prevention Congress, Venice (I), June 4-8, p. 64, 1995

SCHIFANO F, Berto D, Di Furia L, Vettorello C, Bricolo R: Characteristics and psychopathological consequences of MDMA abuse in northern Italy. Proceedings of the 2<sup>nd</sup> European Symposium on Drug Addiction and AIDS, Istanbul (T), October 23-26, p. 132, 1995

SCHIFANO F, Righetto P, Monti D, Fusaro F, Bricolo R: Evaluating and matching the needs of the worst clients: an Italian experience. Proceedings of the 21<sup>st</sup> International Institute on Prevention and Treatment of Drug Dependence, Prague (CS), June 5-10, p. 231, 1994

Gallimberti L, SCHIFANO F, Ferri M, Ferrara SD, Gessa GL: The role of gamma-hydroxybutyric acid for the treatment of alcoholism: A double-blind, placebo-controlled pilot study. Proceedings of the 36<sup>th</sup> International Congress of Alcoholism and Drug Dependence, Glasgow (UK), August 16-21, pp. 344-9, 1992

SCHIFANO F, Renesto V, Grassetto M, Magni G: Mianserin and maprotiline in depressed hospitalized geriatric patients: a double-blind trial. Proceedings of the 5<sup>th</sup> International Congress of Psychiatric Epidemiology, Montreal (Can), June 6-8, p. 147, 1990

Montemurro R, SCHIFANO F, Volontè MV: Effetto antidepressivo della dotiepinina vs amineptina nella pratica ambulatoriale. Proceedings of the 37<sup>th</sup> National Congress of the Società Italiana di Psichiatria, Rome (I), February 6-11, pp 807-15, 1989

SCHIFANO F, De Leo D, Magni G, Nogarè I, Montemurro R, Renda V: Una valutazione del comportamento suicidario nella ULSS n. 18 della Regione Veneto. Proceedings of the 1<sup>st</sup> National Congress of the Italian Society for the Study and Prevention of Suicide, Padova (I), October 10-11, pp 3-19, 1987

SCHIFANO F, Magni G, Renesto V, De Dominicis MG: Valutazione della depressione nel paziente geriatrico internistico ospedalizzato. Proceedings of the National Congress of the Italian Society of Psychogeriatrics, Trieste (I), May 22-24, pp. 31-8, 1986

Magni G, SCHIFANO F, Renesto V, De Dominicis MG: Epidemiology of depression in the hospitalized geriatric patient. Proceedings of the third International Congress of Psychiatric Epidemiology, Bruxelles (B), September 9-11, p. 108, 1985

#### Edited Work (regularly peer reviewed)

1. Recent Changes in Drug Abuse Scenario: The Novel Psychoactive Substances (NPS) Phenomenon. SCHIFANO F (ed); MDPI, Basel, Switzerland; 2018; pages 1-200

#### Edited Works: Contributions (all of these have been regularly peer-reviewed \*)

1. Papanti P GD, Orsolini L, Corkery JM, Chiappini S, Guirguis A, Vento A, SCHIFANO F. Synthetic Cannabinoids, the largest and most diverse group of novel psychoactive substances (NPS). In "Cannabinoids" edited by Dr. Marco Colizzi, Dr. Danilo De Gregorio and Dr. Diego Quattrone. Edizioni Minerva Medica S.p.A.; in press
2. SCHIFANO F. Dipendenze farmacologiche e comportamentali. In: Manuale di Psichiatria. Favaro A (ed); Piccin Nuova Libreria; 2022

3. SCHIFANO F, Chiappini S, Catalani V, Napoletano F, Arillotta D, Zangani C, Guirguis A, Vento AE, Bonaccorso S, Corkery JM. Psychobiological; medical; and psychiatric implications of new/novel psychoactive substance (NPS) use. In: Psychobiological issues of drug misuse. Editor: Murphy P; Routledge, 2020
4. SCHIFANO F, Zangani C, Chiappini S, Guirguis A, Bonaccorso S, Corkery JM. Substance-Use Disorders and Violence. In: Violence and Mental Disorders (Carpiniello B, Vita A, Mencacci C, eds). Springer Nature. Chapter DOI: 10.1007/978-3-030-33188-7\_6, 2019 (\*)
5. Zangani C, Chiappini S, Napoletano F, Orsolini L, SCHIFANO F. Nuove frontiere nell'abuso di sostanze, psiconauti e internet. In Prevenzione, giovani e... come investire nella formazione scolastica per la salute. Modonutti GB (ed); Edizioni Goliardiche Trieste; 2019
6. Chiappini S, SCHIFANO F. Cannabis: evidenze epidemiologiche, cliniche e terapeutiche. In: Unosuquattro. Diffusione e significati del consumo di cannabinoidi tra gli adolescenti: una questione educative (Iori V, Gianotti F, eds). Franco Angeli Publisher; September 2019; EAN: 9788891781109; ISBN: 889178110X, 2019 (\*)
7. Orsolini L, Bellantuono C, De Berardis D, SCHIFANO F. Alcohol Use Disorders in Perinatal Period. In: F. Uguz, L. Orsolini (eds.), *Perinatal Psychopharmacology*, Springer Nature Switzerland AG 2019. [https://doi.org/10.1007/978-3-319-92919-4\\_19](https://doi.org/10.1007/978-3-319-92919-4_19)
8. Orsolini L, Papanti GD, Bellantuono C, De Berardis D, SCHIFANO F. Substance Use Disorders. In: F. Uguz, L. Orsolini (eds.), *Perinatal Psychopharmacology*, Springer Nature Switzerland AG 2019. [https://doi.org/10.1007/978-3-319-92919-4\\_20](https://doi.org/10.1007/978-3-319-92919-4_20)
9. Corkery J, Orsolini L, Papanti GD, SCHIFANO F. Novel psychoactive substances (NPS) and recent scenarios: epidemiological, anthropological and clinical pharmacological issues. In: *Light in Forensic Science: Issues and Application*. Miolo, G., Stair, J. L. & Zloh, M. (eds.). First ed. London: [Royal Society of Chemistry](#), p. 207-256, 2018 (\*)
10. Papanti GD, Orsolini L, Corkery JM, SCHIFANO F. Spice Drugs, Synthetic Cannabinoids, and 'Spicephrenia'. Corazza O, Usterrazu AR (eds). Spice Drugs, Synthetic Cannabinoids, and 'Spicephrenia'. *Handbook of Novel Psychoactive Substances*; Routledge, October 2018; Print ISBN: 9781138068292 (\*)
11. Corkery JM, Guirguis A, Papanti GD, Orsolini L, SCHIFANO F. Synthetic Cathinones—Prevalence and Motivations for Use Chapter 9. In: Publishing AG, part of Springer Nature 2018 J. B. Zawilska (ed.), Synthetic Cathinones, Current Topics in Neurotoxicity 12, [https://doi.org/10.1007/978-3-319-78707-7\\_9](https://doi.org/10.1007/978-3-319-78707-7_9) (\*)

12. SCHIFANO F, Orsolini L, Papanti GD, Corkery JM. Le nuove sostanze psicoattive (NSP). Lugoboni F, editor. Manuale delle Dipendenze, April 2018, (\*)
13. SCHIFANO F, Orsolini L, Papanti GD, Corkery JM. Neurobiologia degli stimolanti. Lugoboni F, editor. Manuale delle Dipendenze, April 2018 (\*)
14. Papanti GD, SCHIFANO F, Orsolini L. Synthetic Cannabinoids and Synthetic Cannabinoid-Induced Psychotic Disorders. In: The Complex Connection between Cannabis and Schizophrenia; 1st Edition. Editors: Compton M, Manseau M. Paperback ISBN: 9780128047910; Imprint: Academic Press; September 2017 (\*)
15. Corazza O, Bersani FS, Valeriani G, SCHIFANO F. Technologies and lifestyles: how the internet has revolutionized the drug market and people's lives. In: Synthetic and Novel Drugs: Emerging Issues, Legal Policy and Public Health. Stogner JM, Miller BL, Khey DN. CRC Press, May 2016 (\*)
16. SCHIFANO F, Orsolini L, Papanti GD, Corkery JM. NPS: Medical Consequences Associated with Their Intake. Springer International Publishing Switzerland 2016; Curr Topics Behav Neurosci; 2016 Jun 7. [Epub ahead of print]; DOI 10.1007/7854\_2016\_15 (\*)
17. SCHIFANO F, Orsolini L, Papanti GD, Corkery JC. Le nuove sostanze psicoattive: aspetti epidemiologici clinici e farmacologici. In: Girardi P, Di Giannantonio M (eds). Psicologia e psicopatologia delle dipendenze e dei comportamenti di abuso. Casa editrice Pacini, 2016 (\*)
18. Corazza O, Valeriani G, Bersani FS, SCHIFANO F. Novel and synthetic drugs: emerging issues, legal policy and public health. In Stogner J (ed). Technologies and Lifestyles: how the Internet has revolutionized the drug market and people's lives. CRC Press, 2017.
19. Vento AE, Brunoro R, Cacciotti M, Carrus D, Ducci G, Martinotti G, Pellicciari G, Santacroce R, SCHIFANO F. Nuove sostanze psicoattive (NPS) e sostanze psicoattive 'di nicchia'; chapter 6. In: Vento AE, Ducci G (eds). Manuale pratico per il trattamento dei disturbi psichici da uso di sostanze. Giovanni Fioriti editore, Roma, Italy, 2018; ISBN: 88-98991-81-9 - EAN: 9788898991815
20. SCHIFANO F, Ferdico M. Doppia Diagnosi: nuove sostanze e trattamenti. In: Nicolò G, Pompili E (eds): Manuale di Psichiatria Territoriale, Pacini Editore, Roma (I), 2012
21. Martinotti G, Santacroce R, Cinosi E, SCHIFANO F, di Giannantonio M. Le nuove sostanze psicoattive, chapter 24. In: Siracusano A et al (eds). Manuale di Psichiatria; Il Pensiero Scientifico Editore, Roma; 2014

22. Corkery JM, SCHIFANO F, Ghodse AH. Mephedrone-related fatalities in the United Kingdom: contextual, clinical and practical issues. In Lazinica A (ed): "Pharmacology", 2012, March. Publisher: InTech, Rijeka, Croatia ISBN 979-953-307-482-4; available from:  
<http://www.intechopen.com/articles/show/title/mephedrone-related-fatalities-in-the-united-kingdom-contextual-clinical-and-practical-issues>
23. SCHIFANO F. Drugs: treatment and management. In: Substance Abuse: Evidence and Experience. Ghodse AH, Herrman H, Maj M and Sartorius N (eds), Wiley-Blackwell, Chichester (UK), 2011 pp. 53-74
24. Bellamoli E, Seri C, Serpelloni G, SCHIFANO F. Il sistema endocannabinoide e le sue funzioni (The endocannabinoid system and its functions). In: Serpelloni G, Bricolo F, Gomma M (eds). Elementi di Neuroscienze e Dipendenze. Dipartimento Dipendenze Verona (I), June 2010
25. SCHIFANO F: Non medical prescribing in mental health. In: Dhillon S et al (eds): Non Medical Prescribing. Pharmaceutical Press, London, UK, 2012
26. SCHIFANO F: Central nervous system case studies. In: Dhillon S, Raymond R: Pharmacy case studies. Pharmaceutical Press, London, 2009; pp: 80-102
27. Winstock A, SCHIFANO F. Disorders relating to the use of ecstasy, other 'party drugs' and khat. In: Gelder M, Andreasen N, Lopez-Ibor JJ, Geddes J (eds): New Oxford Textbook of Psychiatry, Oxford Press, January 2009
28. SCHIFANO F, Corkery J: Decessi ed altri indicatori chiave del consumo di cocaina nel Regno Unito, 1990-2004 (Fatalities and other key cocaine indicators for the United Kingdom, 1990-2004). In: Serpelloni G, Macchia T, Gerra G (eds): Cocaina, La Grafica Publisher, Verona, 2006, pp. 87-101
29. SCHIFANO F, Serpelloni G, Bosco O, Bertonecelli S: Scheda tecnica riassuntiva. Aspetti farmacologici e clinici dei vari prodotti a base di cocaina. In: Serpelloni G, Macchia T, Gerra G (eds): Cocaina, La Grafica Publisher, Verona, 2006, pp. 713-720
30. Di Furia L, Pizza M, Gordon C, SCHIFANO F: The psychological/psychiatric perspectives of co-morbidity. In:

- Baldacchino A, Corkery J (eds). ECCAS monograph no. 4; 'Drug addiction and comorbidity issues', 2006, pp.77-93
31. SCHIFANO F, Rovetto F, Leoni M: Recreational drugs; pharmacological, toxicological and behavioural issues (Le droghe ricreative. Aspetti farmacologici, tossicologici e implicazioni comportamentali). In: Rovetto F, Rossi L (Eds). Forensic Psychology: Harm Evaluation (Psicologia Giuridica: La Valutazione Del Danno), Santa Croce Publisher, Parma (I), 2005, pp. 441-456
  32. Rovetto F, SCHIFANO F, Leoni M: Date rape drugs; clinical issues of drug-assisted rape episodes (Date Rape Drugs. Caratteristiche cliniche delle violenze sessuali effettuate sotto l'influsso di sostanze). In : Rovetto F, Rossi L (Eds). Forensic Psychology: Harm Evaluation (Psicologia Giuridica: La Valutazione Del Danno), Santa Croce Publisher, Parma (I), 2005, pp. 457-463
  33. SCHIFANO F: Substance misuse in the workplace. In: Ghodse AH (ed). Addiction at Work: Tackling Drug Use and Misuse in the Workplace. Gower Publishing Ltd, Aldershot (UK), 2005, pp. 53-67
  34. Pavan L, SCHIFANO F, Rizzardo R: I disturbi da uso di sostanze. In: Pavan L (ed). Psicologia Clinica e Clinica Psichiatrica. Cleup Editore, Padova (I), in press
  35. SCHIFANO F. Drug addiction: aspetti farmacologici, clinici e terapeutici. In: Bellantuono C, Balestrieri M (eds). Trattato di Psicofarmacologia Clinica, Il Pensiero Scientifico Editore, pp. 1041-1063, 2003
  36. SCHIFANO F. Vecchie e nuove droghe tra storia e cultura. In: Celeghin F, Grossi A, Raboni R (eds). Policonsumo di droghe: scenari ed interventi formativi. Franco Angeli Editor, Milan, Italy, pp. 37-42, 2003
  37. SCHIFANO F. Le nuove droghe: aspetti clinici e di contesto. In: Celeghin F, Grossi A, Raboni R (eds). Policonsumo di droghe: scenari ed interventi formativi. Franco Angeli Editor, Milan, Italy, pp. 185-206, 2003
  38. Di Furia L, Della Barba B, SCHIFANO F, Savani N: Maternal Health and Drug Abuse in Italy. In: Ghodse AH, Baldacchino A, Riglietta M, Corkery J (eds). European Centre for Addiction Studies, St George's Hospital Medical School, London, pp. 52-59, 2003

39. SCHIFANO F: Drug-related deaths in Spain and Portugal: A review. In: Ghodse H, Oyefeso A, Corkery J, Baldacchino A (eds) Drug-related mortality: Perspectives across Europe. European Centre for Addiction Studies, St George's Hospital Medical School, London, pp.127-32, 2002
40. Oyefeso A, Ghodse AH, Corkery JM, Clancy C, Baldacchino A, SCHIFANO F: Drug-related mortality. An overview. In: Ghodse H, Oyefeso A, Corkery J, Baldacchino A (eds). Drug-related mortality: Perspectives across Europe. European Centre for Addiction Studies, St George's Hospital Medical School, London, pp.187-90, 2002
41. SCHIFANO F. Pharmacokinetic and pharmacodynamic considerations in old age psychopharmacology. In Copeland JRM, Abou-Saleh M, Blazer DG (eds). Principles and Practice of Geriatric Psychiatry. John Wiley & Sons Ltd, pp. 61-64, 2002
42. SCHIFANO F. European dimension; substance misuse and psychiatric disorders. In: Rassool GH (ed). Dual Diagnosis. Substance Misuse and Psychiatric Disorders. Blackwell Science, pp. 58-65, 2002
43. SCHIFANO F: Introduction to the book: 'Comparative treatments of substance abuse'. Dowd G, Ruge L (eds), Italian edition. The McGraw Hill Companies Publishing Group Italy, 2001
44. SCHIFANO F, Serpelloni G, Gerra G: Effetti da assunzione protratta di ecstasy. In: Linee guida per la prevenzione dell'overdose da eroina e degli effetti acuti dell'ecstasy. In: Serpelloni G, SCHIFANO F (eds). Regione del Veneto, Verona, pp. 10-17, 2000
45. SCHIFANO F, Di Furia L: Abuso di sostanze nell'infanzia e nell'adolescenza. In: Cassano GB, Pancheri P, Pavan L, Pazzagli A, Ravizza L, Rossi R, Smeraldi E, Volterra V (eds). Trattato Italiano di Psichiatria, 2<sup>nd</sup> edition. Masson Editore, Milan (I), pp. 2969-78, 1999
46. Maremmani I, SCHIFANO F, Di Furia L: Amfetamino (simili) e designer drugs. Ibidem, pp. 1407-11, 1999
47. SCHIFANO F, Di Furia L: Dipendenza da cocaina. In: Rigliano P (ed). InDipendenze, Gruppo Abele Editions, Torino (I), pp. 185-95, 1998
48. SCHIFANO F: Malattie psichiatriche; questioni giuridiche. In: Halhuber M (ed). Vademecum di Diagnostica e Terapia d'Urgenza. Piccin Nuova Libreria, Padova (I), pp. 410-1, 1998

49. SCHIFANO F, Corazza O, Forza G: Le sostanze d'abuso del sabato sera. In: Gatti R (ed). Ecstasy e nuove droghe. Franco Angeli Editor, Milano (I), pp. 122-41, 1998
50. SCHIFANO F, Forza G: Open access to MST programmes. In: Ghodse AH et al, Clancy C, Oyefeso A (eds). Methadone substitution therapy in Europe. Policies and practices. European Centre for Addiction Studies, St George's Hospital Medical School, London, pp. 42-5, 1998
51. SCHIFANO F, De Leo D: Pharmacological treatment of suicidal behaviour. In: De Leo D, Schmidtke A, Diekstra RFW (eds). Suicide prevention: A holistic approach. Kluwer Academic Publishers, Dordrecht (NL), pp. 199-210, 1998
52. Gava R, SCHIFANO F: Amisulpride, clonidina transdermica, colina alfosclerato, dexfenfluramina, etizolam, fluvoxamina, foscarnet sodico, paroxetina, sertralina, zolpidem, zopiclone, zuclopentixolo. In: Casiglia E, Gava R (eds). L'Annuario dei Farmaci, Volume di Aggiornamento. Piccin Nuova Libreria, Padova (I), pp. 9-188, 1997
53. SCHIFANO F: La diffusione dell'AIDS ha modificato la tipologia dei consumatori di sostanze stupefacenti? In: ASA (ed). Per una scommessa vincente. Il Ponte Vecchio Editions, Cesena, Bologna (I), pp. 111-23, 1997
54. SCHIFANO F: Farmacologia delle principali sostanze d'abuso. In: Serpelloni G, Rossi A (eds). HIV, AIDS e Droga. Manuale per Operatori di Prevenzione. Leonard Edizioni Scientifiche, Verona (I), pp. 105-27, 1996
55. Pavan L, SCHIFANO F: I disturbi da uso di sostanze. In: Pavan L (ed). Psicologia Clinica e Clinica Psichiatrica. Cleup Editore, Padova (I), pp. 363-84, 1995
56. Ghodse AH, Clancy C, Jones M, Bourquin M, De Las Heras B, Montes M, Keenan E, Lopes I, Riglietta M, Tidone L, Rosinger C, Runge Nielson K, San L, SCHIFANO F, Schoemann P, Cremmers L, Sommer B, Wieviorka S (the ECCAS group): Methadone substitution therapy and its impact on HIV risk behaviours. In: Tagliamonte A, Maremmani I (eds). Drug Addiction and Related Clinical Problems, Springer and Verlag, Wien-New York, pp.199-211, 1995
57. SCHIFANO F: The Padova centre report. In: Tagliamonte A, Maremmani I (eds). Drug addiction and related clinical problems. Springer and Verlag, Wien-New York, pp. 207-9, 1995

58. Gallimberti L, SCHIFANO F, Forza G, Cibir M: Drug therapy and multimodal treatment of heroin addiction. In: Addiction Research Foundation of Italy, Monograph no.7, pp. 67-77, 1994
59. SCHIFANO F: Ansiolitici benzodiazepinici (alprazolam, bromazepam, camazepam, clobazam, clorazepato dipotassico, clordiazepossido, clotiazepam, delorazepam, diazepam, estazolam, flunitrazepam, fluorestone, flurazepam, glaziovina, lorazepam, lormetazepam, mebutamato, medazepam, meprobamato, nitrazepam, nordiazepam, oxazepam, pinazepam, prazepam, temazepam, triazolam, valnottamide). In: Casiglia E, Gava R (eds). L'Annuario dei Farmaci. Farmacologia Clinica e Terapia. Piccin Nuova Libreria, Padova (I), pp. 111-129, 1991
60. SCHIFANO F: Anticonvulsivanti (acido valproico, beclamide, bussamina, carbamazepina, clonazepam, difenilidantoina, etosuccimide, mesuccimide, primidone, sultiamme, valpromide). In: Casiglia E, Gava R (eds). L'Annuario dei Farmaci. Farmacologia Clinica e Terapia. Piccin Nuova Libreria, Padova (I), pp. 371-383, 1991
61. SCHIFANO F: Antidepressivi (amineptina, amitriptilina, butriptilina, calcio ossoglutarato, clomipramina, desipramina, dibenzepina, dossepina, dosulepina, idrossitriptofano, imipramina, isocarbossazide, litio, maprotilina, melitracene, mianserina, minaprina, nomifensina, nortriptilina, opipramolo, protriptilina, tollossatone, trazodone, trimipramina, vilossazina). In: Casiglia E, Gava R (eds). L'Annuario dei Farmaci. Farmacologia Clinica e Terapia. Piccin Nuova Libreria, Padova (I), pp. 387-415, 1991
62. SCHIFANO F: Barbiturici (amobarbitale, barbexaclone, butalbitale, butobarbitale, fenobarbitale, pentobarbitale, prossibarbitale, secobarbitale). In: Casiglia E, Gava R (eds). L'Annuario dei Farmaci. Farmacologia Clinica e Terapia. Piccin Nuova Libreria, Padova (I), pp. 751-7, 1991
63. Silvestri A, Cutrone F, Bertin I, SCHIFANO F: Antipsicotici (benperidolo, cloropromazina, lossapina, omofenazina, periciazina, sultopride, trifluperidolo). In: Casiglia E, Gava R (eds). L'Annuario dei Farmaci. Farmacologia Clinica e Terapia. Piccin Nuova Libreria, Padova (I), pp. 1398-1424, 1991
64. SCHIFANO F: Fluoxetina, naltrexone, oxiracetam. In: Casiglia E, Gava R (eds). L'Annuario dei Farmaci. Farmacologia Clinica e Terapia. Piccin Nuova Libreria, Padova (I), pp. 1886-1929, 1991
65. De Leo D, SCHIFANO F: Farmacoterapia dei comportamenti auto-aggressivi. In: De Leo D (ed). Aspetti clinici del comportamento suicidario. Liviana Editrice, Padova (I), pp. 171-6, 1990

66. SCHIFANO F: L'alcolismo. In: Colombo G, Bertin I (eds).  
Psichiatria per operatori sanitari. CLEUP Editore, Padova (I), pp.  
156-67, 1989
67. SCHIFANO F: Le tossicodipendenze. In: Colombo G, Bertin I  
(eds). Psichiatria per operatori sanitari. CLEUP Editore, Padova  
(I), pp.170-80, 1989
68. Magni G, SCHIFANO F, De Leo D, Renesto V, De Dominicis  
MG, Vianello S: Valutazione dei patterns d'uso degli psicofarmaci  
in un Ospedale Geriatrico. In: De Leo D, Magni G (eds). I disturbi  
affettivi nella terza età. Masson Editore, Milano, pp. 107-16, 1987

#### Editorships: Journals

- Future Pharmacology; MDPI journal; Editor-in-Chief (since 2021)
- Frontiers in Psychiatry (2020-onwards)
- Brain Sciences (2018-onwards)
- Current Drug Abuse Reviews (2007-present)
- Minerva Psichiatrica (2020-onwards)
- Open Neuropsychopharmacology Journal (2008-present)
- Clinical & Experimental Gastroenterology (2008-present)
- Journal of Maintenance in the Addictions (1999-present)
- Dipendenze Patologiche (2006-present)
- Giornale Italiano di Suicidologia (1993-1998)

#### Editorships: newsletter

Substance Misuse Bulletin (1998-2002)

#### Editorials

(\*: **peer-reviewed journal**)

1. SCHIFANO F. 2023: the best year ever for Future Pharmacology (and even better years to come). Future Pharmacology, in press (\*)
2. Chiappini S, SCHIFANO F. An update on psychoactive substances: Pharmacology and Toxicology issues. Pharmaceuticals, 2023 Aug 18;16(8):1177. (\*)
3. Pirani F, Chiappini S, SCHIFANO F, Giorgetti A. Misuse and Abuse of Prescription Drugs in Custodial Settings. Frontiers in Psychiatry, in press (\*)
4. Chiappini S, Papanti GD, Vickers-Smith R, Corkery JM, Guriguis A, Martinotti G, SCHIFANO F. Exploring the Nexus of Binge Eating Disorder (BED), New Psychoactive Substances (NPS), and Misuse of Pharmaceuticals: Charting a Path Forward. Expert Opinion on Pharmacotherapy, 2023 Oct 19:1-4. (\*)

5. Munafò A, Arillotta D, Mannaioni G, SCHIFANO F, Bernardini R, Cantarella G. Psilocybin for Depression: From Credibility to Feasibility, What's missing? *Pharmaceuticals*, 2022 Dec 31;16(1):68 (\*)
6. Chiappini S, SCHIFANO F, Martinotti G. Editorial: Prescribing psychotropics: Misuse, abuse, dependence, withdrawal and addiction, Volume II. *Front Psychiatry*. 2022 Oct 18;13:1053896.
7. Chiappini S, SCHIFANO F, Martinotti G. Prescribing Psychotropics: Misuse, Abuse, Dependence, Withdrawal and Addiction. *Frontiers in Psychiatry*, 2021 Apr 30;12:688434 (\*)
8. SCHIFANO F. The New 'Future Pharmacology' Journal: A Cutting-Edge Opportunity for Rapidly Sharing and Widely Disseminating the Most Advanced Research Ideas and Findings. *Future Pharmacology*, 2021, 1(1), 1-2; <https://doi.org/10.3390/futurepharmacol1010001> (\*)
9. Chiappini S, SCHIFANO F, Martinotti G. Prescribing Psychotropics: Misuse, Abuse, Dependence, Withdrawal and Addiction. Editorial. *Frontiers in Psychiatry*, 2021 Apr 30;12:688434. (\*)
10. Chiappini S, SCHIFANO F. What about 'pharming'? Issues regarding the misuse/abuse of prescription and over-the-counter drugs. Editorial. *Brain Sciences*, 2020 Oct 14;10(10):736. doi: 10.3390/brainsci10100736. (\*)
11. SCHIFANO F. Coming off prescribed psychotropic medications: insights from their use as recreational drugs. *Psychotherapy and Psychosomatics*, editorial, 2020;89(5):274-282 (\*)
12. Chiappini S, Guirguis A, John A, Corkery JM, SCHIFANO F. COVID-19: The hidden impact on mental health and drug addiction. *Frontiers in Psychiatry*, opinion article; doi: 10.3389/fpsy.2020.00767
13. SCHIFANO F. Analyzing the open/deep web to better understand the New/Novel Psychoactive Substances (NPS) scenarios; suggestions from CASSANDRA and NPS.Finder® research projects. *Brain Sciences*, editorial, 2020 Mar 4;10(3). pii: E146. (\*)
14. SCHIFANO F. Recent Changes in Drug Abuse Scenarios: The New/Novel Psychoactive Substances (NPS) Phenomenon. *Brain Sciences*, Brain Sciences, editorial, 2018, 8, 221; doi:10.3390/brainsci8120221 (editorial) (\*)
15. SCHIFANO F. Novel psychoactive substances: novel challenges for mental health professionals. *Research Advances in Psychiatry*, editorial, 1: 1-5, 2014 (\*)
16. Rawaf S, SCHIFANO F: The internet, children, young people and substance misuse: coordinated approaches are needed to minimise

the abuse of E-commerce and prevent substance misuse. *Public Health Medicine*, editorial, 2: 96, 2000 (\*)

Journal letters, case reports, notes, etc

(\*: peer-reviewed journal)

1. Miuli A, Marrangone C, Di Marco O, Stigliano G, Mosca A, Pettorruso M, SCHIFANO F, Martinotti G. Could Cariprazine be a possible choice in High Functioning Autism? A case report. *Future Pharmacology*, in press (\*)
2. SCHIFANO F, Chiappini S. Pregabalin: a range of misuse-related unanswered questions. *CNS Neuroscience & Therapeutics*; 2019 May;25(5):659-660 (\*)
3. Moccia L, Tofani A, Mazza M, Covino M, Martinotti G, SCHIFANO F, Janiri L, Di Nicola M. Dorsal Prefrontal Impairment in Methoxetamine-Induced Psychosis: an <sup>18</sup>F-FDG PET/CT Case Study. *J Psychoactive Drugs*. 2019 Feb 9:1-6. doi: 10.1080/02791072.2019.1578444. (\*)
4. Caloro M, Calabrò G, de Pisa E, Rosini E, Kotzalidis GD, Lonati D, Locatelli CA, Papa P, SCHIFANO F, Girardi P. Combined NMDA Inhibitor Use in a Patient With Multisubstance-induced Psychotic Disorder. *J Addict Med*. 2018 Feb 2. doi: 10.1097/ADM.0000000000000390. (\*)
5. Corkery J, SCHIFANO F, Guirguis A. Commentary on: Attafi IM, Albeishy MY, Oraiby ME, Khardali IA, Shaikhain GA, Fageeh MM. Postmortem Distribution of Cathinone and Cathine in Human Biological Specimens in a Case of Death Associated with Khat Chewing. *Arab J Forensic Sci Forensic Med*. 2018 Jun 7;1(7).
6. Simonato P, Laura B, Attilio N, Gurjeet K B, Pessa G, Mioni D, Borgherini G, Martinotti G, SCHIFANO F, Perini G, Corazza O. Marvin, the Paranoid Android": The Case of an Alpha-PVP User in the Expanding Galaxy of NPS. *J Psychoactive Drugs* 2018; 50:306-313; doi: 10.1080/02791072.2018.1447172 (\*)
7. Corkery JM, Orsolini L, Papanti GD, SCHIFANO F. From concept(ion) to life after death/the grave: the 'natural' history and life-cycle(s) of Novel Psychoactive Substances (NPS). *Human Psychopharmacology: Clinical and Experimental*, 2017 May;32 (3). doi: 10.1002/hup.2566 (\*)
8. Dirks H, Esser S, Brockmeyer N, Bonnet U, SCHIFANO F, Scherbaum N. Dramatic changes over time of methamphetamine intake in a German, HIV-positive, sample of men-who-have-sex-with-men (MSM). *Pharmacopsychiatry*, 50: 123-124, 2017 (\*)
9. Caloro M, Calabrò G, Kotzalidis GD, Cuomo I, Corkery JM, Vento AE, Lionetto L, De Filippis S, Ranieri V, Lonati D, Locatelli CA, de Pisa E, Di Tommaso A, Girardi P, SCHIFANO F. Use of benzylglycinamide by a HIV-seropositive polysubstance user: the changing pattern of novel psychoactive substance use among youths, *Addictive Behaviors*, 60:53-7, 2016 (\*)

10. Parrott AC, Corazza O, SCHIFANO F, Griffiths P, Sedefov R, Gallegos A, Murray RM, Demetrovics S, Curran V, Bersani G, Singer LT. Second International Conference on Novel Psychoactive Substances (NPSs): Keynote Addresses and Conference Abstracts; Editorial. *Current Drug Abuse Reviews*, 6: 255-6, 2014. (\*)
11. Vento AE, SCHIFANO F, Gentili F, Pompei F, Corkery JM, Kotzalidis GD, Girardi P. Bupropion perceived as a stimulant by two patients with a previous history of cocaine misuse. *Annals of the Higher Institute of Health (Annali Istituto Superiore di Sanita')*, 49: 402-405, 2013 (\*)
12. SCHIFANO F. Hamid Ghodse (1938-2012). *Addiction*, 2013 Apr 25. doi: 10.1111/add.12197. [Epub ahead of print] (\*)
13. Corazza O, Demetrovics Z, van den Brink W, SCHIFANO F. Reasons for avoiding the term "legal highs" for "novel psychoactive drugs" in drug prevention and scientific debates. *International Journal of Drug Policy*, 24: 82-3; 2013 (\*)
14. Carrus D, SCHIFANO F. Pregabalin misuse related issues; intake of large dosages, drug smoking allegations, and association with myositis: two case reports. *Journal of Clinical Psychopharmacology*, 2012 (\*)
15. Shapiro H, Corazza O, Simonato P, SCHIFANO F. on behalf of the ReDNet Research Project. An introduction to the new phenomenon of Internet-based drugs. *Italian Journal on Addictions*, 1: 66-67, 2011. (\*)
16. Minervini L, Antonielli Romanini F, Solmi M, Passamani A, Sferrazza E, SCHIFANO F. Acute psychotic episode associated with the intake of a testosterone-enhancer herbal mixture purchased online. *Psychotherapy and Psychosomatics*, 2012; 81: 248-249 (DOI: 10.1159/000335042) (\*)
17. Corkery JM, SCHIFANO F, Ghodse AH. UK fatality involving phenazepam. *BMJ rapid responses*; available from: [http://www.bmj.com/content/343/bmj.d4207/reply#bmj\\_el\\_269156](http://www.bmj.com/content/343/bmj.d4207/reply#bmj_el_269156) (electronic letter; not refereed; published August 26<sup>th</sup>, 2011)
18. Specka M, Lieb B, Kuhlmann Th, Frommann N, Wobrock T, SCHIFANO F, Gaebel W, Scherbaum N. Marked reduction of heavy drinking did not reduce nicotine use over 1 year in a clinical sample of alcohol dependent patients. *Pharmacopsychiatry*, 44: 1-2, 2011. (\*)
19. Corkery JM, Button J, Vento A, SCHIFANO F: Two UK suicides using nicotine extracted from tobacco employing instructions available on the Internet. *Forensic Science International* 2010, 199(1-3):e9-13. (\*)
20. Quaglio GL, SCHIFANO F, Lugoboni F. Venlafaxine dependence in a patient with a history of alcohol and amineptine misuse. *Addiction* 2008; 103:1572-4 (\*)

21. Scherbaum N, Bonnet U, SCHIFANO F, Birkemeyer W, Hufnagel A, Schmitz D, Sipal SC, Wiemer P, Wurthmann C. Low hospital admission rates following MDMA (ecstasy) intake in Essen (Germany). *American Journal on Addictions*, 2007; 16:428-9. (\*)
22. Boland B, SCHIFANO F, Drummond C. The relative safety and efficacy of methadone and buprenorphine. *BMJ.com*, 13 January 2006 (<http://bmj.bmjournals.com/cgi/eletters/331/7529/1352>) (electronic letter; not refereed)
23. Arnone D, SCHIFANO F: Can psychedelics have a role in psychiatry once again? *British Journal of Psychiatry*, 188: 88, 2006 (letter) (\*)
24. Kouimtsidis C, SCHIFANO F, Sharp T, Ford L, Robinson J, Magee C. Neurological and psychopathological sequelae associated with a forty-thousand ecstasy tablets lifetime intake. *Psychosomatics*, 47: 86-87, 2006 (case report) (\*)
25. SCHIFANO F, Abou-Saleh M: Take home naloxone: a contribution for the ongoing debate. *BMJ.com*, 27 May 2001 (<http://www.bmj.com/cgi/eletters/322/7291/895>) (electronic letter; not refereed)
26. Vannucchi T, Manfredi A, Vigliotti A, SCHIFANO F, Miconi L, Villani P: Paresthesia during naltrexone treatment: a case-report. *American Journal on the Addictions*, 4:177-8, 1995 (letter) (\*)
27. SCHIFANO F, Miconi L, Gallimberti L: The addictive potential of trimebutine: a case-report. *Annals of Pharmacotherapy*, 28: 537-8, 1994 (letter) (\*)
28. SCHIFANO F, Forza G, Caneva A, Gallimberti L, Ferrara SD: Road casualties in ecstasy consumers: two case reports (Incidenti stradali in consumatori di ecstasy come possibile espressione di aggressività auto- ed etero-diretta: due casi clinici). *Giornale Italiano di Suicidologia*, suppl.1: 141-2, 1993 (letter) (\*)
29. SCHIFANO F: Chronic atypical psychosis associated with MDMA (“ecstasy”) abuse. *The Lancet*, 338: 1335, 1991 (letter) (\*)
30. Baffo N (alias SCHIFANO F): Suicide prevention and the rationale for pharmacological treatment of aggression (Le basi razionali della terapia del comportamento etero-aggressivo come spunto di riflessione sulla prevenzione del suicidio). *Giornale Italiano di Suicidologia*, 1: 47-8, 1991 (letter) (\*)
31. SCHIFANO F: EST and suicide prevention (Elettroshockterapia e prevenzione del comportamento suicidario). *Giornale Italiano di Suicidologia*, 1: 125-6, 1991 (letter) (\*)

32. SCHIFANO F, Magni G: Panic attacks and major depression after discontinuation of long-term diazepam abuse. *Drug Intelligence and Clinical Pharmacy; the Annals of Pharmacotherapy*, 23: 989-90, 1989 (letter) (\*)
33. SCHIFANO F, Marra R: Diazepam tapering down and withdrawal: a case report (Sindrome astinenziale dopo graduale disassuefazione da diazepam). *Giornale di Clinica Medica*, 19: 327-9, 1989 (letter) (\*)
34. SCHIFANO F, Marra R, Magni G: Orphenadrine abuse. *Southern Medical Journal*, 81: 546-7, 1988 (letter) (\*)
35. Magni G, SCHIFANO F, De Leo D: Low utility of Cortisol Suppression Index (CSI) in depressed elderly patients with medical disturbances. *Journal of Clinical Psychiatry*, 47: 5, 1986 (letter) (\*)
36. Magni G, SCHIFANO F, Psychological distress after stroke. *Journal of Neurology, Neurosurgery and Psychiatry*, 47: 567-8, 1984 (letter) (\*)
37. De Leo D, Magni G, SCHIFANO F, Rossi F, Rossetto C: Psychologische faktoren beim Sudeck syndrome. *Deutsche Medizinische Wochenschrift*, 18: 719, 1983 (letter) (\*)
38. Magni G, De Leo D, SCHIFANO F. Cirrhose du foie et depression. *Gastroenterologie Clinique et Biologique*, 7: 551-2, 1983 (letter) (\*)

#### Academic Journal Papers

(Note: **all** the following are either **research or systematic review** papers) (\*: **peer reviewed journal**)

1. Mullin A, Scott M, Vaccaro G, Floresta G, Arillotta D, Catalani V, Corkery JM, Stair JL, SCHIFANO F, Guirguis A. Benzodiazepine Boom: Tracking Etizolam, Pyrazolam and Flubromazepam from Pre-Psychoactive Act 2016 to Present Using Analytical and Social Listening Techniques. *Pharmacy*, in press (\*)
2. Arillotta D. Floresta G, Guirguis A, Corkery JM, Catalani V, Martnotti G, Sensi SL, SCHIFANO F: GLP-1 receptor agonists and related mental health issues; insights from a range of social media platforms using a mixed-methods approach. *Brain Sciences*, 2023 Oct 24;13(11):1503. (\*)
3. Baldini S, Khattak A, Capogrosso P, Antonini G, Dehò F, SCHIFANO F, Schifano N. The possible role of prescribing medications, including central nervous system drugs, in contributing to male-factor infertility (MFI):

- assessment of the Food and Drug Administration (FDA) pharmacovigilance database. *Brain Sciences*, in press (\*)
4. Sharif S, Fergus S, Smeeton N, Guirguis A, SCHIFANO F. Exploring the understanding, source of availability and level of access of cognitive enhancers among university students in the United Arab Emirates: a qualitative study. *Human Psychopharmacology: Clinical and Experimental*, 2023 Nov 30:e2888. (\*)
  5. Holborn T, Page R, SCHIFANO F, Deluca P: Self-medication with Novel psychoactive substances (NPS): A systematic review. *International Journal of Mental Health and Addiction*, 023 Aug;118:104109. (\*)
  6. Scherbaum N, Specka M, Kröckert T, Trilling T, Bonnet U, SCHIFANO F. Opiate Maintenance Patients' Attitudes and Self-Reported Adherence to Protective Measures against SARS-CoV-2 Infections. *Frontiers in Psychiatry* 2023 Sep 14;14:1254053. (\*)
  7. Jones MB, Guirguis A, Watkins A, Bradshaw C, Mohamed L, SCHIFANO F, Guirguis A. Obstacles to Treatment retention in Opioid Use Disorder: An International Substance Use Disorder Treatment Worker Survey. *Human Psychopharmacology: Clinical and Experimental*, 2023 Sep;38(5):e2882. (\*)
  8. Chiappini S, Vickers-Smith R, Harris D, Papanti Pelletier GD, Corkery JM, Guirguis A, Martinotti G, Sensi SL, SCHIFANO F. Is there a risk for Semaglutide Misuse? Focus on the Food and Drug Administration-FDA Adverse Events Reporting System (FAERS) pharmacovigilance dataset. *Pharmaceuticals*, 2023 Jul 11;16(7):994. (\*)
  9. Scherbaum N, Mikoteit T, Witkowski L, Bonnet U, Specka M, SCHIFANO F, Lieb B. New access routes to undertreated populations; how do problem substance users recruited from an unemployment office differ from drug detoxification treatment inpatients? *International Journal of Environmental Research and Public Health*, 2021 Dec 9;18(24):13014. (\*)
  10. Mullin A, Scott M, Vaccaro G, Gittins R, Ferla S, SCHIFANO F, Guirguis A. Handheld Raman Spectroscopy in the first UK Home Office Licensed Pharmacist-Led Community Drug Checking Service. *International Journal of Environmental Research and Public Health*, 2023 Mar 8;20(6):4793. (\*)
  11. Chiappini S, Ceci F, Mosca A, Di Carlo F, Burkauskas J, Pettorruso M, Martinotti G, Guirguis A, Corkery JM, Scherbaum N, SCHIFANO F, Di Giannantonio M. Knowledge and use of over-the-counter drugs in Italy: an exploratory survey-based study in the general population. *Current Neuropharmacology*, 2023;21(1):133-141 (\*).
  12. Corkery JM, Martinotti G, SCHIFANO F. Contribution of drugs to drownings in Scotland, 1996-2020. *Curr Neuropharmacol* 2022 Aug 30. Online ahead of print (\*)

13. Catalani V, Floresta G, Botha M, Corkery JM, Guirguis A, Vento, A, Abbate V, SCHIFANO F. In Silico Studies on Recreational Drugs: 3D-QSAR Prediction of Classified and de Novo Designer Benzodiazepines. *Chemical Biology Drug Design* 2023, 2023 Jan;101(1):40-51. (\*)
14. Chiappini S, Vickers-Smith R, Guirguis A, Corkery JM, Martinotti G, SCHIFANO F. Pharmacovigilance signals of the opioid epidemic over 10 years: an analysis of pharmacovigilance datasets collecting Adverse Drug Reactions (ADRs) reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS). *Pharmaceuticals*, 2022 May 27;15(6):675. (\*)
15. Catalani V, Botha M, Corkery JM, Guirguis A, Vento A, SCHIFANO F. Designer benzodiazepines' activity on opioid receptors: a docking study. *Curr Pharm Des* 2022 May 10. doi: 10.2174/1381612828666220510153319.
16. Corkery JM, Guirguis A, Chiappini S, Martinotti G, SCHIFANO F. Alprazolam-related deaths in the United Kingdom: patterns and associated factors. *Journal of Psychopharmacology*, 2022 Sep;36(9):1020-1035 (\*)
17. Chiappini S, Vickers-Smith R, Guirguis A, Corkery JM, Martinotti, SCHIFANO F. Discontinuation issues with Selective Serotonin Reuptake Inhibitors (SSRIs)? Analysis of both the European EMA and the US FAERS pharmacovigilance databases. *Pharmaceuticals*, 2022 May 1;15(5):565. (\*)
18. Specka M, Kuhlmann T, Bonnet U, Sawazki J, Schaaf L, Kühnhold S, Steinert R, Grigoleit T, Eich H, Zeiske B, Niedersteberg A, Steiner K, Schifano F, Scherbaum N. Novel Synthetic Opioids' (NSO) Use in Opioid Dependents Entering Detoxification Treatment. *Frontiers in Psychiatry*, 2022 Jun 1;13:868346. (\*)
19. Schifano N, Capogrosso P, Boeri L, Fallara G, Chiappini S, Rewhorn M, Cakir OO, Harvey H, Castiglione F, Alnajjar H, Muneer A, Deho' F, SCHIFANO F, Montorsi F, Salonia A. Medications mostly associated with priapism events: assessment of the 2015-2020 Food and Drug Administration (FDA) pharmacovigilance database entries. *International Journal of Impotence Research*, 2022 May 21. doi: 10.1038/s41443-022-00583-3 (\*)
20. Chiappini S, Mosca A, Miuli A, Semeraro F, Mancusi G, Santovito MC, Di Carlo F, Pettorruso M, Guirguis A, Corkery JM, Martinotti G, SCHIFANO F, Di Giannantonio M. Misuse of anticholinergic medications: a systematic review. *Biomedicines*, 2022 Feb 1;10(2):355. (\*)
21. Schifano N, Capogrosso P, Boeri L, Chiappini S, Cakir OO, Rewhorn M, Castiglione F, Alnajjar H, Muneer A,<sup>6,7</sup> Deho' F, SCHIFANO F, Montorsi F, Salonia A. Is finasteride intake associated with penile curvature/Peyronie's disease? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases. *International Journal of Impotence Research*, in press (\*)

22. Sharif S, Guirguis A, Fergus S, Smeeton N, SCHIFANO F. Assessing prevalence, knowledge and use of cognitive enhancers among university students in the United Arab Emirates: a quantitative study. *PLOS ONE*, 17 (1): e0262704, 2022 (\*)
23. Zangani C, Ostinelli EG, Giordano B, D'Agostino A, Martinotti G, Clerici M, Gambini O, SCHIFANO F. Knowledge and use of Novel Psychoactive Substances in Italy: a survey-based study in the general population. *International Journal of Mental Health and Addiction*; <https://doi.org/10.1007/s11469-021-00683-z1> 3, 2021 (\*)
24. Catalani V, Botha MJ, Corkery JM, Guirguis A, Vento A, Scherbaum N, SCHIFANO F. The psychonauts' benzodiazepines; quantitative structure-activity relationship (QSAR) analysis and docking prediction of their biological activity. *Pharmaceuticals*, 2021 Jul 26;14(8):720. (\*)
25. Tirri M, Frisoni P, Bilel S, Arfè R, Trapella C, Fantinati A, Corli G, Marchetti B, De Giorgio F, Camuto C, Mazzarino M, Gaudio RM, Serpelloni G, SCHIFANO F, Botrè F, Marti M. Worsening of the toxic effects of (±)cis-4,4'-DMAR following its co-administration with (±)trans-4,4'-DMAR: neuro-behavioural, physiological, immunohistochemical and metabolic studies in mice. *International Journal of Molecular Sciences*, 22: 8771, 2021 (\*)
26. Schifano N, Capogrosso P, Boeri L, Chiappini S, Pozzi E, Belladelli F, Cakir OO, Reewhorn M, Castiglione F, Alnajjar HM, Muneer A, Deho F, SCHIFANO F, Montorsi F, Salonia A. Medications mostly associated with priapism events: assessment of the 2015-2020 food and drug administration (FDA) pharmacovigilance database entries (PD30-08). *The Journal of Urology*, 206: Issue Supplement 3; e535-e535; 2021. (\*)
27. Schifano N, Capogrosso P, Boeri L, Chiappini S, Pozzi E, Belladelli F, Cakir OO, Reewhorn M, Castiglione F, Alnajjar HM, Muneer A, Deho F, SCHIFANO F, Montorsi F, Salonia A. Drugs associated the most with male-factor infertility: assessment of the 2010-2020 food and drug administration (FDA) pharmacovigilance database (PD29-07). *The Journal of Urology*, 206: Issue Supplement 3; e529-e529, 2021. (\*)
28. Arillotta D, Guirguis A, Corkery JM, Scherbaum N, SCHIFANO F. Covid-19 pandemic impact on substance misuse: a social media listening, mixed method analysis. *Brain Sciences*, 11(7):907, 2021 (\*)
29. Chiappini S, Mosca A, Miuli A, Santovito MC, Orsolini L, Corkery JM, Guirguis A, Pettorruso M, Martinotti G, Di Giannantonio M, SCHIFANO F. New Psychoactive Substances and suicidality: a systematic re-view of the current literature. *Medicina (Kaunas)*. 2021 Jun 6;57(6):580. (\*)
30. Martinotti G, Merino del Villar C, Cordoba AG, Tubau AL, Sánchez IC, Di Carlo F, Chiappini S, Pettorruso M, SCHIFANO F, Di Giannantonio

- M. Club drugs and psychiatric sequelae: an issue of vulnerability and previous psychiatric history. *International Journal of Environmental Research and Public Health* 18(13):6944, 2021. (\*)
31. Catalani V, Corkery JM, Guirguis A, Napoletano F, Arillotta D, Zangani C, Vento A, SCHIFANO F. The psychonauts' psychedelics: a systematic, multilingual, web-crawling exercise. *European Neuropsychopharmacology*, 49: 69-92, 2021 (\*)
  32. Corkery JM, Hung W-C, Claridge H, Goodair C, Copeland C, SCHIFANO F. Recreational ketamine-related deaths notified to the National Programme on Substance Abuse Deaths, England, 1997-2019. *Journal of Psychopharmacology*, 2021 Nov;35(11):1324-1348. (\*)
  33. SCHIFANO F, Chiappini S, Miuli A, Mosca A, Santovito MC, Corkery JM, Guirguis A, Pettorruso M, Di Giannantonio M, Martinotti G. Focus on over-the-counter drugs' misuse; a systematic review on antihistamines, cough medicines and decongestant. *Frontiers in Psychiatry*, 2021 May 7;12:657397 (\*)
  34. Scherbaum NL, Bonnet U, Hafermann H, SCHIFANO F, Bender S, Grigoleit T, Kuhn J, Nyhuis P, Preuss UW, Reymann G, Schneider G, Shibata J, Specka M. Availability of illegal drugs during the COVID-19-pandemic in Western Germany. *Frontiers in Psychiatry*, 2021 Apr 23;12:648273. (\*)
  35. Claus BB, Specka M, McAnally H, Scherbaum N, SCHIFANO F, Bonnet U. Is the urine cannabinoid level measured via a commercial point-of-care semi-quantitative immunoassay a cannabis withdrawal syndrome severity predictor? *Frontiers in Psychiatry*, 2020 Dec 3;11:598150. (\*)
  36. Sharif S, Guirguis A, Fergus S, SCHIFANO F. The use and impact of cognitive enhancers among university students: a systematic review. *Brain Sciences*, 2021 Mar 10;11(3):355. (\*)
  37. SCHIFANO F, Chiappini S, Miuli A, Corkery JM, Scherbaum N, Napoletano F, Arillotta D, Zangani C, Catalani V, Vento A, Pettorruso M, Martinotti G, di Giannantonio M, Guirguis A. New Psychoactive Substances (NPS) and Serotonin Syndrome onset: a Systematic Review. *Experimental Neurology*, Feb 8;339:113638. (\*)
  38. Bonaccorso S, Ricciardi A, Ouabbou S, Theleritis C, Ross-Michealides A, Metastasio A, Stewart N, Mohammed M, SCHIFANO F. Clozapine, neutropenia and Covid-19: should clinicians be concerned? Clozapine, neutropenia and Covid-19: should clinicians be concerned? A 3-month report. *Brain, Behavior, & Immunity – Health*, 2021 May;13:100212. (\*)
  39. Chiappini S, SCHIFANO F, Martinotti G, Strasser C, Bonnet U, Scherbaum N. Opioid painkillers' dependence in a sample of elderly medical inpatients. *Psychogeriatrics*, 2021 Feb 16. doi: 10.1111/psyg.12658 (\*)

40. Catalani V, Arillotta D, Corkery JM, Guirguis A, Vento A, SCHIFANO F. Identifying new/emerging psychoactive substances at the time of COVID-19; a web-based approach. *Frontiers in Psychiatry*, 2021 Feb 9;11:632405. (\*)
41. Chiappini S, Miuli A, Mosca A, Pettorruso M, Guirguis A, Corkery JM, Martinotti G, Di Giannantonio M, SCHIFANO F. The benzydamine experience: a systematic review of benzydamine abuse. *Current Neuropharmacology*, 2021 Oct 18;19(10):1728-1737 (\*)
42. Di Giannantonio M, Negri A, Schiavone S, Vannini C, Pettorruso M, De Giorgio F, Verrastro V, Trabace L, Corbo M, Gottardo R, Camuto C, Mazzarino M, Barra A, De Berardis D, Iglesias Lopez J, Merino Del Villar C, SCHIFANO F, Martinotti G. Prescription drugs misuse in “clubbers” and disco goers in Ibiza. *Frontiers in Psychiatry*, 2020 Dec 15;11:592594.
43. Napoletano F, SCHIFANO F, Corkery JM, Guirguis A, Arillotta D, Zangani C, Vento A. The psychonauts’ world of cognitive enhancers. *Frontiers in Psychiatry*, 2020 Sep 11;11:546796. doi: 10.3389/fpsy.2020.546796 (\*)
44. Scherbaum N, Seiffert F, SCHIFANO F, Specka M, Bonnet U, Bender S. High lifetime, but low current, prevalence of new psychotropic substances (NPS) use in German drug detoxification treatment young inpatients. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 2020 Oct 19:110144. doi: 10.1016/j.pnpbp.2020.110144. (\*)
45. Schifano N, Chiappini S, Castiglione F, Salonia A, SCHIFANO F. Is medicinal ketamine associated with urinary dysfunction issues? Assessment of both the European Medicines Agency (EMA) and the UK Yellow Card Scheme pharmacovigilance database-related reports. *LUTS*, 13: 230-237, 2021 (\*)
46. Chiappini S, SCHIFANO F, Corkery JM, Guirguis A. Beyond the ‘*purple drank*’. study of promethazine abuse according to the European Medicines Agency (EMA) adverse drug reactions (ADR) reports. *Journal of Psychopharmacology*, 2020 Oct 9. doi: 10.1111/luts.12355. (\*)
47. Martinotti G, Negri A, Schiavone S, Vannini C, Montemitro C, Baroni G, Pettorruso M, De Giorgio F, Giorgetti R, Verrastro V, Chillemi L, Garcia E, Castro I, Iglesias Lopez J, Merino Del Villar C, SCHIFANO F, Di Giannantonio M. Club drugs: psychotropic effects and psychopathological characteristics of a sample of inpatients. *Frontiers in Psychiatry*, 2020 Aug 31;11:879. doi: 10.3389/fpsy.2020.00879 (\*)
48. Miuli A, Stigliano G, Lalli A, Coladonato M, D’Angelo L, Esposito F, Cappello C, Pettorruso M, Martinotti G, SCHIFANO F, Di Giannantonio M. “Purple Drank” (Codeine and Promethazine Cough Syrup): A Systematic Review of a Social Phenomenon with Medical Implications, *Journal of Psychoactive Drugs*, 52:453-462, 2020 (\*)

49. Zangani C, SCHIFANO F, Napoletano F, Arillotta D, Gilgar L, Guirguis A, Corkery JM, Gambini O, Vento A. The e-Psychonauts' 'Spiced' World; Assessment of the Synthetic Cannabinoids' Information Available Online. *Current Neuropharmacology*, 18(10):966-1051, 2020 (\*)
50. Guirguis A, Gittins R, SCHIFANO F. Piloting the UK's First Home-Office-licensed Pharmacist-Led Drug Checking Service at a Community Substance Misuse service. *Behavioural Sciences*, 2020 Jul 25;10(8):E121. doi: 10.3390/bs10080121. (\*)
51. Guirguis A, Moosa I, Gittins R, SCHIFANO F. What about drug checking? Systematic review and netnographic analysis of social media. *Current Neuropharmacology*, 18: 906-917, 2020 (\*)
52. Chiappini S, SCHIFANO F, Corkery JM, Guirguis A. Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database. *Brain Sciences*, 2020 Feb 16;10(2). pii: E105. doi: 10.3390/brainsci10020105 (\*)
53. Ramos, C., Guirguis, A., Smeeton, N., Zaman, H., Felice, A-M., Bancroft, S., Gittins, R., Hawksworth, G., Corkery, J.M., SCHIFANO, F. Exploring the baseline knowledge and experience of healthcare professionals in the United Kingdom on Novel Psychoactive Substances. *Brain Sciences*, 2020 Mar 2;10(3). pii: E142. (\*)
54. Arillotta D, SCHIFANO F, Napoletano F, Zangani C, Gilgar L, Guirguis A, Corkery JM, Aguglia E, Vento A. Novel opioids: systematic web crawling within the e-psychonauts' scenario. *Frontiers in Neuroscience-Neuropharmacology*, 2020 Mar 18;14:14 (\*)
55. Orsolini L, Chiappini S, Corkery JM, Guirguis A, Papanti D, SCHIFANO F . The use of new psychoactive substances (NPS) in young people and its association with mental health issues: a systematic review. *Expert Review of Neurotherapeutics*, 2019 Dec;19(12):1253-1264. (\*)
56. Orsolini L, Corkery JM, Chiappini S, Guirguis A, Vento A, De Berardis D, Papanti D, SCHIFANO F. New/Designer Benzodiazepines': an analysis of the literature and psychonauts' trip reports. *Current Neuropharmacology* 2020;18(9):809-837. (\*)
57. Pisarska A, Deluca P, Demetrovics S, Moskalewicz J, and the ReDNet group (Ornella Corazza, Sulaf Assi, Zoe Davey, Pierluigi Simonato, John Corkery, Jacqueline Stair, Suzanne Fergus, Cinzia Pezsolesi, Manuela Pasinetti, Colin Drummond, Urszula Blaszkó, Barbara Mervo', Lucia Di Furia, Magi Farre, Liv Flesland, Harry Shapiro, Holger Siemann, Arvid Skutle, Marta Torrens, Ferran Sambola, Peer van der Kreeft, Norbert Scherbaum, Fabrizio Schifano). Novel psychoactive substances (NPS) – knowledge and experiences of drug users from Hungary, Poland, the UK and the USA. *Neuropsychopharmacologia Hungarica* 2019; 21 (\*)

58. Corkery, J.M., SCHIFANO, F., Martinotti, G. How deaths can help clinicians and policy makers understand the risks of Novel Psychoactive Substances. *British Journal of Clinical Pharmacology*, 2019 Nov 26. doi: 10.1111/bcp.14183 (\*)
59. SCHIFANO F, Orsolini L, Guirguis A, Papanti GD, Chiappini S, Corkery JM. Psychiatry and the psychonauts' psychedelics: a netnographic study. *Research and Advances in Psychiatry*, in press (\*)
60. Vento AE, Kotzalidis GD, Cacciotti M, Papanti GD, Orsolini L, Rapinesi C, Savoia V, Calabrò G, Del Casale A, Piacentino D, Caloro M, Girardi P, SCHIFANO F. Quetiapine abuse fourteen years later: where are we now? A systematic review. *Substance Use and Misuse*, 2020; 55(2):304-313 (\*)
61. SCHIFANO F, Napoletano F, Arillotta D, Zangani C, Gilgar L, Guirguis A, Corkery JM, Vento A. The clinical challenges of synthetic cathinones. *British Journal of Clinical Pharmacology*, 2020 Mar;86(3):410-419. <https://doi.org/10.1111/bcp.14132> (\*)
62. Deligianni E, Daniel OJ, Corkery JM, SCHIFANO F, Lione L. Impact of the UK Psychoactive Substances Act on awareness, use, experiences and knowledge of potential associated health risks of NPS. *British Journal of Clinical Pharmacology* 86: 505-516, 2020 (\*)
63. Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, SCHIFANO F. Cannabidiol (CBD) Use in Psychiatric Disorders; A Systematic Review. *Neurotoxicology*, 2019 Sep;74:282-298. (\*)
64. Corkery JM, Streete P, Claridge H, Goodair C, Papanti GD, Orsolini L, SCHIFANO F, Sikka K, Korber S, Hendricks A. Characteristics of deaths associated with Kratom use. *Journal of Psychopharmacology*, 2019 Sep;33(9):1102-1123. (\*)
65. SCHIFANO F, Napoletano F, Chiappini S, Guirguis A, Corkery JM, Bonaccorso S, Ricciardi A, Scherbaum N, Vento A. New/emerging psychoactive substances and associated psychopathological consequences. *Psychological Medicine*, 2019 Jul 22:1-13. (\*)
66. SCHIFANO F, Chiappini S, Corkery J, Guirguis A. Assessing the 2004-2018 fentanyl misusing issues reported to an international range of adverse reporting systems. *Frontiers in Pharmacology*, 10 (46), 2019 <https://doi.org/10.3389/fphar.2019.00046> (\*)
67. SCHIFANO F, Chiappini S, Corkery JM, and Guirguis A. An insight into Z-drugs abuse and dependence: an examination of reports to the European Medicines Agency (EMA) database of suspected Adverse Drug Reactions (ADR). *International Journal of Neuropsychopharmacology*, 2019 Apr 1;22(4):270-277 (\*)

68. Orsolini L, St John-Smith P, McQueen D, SCHIFANO F. Evolutionary and dual inheritance models of initiation and use of psychoactive substances, including novel psychoactive substances. *Research Advances in Psychiatry*, 5: 63-74, 2018
69. Clerici M, de Bartolomeis A, De Filippis S, Ducci S, Maremmani I, Martinotti G, SCHIFANO F. Patterns of management of patients with dual disorder (psychosis) in Italy: a survey of psychiatrists and other physicians focusing on clinical practice. *Frontiers in Psychiatry, section Addictive Disorders*; *Frontiers in Psychiatry*, 2018 Nov 13;9:575. doi: 10.3389/fpsyt.2018.00575. eCollection 2018. (\*)
70. SCHIFANO F, Chiappini S, Corkery JM, Guirguis A. Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review. *Brain Sciences*, Apr 22;8(4). pii: E73.. (\*)
71. SCHIFANO F, Chiappini S. Is there such a thing as a 'loper' dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports. *PLOS One*, 2018 Oct 4;13(10):e0204443. doi: 10.1371/journal.pone.0204443. eCollection 2018. (\*)
72. SCHIFANO F, Chiappini S. Is There A Potential Of Misuse For Venlafaxine And Bupropion? Analysis of the European Medicines' Agency/EMA Adverse Drug Reactions' Database. *Frontiers in Pharmacology*, 2018 Mar 21; 9:239. doi: 10.3389/fphar.2018.00239 (\*)
73. Bender, Specka M, Buckholz A, Holscher F, Rist F, Heinz TW, SCHIFANO F, Scherbaum N. Joint vs separate inpatient rehabilitation treatment for patients for alcohol or drug use disorder: an observational study. *Substance Abuse and Rehabilitation*, 9: 23-29, 2018 (\*)
74. Milano G, Chiappini S, Mattioli F, Martelli A, SCHIFANO F. beta-2 agonists as misusing drugs? Assessment of both clenbuterol- and salbutamol-related European Medicines Agency (EMA) pharmacovigilance database reports. *Basic & Clinical Pharmacology & Toxicology*, 2018 Aug;123(2):182-187. (\*)
75. Orsolini L, Papanti GD, De Berardis D, Guirguis A, Corkery JM, SCHIFANO F. The 'Endless Trip': Psychopathology and Psychopharmacology in the Hallucinogen Persisting Perception Disorder/HPPD and the NPS. A systematic review. *Frontiers in Psychiatry*, 8:240, 2017 (\*)
76. Corkery JM, Loi B, Claridge H, Goodair C, SCHIFANO F. Deaths in the Lesbian, Gay, Bisexual and Transgender United Kingdom communities associated with GHB and precursors. *Current Drug Metabolism*, 2018;19(13):1086-1099. (\*)
77. Nyhuis PW, Niederhofer E, Scherbaum N, SCHIFANO F, Bonnet U, Dembski N, Niederhofer A, Specka M, Tenbergen M. Effectiveness of Psychoanalytic-Interactional Group Therapy vs. Behavioral Group Therapy in Routine

- Outpatient Treatment of Alcohol-Dependent Patients. Substance Use and Misuse 53: 426-431, 2018 (\*)
78. Chiappini S, SCHIFANO F. Is there a potential of misuse for quetiapine? Literature review and analysis of the European Medicines Agency (EMA) Adverse Drug Reactions' database. Journal of Clinical Psychopharmacology, 38:72-79, 2018 (\*)
79. Mazoruk S, Huxley A, Alexis-Garsee C. Prevalence of somatisation as a determinant of burnout amongst staff working in drug and alcohol services. Drugs and Alcohol Today, Drugs and Alcohol Today, 17: 242-249, 2018 <https://doi.org/10.1108/DAT-05-2017-0018> (\*)
80. Baroni G, Montemitro C, Corbo M, Santacroce R, Pasquini A, Angelini F, Tenuta S, di Taranto C, Lecciso U, De Angelis M, Rondoni A, Catalano G, Carenti ML, Chillemi E, SCHIFANO F, Gordillo MJ, Merino del Villar C, Martinotti G, Di Giannantonio M. Induced psychiatric symptoms: socio-demographic and clinical features of a sample of substance users in Ibiza. Research Advances in Psychiatry, 4: 18-26, 2017 (\*)
81. Deligianni E, Corkery J, SCHIFANO F, Lione, L. An international Survey on the awareness, use, preference and health perception of Novel Psychoactive Substances (NPS). Human Psychopharmacology: Clinical and Experimental, 2017 May;32(3). doi: 10.1002/hup.2581. Epub 2017 May 8. (\*)
82. Corkery JM, Claridge H, Goodair C, SCHIFANO F. An exploratory study of information sources and key findings on UK cocaine-related deaths. Journal of Psychopharmacology, 31: 1996-2014; 2017 (\*)
83. Santacroce R, Ruiz Bennasar C, Sancho Jaraiz JR, Fiori F, Sarchione F, Angelini F, Catalano G, Carenti ML, Corkery JM, SCHIFANO F, Di Giannantonio M, Martinotti G. A matter of life and death: substance-caused and substance-related fatalities in Ibiza in 2015. Human Psychopharmacology: Clinical and Experimental, 2017 May; 32(3). doi: 10.1002/hup.2592. Epub 2017 May 18. (\*)
84. Martinotti G, Cinosi E, Santacroce R, Papanti GD, Pasquini A, Mancini V, Corbo M, Fiori F, Sarchione F, Marchetti D, Verrocchio MC, Di Giannantonio M, Torrens M, SCHIFANO F, Morlan Coarasa MJ, Merino del Villar C. Substance-related psychopathology and aggressiveness in a nightlife holiday resort: results from a pilot study in a psychiatric inpatient unit in Ibiza. Human Psychopharmacology: Clinical and Experimental, 2017 May;32(3). (\*)
85. Simonato P, Bersani FS, Santacroce R, Cinosi E, SCHIFANO F, Bersani G, Martinotti G, Corazza O. Can mobile phone technology support a rapid sharing of information on Novel Psychoactive Substances among health and other professionals internationally? Human Psychopharmacology: Clinical and Experimental, 2017 May; 32(3). (\*)

86. Acciavatti T, Lupi M, Santacroce R, Aguglia A, Attademo L, Bandini L, Ciambrone P, Lisi G, Migliarese G, Pinna F, Quattrone D, Ribolsi M, Signorelli M, Calò S, SCHIFANO F, di Giannantonio M, Martinotti G. Novel psychoactive substances consumption is more represented in bipolar disorder than in psychotic disorders: a multicenter - observational study. *Human Psychopharmacology: Clinical and Experimental* 2017 May;32(3). (\*)
87. Loi B, Zloh M, De Luca MA, Pintori N, Corkery JM, SCHIFANO F. 4,4'-dimethylaminorex ('4,4'-DMAR'; 'Serotoni') misuse; a web-based study. *Human Psychopharmacology Clinical and Experimental*, 2017 May;32(3). (\*)
88. Chiappini S, SCHIFANO F. A decade of gabapentinoid misuse: an analysis of the European Medicines Agency/EMA 'suspected adverse drug reactions' database. *CNS Drugs*, 2016; 30:647-54. (\*)
89. De Luca MA, Castelli MP, Porcu A, Loi B, Martorelli M, Miliano C, Davidson C, Stair J, SCHIFANO F, Di Chiara G. Native CB1 receptor affinity, intrinsic activity, and accumbens shell dopamine stimulant properties of third generation Spice/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135. *Neuropharmacology*, 105:630-8, 2016 (\*)
90. Corazza O, Bersani FS, Brunoro R, Valeriani G, Martinotti G, SCHIFANO F. Performance and Image Enhancing Drugs: the abuse of cognitive enhancer Piracetam. *Substance Use and Misuse*, 49: 1849-1856, 2014 (\*)
91. Guirguis A, Corkery J, Stair J, Kirton S, Zloh, M, Goodair C, SCHIFANO F, Davidson C. Survey of knowledge of legal highs (novel psychoactive substances) amongst London pharmacists. *Drugs and Alcohol Today*, 15: 93-99, 2015 (\*)
92. SCHIFANO F. Novel psychoactive substances (NPS): clinical and pharmacological issues. *Drugs and Alcohol Today*, 15: 21-27, 2015 (\*)
93. Bansal D, Bhaght A, SCHIFANO F, Gudala K. Role of Patient-Reported Outcomes and other efficacy endpoints in the Drug Approval Process in Europe (2008-2012). *Journal of Epidemiology and Global Health*, 5:385-95, 2015; available from: <http://dx.doi.org/10.1016/j.jegh.2015.04.006> (\*)
94. Santacroce R, Martinotti G, Lupi M, Chillemi E, Bonifaci L, SCHIFANO F, Di Giannantonio M. New psychoactive substances: preliminary data on their knowledge and use in a sample of Italian youth. *Research and Advances in Psychiatry*, 2: 33-35, 2015 (\*)
95. Corkery JM, Loi B, Claridge H, Goodair C, Corazza O, Elliott S, SCHIFANO F. Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4 butanediol (1,4-BD; BDO): a literature review with a focus on UK fatalities related to non-medical use. *Neuroscience & Biobehavioral Reviews*, 53: 52-78, 2015 (\*)

96. Orsolini L, Papanti GD, Francesconi G, SCHIFANO F. Mind navigators or chemicals' experimenters? A web-based description of the e-psychonauts. *Cyberpsychology, Behavior, and Social Networking*, 18: 296-300, 2015 (\*)
97. Valeriani G, Corazza O, Bersani FS, Melcore C, Metastasio A, Bersani G, SCHIFANO F. Olanzapine as the ideal 'trip terminator'? Analysis of online reports relating to antipsychotics' use and misuse following the occurrence of novel psychoactive substance-related psychotic symptoms. *Human Psychopharmacology Clinical and Experimental*, 30: 249-54, 2015 (\*)
98. Orsolini L, Papanti GD, Francesconi G, SCHIFANO F. Profiling online recreational/prescription drugs' customers and overview of drug vending virtual marketplaces. *Human Psychopharmacology, Clinical and Experimental*, 30: 302-18, 2015 (\*)
99. Alghannam A, Aslanpour Z, Evans SJ, SCHIFANO F. A systematic review of counterfeit and substandard medicines in field quality surveys. *Integrated Pharmacy Research and Practice*, 1:18, 2014 (\*)
100. Vento A, Martinotti G, Cinosi E, Lupi M, Acciavatti T, Carrus D, Santacroce R, Chillemi E, Bonifaci L, Di Giannantonio M, Corazza O, SCHIFANO F. Substance use in the club scene in Rome; a pilot study. *BioMed Res International*, vol. 2014, Article ID 617546, 5 pages, 2014. doi:10.1155/2014/617546 (\*)
101. Loi B, Claridge H, Goodair C, Corkery J, Chiappini S, SCHIFANO F. Deaths of individuals aged 16-24 in the UK after using mephedrone. *Human Psychopharmacology Clinical and Experimental*, 30: 225-32, 2015 (\*)
102. Chiappini S, Claridge H, Corkery J, Gimeno Clemente C, Goodair C, Loi B, SCHIFANO F. Methoxetamine related fatalities in the UK. *Human Psychopharmacology Clinical and Experimental*, 30: 244-8, 2015 (\*)
103. Corazza O, Martinotti G, Santacroce R, Chillemi E, Di Giannantonio M, Celtek S, SCHIFANO F. Sexual enhancement products for sale online: raising awareness of the psychoactive effects of Yohimbine, Maca, Horny Goat Weed and Ginkgo Biloba. *BioMed Research International*; doi: 10.1155/2014/841798. 2014 (\*)
104. Corazza O, Assi S, Malekianragheb S, Naderii Beni M, Bigdeli I, Aslanpour Z, SCHIFANO F. Monitoring novel psychoactive substances allegedly offered online for sale in Persian and Arabic languages. *International Journal on Drug Policy*, in press (\*)
105. Corazza O, Simonato P, Corkery J, Trincas G, SCHIFANO F. Legal highs": paradisi sicuri e legali? Uno studio sulla diffusione, conoscenza e consapevolezza del rischio delle nuove droghe psicoattive tra gli studenti del Regno Unito. *Rivista di Psichiatria*, 2014; doi: 10.1708/1461.16147.

106. Bansal D, Badhan Y, Gudala K, SCHIFANO F. Ruboxistaurin for the treatment of peripheral diabetic neuropathy; a systematic review of randomized clinical trials. *Diabetes and Metabolism Journal*, 37: 375-84, 2013 (\*)
107. Specka M, Böning A, Kluwig J, SCHIFANO F, Banger M, Lange W, Lax H, Marrziniak B, Schüngel C, Scherbaum N. Can reinforcement-based interventions to reduce drug use successfully be adapted to routine opioid maintenance treatment? *Annali Istituto Superiore Sanita* 49: 358-64, 2013. (\*)
108. Pisarska A., Moskalewicz J., Corazza O., Assi S., Simonato P., Demetrovics Z., Stair J., Fergus S., Pezzolesi C., Pasinetti M., Davey Z., Deluca P., Drummond C., Blaszkowski U., Mervo B., Di Furia L., Farre M., Flesland L., Shapiro H., Siemann H., Skutle A., Torrens M., Sambola F., van der Kreeft P., Scherbaum N., SCHIFANO F. (2013), Nowe substancje psychoaktywne – wiedza i doświadczenia polskiej młodzieży. *Alkoholizm i Narkomania* (in Polish), 26 (3): 275–294. (\*)
109. Pisarska A, Moskalewicz J, Corazza O, Assi s, Simonato P, Corkery J, Demetrovics Z, Stair J, Fergus S, Pezzolesi C, Pasinetti M, Deluca P, Drummond DC, Balszko U, Mervo B, Di Furia L, Farre M, Flesland L, Shapiro H, Siemann H, Skutle A, Torrens M, Sambola F, van der Kreeft P, Scherbaum N, SCHIFANO F. Nowe substancje psychoaktywne- potrzeby informacyjne mlodoziezy I profesjonalistow. *Serwin Informacyjny. Narkomania* (in Polish), 1: 5-9, 2013 (\*)
110. SCHIFANO F, Corazza O, Marchi A, Di Melchiorre G, Sferrazza E, Enea A, Davey Z, Blaszkowski U, Deluca P, Psychonaut Web Mapping e ReDNet research projects. Analysis of online reports on the potential of misuse of benzydamine. *Rivista di Psichiatria*, 48: 182-186, 2013 (\*)
111. Bersani FS, Corazza O, Simonato P, Mylokosta A, Levari E, Lovaste R, SCHIFANO F. Drops of Madness? Recreational misuse of Tropicamide collyrium: early warning alerts from Russia and Italy. *General Hospital Psychiatry*, 2013 May 23. doi:pii: S0163-8343(13)00134-5. 10.1016/j.genhosppsy.2013.04.013. (\*)
112. Bigdeli I, Corazza O, Aslanpour Z, SCHIFANO F. Novel Psychoactive Substances (NPS): a study on Persian Languages. *Iranian Journal of Public Health*, 2013 (\*)
113. Corazza O, Assi, S, Simonato P, Corkery J, Bersani S, Demetrovics Z, Fergus S, Pezzolesi C, Pasinetti M, Deluca P, Drummond C, Blaszkowski U, Moskalewicz J, Mervo' B, Di Furia L, Farre M, Flesland L, Pisarska A, Shapiro H, Siemann H, Skutle A, Sferrazza E, Torrens M, Sambola F, van der Kreeft P, Scherbaum N, SCHIFANO F. Promoting innovation and excellence to face the rapid diffusion of Novel Psychoactive Substances (NPS) in the EU: the outcomes of the ReDNet project. *Human Psychopharmacology Clinical and Experimental*, published online on 25/07/2013 (\*)

114. Bansal D, Kapil G, Kaur M, SCHIFANO F, Bhansali A. Diabetes and risk of dementia: A meta-analysis of prospective observational studies. *Journal of Diabetes Investigation*, doi: 10.1111/jdi.12087, 2013 (\*)
115. Simonato PL, Corazza O, Santonastaso P, Corkery J, Deluca P, Davey Z, Blaszkowski U, SCHIFANO F. Novel psychoactive substances as a novel challenge for health professionals; results from an Italian survey. *Human Psychopharmacology: Clinical and Experimental*, 2013 Jul;28(4):324-31. (\*)
116. Pezzolesi C, Manser T, SCHIFANO F, Kostrzewski A, Pickles J, Nicholls H, Warren I, Dhillon S. Human factors in clinical handover: development and testing of a 'Handover Performance Tool' for doctors' shift handovers. *International Journal for Quality in Health Care*, in press (\*)
117. Davey Z, SCHIFANO F, Corazza O, Deluca P: e-Psychonauts: Conducting research in online drug forum communities. *Journal of Mental Health*; 21: 386-394, 2012
118. Bansal D, Undela K, D'Cruz S, SCHIFANO F. Statin Use and Risk of Prostate Cancer: A Meta-analysis of Observational Studies, *PLoS ONE* 7(10): e46691. doi:10.1371/journal.pone.0046691, 2012 (\*)
119. Deluca P, Davey Z, Corazza O, Di Furia L, Farre M, Flesland L, Mannonen M, Majava A, Peltoniemi T, Pasinetti M, Pezzolesi C, Scherbaum N, Siemann H, Skutle A, Torrens M, Van Der Kreeft P, Iversen E, SCHIFANO F. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. *Progress in Neuro-psychopharmacology and Biological Psychiatry*, 39:221-226, 2012 (\*)
120. Pezzolesi C, Manser T, SCHIFANO F, Kostrzewski A, Pickles J, Nicholls H, Fishman D, Arshad M, Dhillon S. Does clinical handover promote situation awareness? *International Journal of Person Centered Medicine*, in press (\*)
121. Ali M, SCHIFANO F, Robinson P, Phillips G, Doherty L, Melnick P, Laming L, Sinclair A, Dhillon S. Impact of community pharmacy diabetes monitoring and education programme on diabetes management: a randomised controlled study. *Diabetic Medicine*, 29: e326-e333, 2012 (\*)
122. SCHIFANO F, Corkery J, Ghodse AH: Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone; 'meow meow') in the UK. *Journal of Clinical Psychopharmacology*, 32: 710-714, 2012 (\*)
123. Corazza, O., Simonato, P., Corkery, J.M., Trincas, G., SCHIFANO F et al. Legal highs; safe and legal heavens? A study on the diffusion, knowledge and risk awareness of novel psychoactive drugs among students in the UK. *Rivista di Psichiatria*, in press (\*)

124. Corazza O, SCHIFANO F, Simonato PL, Fergus S, Assi S, Stair J, Corkery J, Trincas G, Deluca P, Davey Z, Blaszkó U, Demetrovics Sz, Moskalewicz J, Enea A, di Melchiorre G, Mervo' B, Di Furia L, Farre' M, Flesland L, Pasinetti M, Pezzolesi C, Pisarska A, Shapiro H, Siemann H, Skutle A, Sferrazza E, Torrens M, van der Kreeft P, Zummo D, Scherbaum N. Phenomenon of new drugs on the Internet: the case of the ketamine derivative methoxetamine ("MXE"). *Human Psychopharmacology: Clinical and Experimental*, 27: 145-149, 2012 (\*)
125. Specka M, Bonnet U, Heilmann M, SCHIFANO F, Scherbaum N. Longitudinal patterns of benzodiazepine consumption in a German cohort of methadone maintenance treatment patients. *Human Psychopharmacology Clinical and Experimental*, in press (\*)
126. Corazza O, SCHIFANO F, Farre' M, Deluca P, Davey Z, Torrens M, Demetrovics S, Di Furia L, Fliesland L, Blaszkó U, Siemann H, Skutle A, Van Der Kreeft P, Scherbaum N. Designer Drugs on the Internet: a Phenomenon Out-of-Control? Analysis of anecdotal online reports relating to the hallucinogenic drug Bromo-Dragonfly. *Current Clinical Pharmacology*, 6:125-9; 2011 (\*)
127. SCHIFANO F, Martinotti G, Cunniff A, Reissner V, Scherbaum N, Ghodse AH. Impact of an 18-month, NHS-based, treatment exposure for heroin dependence; results from the London area Treat 2000 study. *American Journal on Addictions*, 21:268-273, 2012. doi: 10.1111/j.1521-0391.2012.00226 (\*)
128. Demetrovics Zs., Mervó B., Corazza O., Davey Z., Deluca P., Drummond C., Enea A., Moskalewicz J., Di Melchiorre G., Di Furia L., Farre M., Flesland L., Floridi L., Iszák F., Scherbaum N., Siemann H., Skutle A., Torrens M., Pasinetti M., Pezzolesi C., Pisarska A., Shapiro H., Sferrazza E., van der Kreeft P., SCHIFANO F. (2010). Az elektronikus prevenció lehetőségei az új (szintetikus) drogok használatának megelőzésében: a Rekreatív Drogok Európai Hálózatának (Recreational Drugs European Network) bemutatása. [Possibilities of E-prevention in the field of novel compounds: Role of Recreational Drugs European Network] *Addictologia Hungarica*, 9(4), 289-297, 2012 (\*)
129. Vento AE, SCHIFANO F, Corkery JM, Pompili M, Innamorati M, Girardi P, Tatarelli R, Ghodse AH. Suicide verdicts as opposed to accidental deaths in substance-related fatalities (UK, 2001-2007). *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 35:1279-83; 2011 (\*)
130. Zamparutti G, SCHIFANO F, Corkery JM, Oyefeso A, Ghodse AH: Deaths of opiate/opioid misusers involving dihydrocodeine, UK, 1997-2007. *British Journal of Clinical Pharmacology*, published online on 14 January 2011 | DOI: 10.1111/j.1365-2125.2011.03908.x (\*)
131. Reissner V, Kokkevi A, SCHIFANO F, Room R, Storbjörk J, Stohler R, Di Furia L, Rehm J, Ghodse AH, Geyer M, Hölscher F, Scherbaum N.

Drug consumption, comorbidity and treatment utilization of drug addicts in six European urban regions (TREAT-project). *European Psychiatry*, 2011 January 28th (Epublication ahead of print) (\*)

132. SCHIFANO F, D'Offizi S, Piccione M, Corazza O, Deluca P, Davey Z, Di Melchiorre G, Di Furia L, Farre' M, Flesland L, Mannonen M, Majava A, Pagani S, Peltoniemi T, Siemann H, Skutle A, Torrens M, Pezzolesi C, van der Kreeft P, Scherbaum N. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. *Psychotherapy and Psychosomatics*, 2011;80:118-122 (DOI: 10.1159/000321079) (\*)
133. Pezzolesi C, SCHIFANO F, Pickles J, Randell W, Hussain, Z, Muir H, Dhillon S. Clinical handover incident reporting in one UK general hospital. *International Journal for Quality in Health Care* 2010; doi: 10.1093/intqhc/mzq048 (\*)
134. Winstock A, Mitcheson L, Deluca P, Davey Z, Corazza O, SCHIFANO F. Mephedrone; new kid for the chop. *Addiction*, 106: 154-161, 2011 (\*)
135. Corkery JM, SCHIFANO F, Oyefeso A, Ghodse AH, Tonia T, Naidoo V, Button J. 'Bundle of fun' or 'bunch of problems'? Case series of khat-related deaths in the UK. *Drugs Education, Prevention and Policy*, 18: 408–425, 2011 (\*)
136. Schmidt MM, Sharma A, SCHIFANO F, Feinmann C. Legal highs on the net; evaluation of UK based websites, products and product information. *Forensic Science International*, 2011; 206:92-97 (\*)
137. SCHIFANO F, Ricciardi A, Corazza O, Deluca P, Davey Z, Rafanelli C, and the a "Psychonaut web mapping" research project. Novel psychoactive drugs on the web; role of the Psychonaut Web Mapping project (Nuove sostanze d'abuso sul Web: il ruolo dello Psychonaut Web Mapping Project). *Rivista di Psichiatria*, 45: 88-93, 2010 (\*)
138. SCHIFANO F, Corkery J, Naidoo V, Oyefeso A, Ghodse AH: Comparison between amphetamine/methylamphetamine and ecstasy (MDMA, MDEA, MDA, 4-MTA) mortality data in the UK (1997-2007). *Neuropsychobiology*, 61:122-130; 2010 (DOI: 10.1159/000279302) (\*)
139. Reissner V, Baune B T, Kokkevi A, SCHIFANO F, Room R, Palm J, Stohler R, Di Furia L, Rehm J, Hölscher F, Schwarzer C, Scherbaum N. Burnout, coping and job satisfaction in service staff treating opioid addicts – from Athens to Zurich. *Stress and Health*, 26: 149-159, 2010 (\*)
140. Corazza O, SCHIFANO F. Ketamine-induced 'near-death experience' states in a sample of 50 misusers. *Substance Use and Misuse*, 45: 916-924, 2010 (\*)

141. Scherbaum N., Specka M., SCHIFANO F, Bombeck J., Marrziniak B. Longitudinal observation of a sample of German drug consumption facility clients. *Substance Use and Misuse*, 45: 176-189, 2010 (\*)
142. SCHIFANO F, Corazza O, Davey Z, Deluca P, Di Furia L, Farre' M, Flesland L, Mannonen M, Pagani S, Peltoniemi T, Pezzolesi C, Scherbaum N, Siemann H, Skutle A, Torrens M, van der Kreeft P: Psychoactive drug or mystical incense? Overview of the online available information on Spice products. *International Journal of Culture and Mental Health*, 2: 137-144, 2009 (\*)
143. Hölscher F, Reissner V, Di Furia L, Room R, SCHIFANO F, Stohler R, Yotsidi V, Scherbaum N. Differences between men and women in the course of opiate dependence: is there a telescoping effect? *Eur Arch Psychiatry Clin Neurosci.* 260: 235-241, 2010 (\*)
144. SCHIFANO F, Corkery J, Oyefeso A, Tonia T, Ghodse AH: Trapped in the 'K-hole'; overview of deaths associated with ketamine misuse in the UK (1993-2006). *Journal of Clinical Psychopharmacology*, 28:114-116, 2008 (\*)
145. SCHIFANO F, Corkery J: Cocaine/crack cocaine consumption, treatment demand, seizures, related offences, prices, average purity levels and deaths in the UK (1990-2004). *Journal of Psychopharmacology*, 22:71-79, 2008 (\*)
146. Deluca P, SCHIFANO F: Searching the Internet for drug related websites; analysis of online available information on ecstasy (MDMA). *American Journal on Addictions*, 16:479-83, 2007 (\*)
147. Janiri L, Martinotti G, Dario T, SCHIFANO F, Bria P. The temperament and character inventory (TCI) personality profile of social and pathological gamblers. *Substance Use and Misuse*, 42:975-84, 2007 (\*)
148. SCHIFANO F, Corkery JM, Cuffolo G: Smokable ('Ice'; 'crystal meth') and non smokable amphetamine-type stimulants; clinical pharmacological and epidemiological issues, with special reference to the UK. *Annali Istituto Superiore di Sanita'*, 43: 110-115, 2007 (\*)
149. Perrella C, Carrus D, Costa E, SCHIFANO F: Quetiapine for the treatment of borderline personality disorder; an open label study. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 31: 158-163, 2007 (2006 Oct 10, Epub ahead of print) (\*)
150. SCHIFANO F, Zamparutti G, Zambello F, Oyefeso A, Deluca P, Balestrieri M, D'Anna L, Ghodse AH. Review of deaths related to analgesic- and cough suppressant-opioids, England and Wales, 1996-2002. *Pharmacopsychiatry*, 39: 185-191, 2006 (\*)

151. SCHIFANO F, Deluca P, Baldacchino A. Online availability of dextropropoxyphene over time (2003-2005) *Cyberpsychology and Behavior*, 9: 404-409, 2006 (\*)
152. Siemann H, Specka M, SCHIFANO F, Deluca P, Scherbaum N. *Salvia divinorum – Präsenz einer neuen Droge im Internet (Salvia divinorum on the web)*. *Das Gesundheitswesen*, 68: 323-327, 2006 (\*)
153. Oyefeso A, SCHIFANO F, Ghodse AH, Cobain K, Dryden R, Corkery J. Fatal injuries while under the influence of psychoactive drugs: A cross-sectional exploratory study in England. *BMC Public Health*, 6: 148, 2006; republication ahead of printing 06 June 2006 (\*)
154. SCHIFANO F, Deluca P, Baldacchino A, Peltoniemi T, Scherbaum N, Torrens M, Farre' M, Flores I, Rossi M, Eastwood D, Guionnet C, Rawaf S, Agosti L, Di Furia L, Brigada R, Majava A, Siemann H, Leoni M, Tomasin A, Rovetto F, Ghodse AH on behalf of the Psychonaut 2002 research group. *Drugs on the web; the Psychonaut 2002 EU project. Progress in Neuropsychopharmacology and Biological Psychiatry*, 30: 640-646, 2006 (\*)
155. SCHIFANO F, Corkery J, Deluca P, Oyefeso A, Ghodse AH. Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994-2003). *Journal of Psychopharmacology*, 20: 456-463, 2006 (\*)
156. SCHIFANO F, Deluca P, Agosti L, Martinotti G, Corkery JM and the Psychonaut 2002 research group: New trends in the cyber and street market of recreational drugs? The case of 2C-T-7 ("Blue Mystic"). *Journal of Psychopharmacology*, 19: 675-679, 2005 (\*)
157. SCHIFANO F, Corkery J, Gilvarry E, Deluca P, Oyefeso A, Ghodse AH. Buprenorphine mortality, seizures and prescription data in the UK (1980-2002). *Human Psychopharmacology: Clinical and Experimental* 20: 343-348, 2005 (\*)
158. Milani RM, Parrott AC, SCHIFANO F, Turner JJD. Pattern of cannabis use in ecstasy polydrug users: moderate cannabis use may compensate for self-rated aggression and somatic symptoms. *Human Psychopharmacology: Clinical and Experimental*, 20: 249-261, 2005 (\*)
159. Littlejohn C, Baldacchino A, SCHIFANO F, Deluca P. Internet pharmacies and online prescription drug sales: a cross-sectional study. *Drugs: Education, Prevention and Policy*, 12: 75-80, 2005 (\*)
160. Cheeta S, SCHIFANO F, Oyefeso A, Webb L, Ghodse AH. The profile of antidepressant related deaths and antidepressant prescriptions in England and Wales (1998-2000). *British Journal of Psychiatry*, 184: 41-47, 2004 (**prize winner for best psychopharmacology paper published in 2004**)

**in the British Journal of Psychiatry. Data from this study have informed the UK NICE depression guidelines).**

161. SCHIFANO F, Oyefeso A, Webb L, Pollard M, Corkery J, Ghodse AH: Review of deaths related to taking ecstasy, England and Wales, 1997-2000. *British Medical Journal*, 326: 80-81, 2003 (\*)
162. SCHIFANO F, Leoni M, Martinotti G, Rawaf S, Rovetto F: Importance of cyberspace for the assessment of the drug abuse market: preliminary results from the Psychonaut 2002 Project. *CyberPsychology and Behavior*, 6: 405-410, 2003 (\*)
163. Webb L, Oyefeso A, SCHIFANO F, Cheeta S, Pollard M, Ghodse AH. Cause and manner of death in drug-related fatality: An analysis of drug-related deaths recorded by coroners in England & Wales in 2000. *Drug and Alcohol Dependence*, 72:67-74, 2003 (\*)
164. Ghodse H, Clancy C, Oyefeso A, Rosinger C, Finkbeiner T, SCHIFANO F, Forza G, Sommer B, Nielson KR, Schodt J. The impact of methadone substitution therapy (MST) on illicit drug use and drug abuse-related quality of life: A European study. *Heroin Addiction and Related Clinical Problems*, 5:5-16, 2003 (\*)
165. SCHIFANO F, Oyefeso A, Corkery J, Cobain K, Jambert-Gray R, Martinotti G, Ghodse AH. Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales, 1996-2002. *Human Psychopharmacology Clinical and Experimental*, 18: 519-524, 2003 (\*)
166. Quaglio GL, Talamini G, Lugoboni F, Lechi A, Venturini L, Accordini A, Bellio G, Bossi C, Cantiero D, Ceravolo R, Cicciu' G, Civitelli P, Corso F, Faccini M, Forza G, Manera R, Manzato E, Mecenero V, Pajusco B, Parolin A, Residori M, Sabbion R, Saccardi C, SCHIFANO F; Smacchia C, Vendramin A, Des Jarlais DC, Mezzelani Paolo. Compliance with hepatitis B vaccination in 1175 heroin users and risk factors associated with lack of vaccine response. *Addiction* 97: 985-992, 2002 (\*)
167. Quaglio GL, Talamini G, Lechi A, Venturini L, Lugoboni F, Arisi F, Baggio E, Balestra V, Barbiero D, Bellio G, Bortolomasi M, Bossi C, Bressan R, Bricolo R, Cantiero D, Capra C, Carraro L, Celeghin F, Ceravolo R, Cicciu' G, Civitelli P, Corso F, Danieli D, Dariol D, Dellantonio E, Didone G, Durano B, Faccini M, Ferrari S, Ferremi D, Forza G, Frezza M, Ghirardello G, Giacomini MA, Giusto R, Guidoboni F, Levarda E, Lo Russo A, Lovaste R, Mantovani G, Manzato E, Mazzo M, Mecenero V, Nardi PG, Padovani A, Pani A, Parolin A, Pili P, Polli S, Residori M, Rovea A, Sabbion R, Saccardi C, Satori L, Scaggiante M, Scandolari A, SCHIFANO F, Smacchia C, Sonnerer K, Spilimbergo I, Stimolo C, Tito P, Vasi V, Vendramin A, Viviani F, Von Solder M, Zuin F, Mezzelani P. Study of 2708 heroin-related deaths in north-eastern Italy 1985-98 to establish the main causes of death. *Addiction* 96: 1127-1137, 2001 (\*)

168. Dughiero G, SCHIFANO F, Forza G. Personality dimensions and psychopathological profiles of ecstasy users. *Human Psychopharmacology Clinical and Experimental*, 16: 635-639, 2001 (\*)
169. SCHIFANO F: Potential human neurotoxicity of MDMA (ecstasy): subjective self-reports, evidence from an Italian drug addiction centre and clinical case studies. *Neuropsychobiology*, 42: 25-33, 2000 (\*)
170. Maroli A, Forza G, SCHIFANO F: Psychoactive drugs' use and sexual behaviour: a survey (Indagine conoscitiva su uso di sostanze psicoattive e sessualita'). *Drug and Alcohol Bulletin (Bollettino per le Farmacodipendenze e l'Alcolismo)*, 4: 1-15, 2000 (\*)
171. SCHIFANO F, Di Furia L, Forza G, Minicuci N, Bricolo R: MDMA ("ecstasy") consumption in the context of poly-drug abuse: A report on 150 patients. *Drug and Alcohol Dependence*, 52: 85-90, 1998 (\*)
172. Lecrubier Y, Bourin M, Moon CAL, SCHIFANO F, Blanchard C, Danjou PH, Hackett D: Efficacy of venlafaxine in depressive illness in general practice. *Acta Psychiatrica Scandinavica*, 95: 485-93, 1997 (\*)
173. Santi M, Borselli D, Bertolotti S, Giaccherini S, Mingione E, SCHIFANO F: Ecstasy use and youths' risk perception (Giovani ed ecstasy; quale percezione del rischio?). *Drug and Alcohol Bulletin (Bollettino per le Farmacodipendenze e l'Alcolismo)*, 20: 39-43, 1997 (\*)
174. SCHIFANO F, Berto D, Bricolo R: Validation of a semi-structured interview for entactogens' misuse assessment (Proposta di un'intervista semistrutturata per la rilevazione dell'uso di entactogeni). *Drug and Alcohol Bulletin (Bollettino per le Farmacodipendenze e l'Alcolismo)*, 20: 44-7, 1997 (\*)
175. Miconi L, SCHIFANO F, Snenghi R, Benciolini P, Bricolo R: Naloxone take-away dosages for opiate overdose prevention: an open trial (Sperimentazione del naloxone come prevenzione dei decessi da overdose). *Drug and Alcohol Bulletin (Bollettino per le Farmacodipendenze e l'Alcolismo)*, 19: 100-1, 1996 (\*)
176. SCHIFANO F: Dangerous driving and MDMA ("ecstasy") abuse. *Journal of Serotonin Research*, 1: 53-7, 1995 (\*)
177. Vettorello C, SCHIFANO F, Forza G, Montemurro R, Zuin F, Curtrone F, Colombo G, De Leo D: Contribution to Italian

adaptation of the Suicide Probability Scale (SPS). (Contributo alla taratura della Suicide Probability Scale). *Giornale Italiano di Suicidologia*, 5: 85-101, 1995 (\*)

178. Bricolo R, Berto D, SCHIFANO F: New drugs and new clients? Primary substances of misuse reported by an Addiction Treatment Unit new referrals; 1992-1995 (Nuove droghe, nuovi utenti? Una rilevazione delle sostanze d'abuso utilizzate dai primi ingressi di un Sert; 1992-1995). *Drug and Alcohol Bulletin (Bollettino per le Farmacodipendenze e l'Alcolismo)*, 18: 89-91, 1995 (\*)
179. SCHIFANO F, Curran HV: Pharmacological models of memory dysfunctions? A comparison of the effects of scopolamine and lorazepam on word valence ratings, priming and recall. *Psychopharmacology*, 115:430-4, 1994 (\*)
180. SCHIFANO F, Forza G, Gallimberti L, Ferrara SD: Smoking habit and psychological distress in student adolescent females. *American Journal on the Addictions*, 3:100-5, 1994 (\*)
181. SCHIFANO F, Magni G: MDMA ("ecstasy") abuse: psychopathological features and chocolate craving: a case series. *Biological Psychiatry*, 36: 763-7, 1994 (\*)
182. Gallimberti L, SCHIFANO F, Forza G, Miconi L, Ferrara SD: Clinical efficacy of gamma-hydroxybutyric acid in treatment of opiate withdrawal. *European Archives of Psychiatry and Clinical Neuroscience*, 244: 113-4, 1994 (\*)
183. Curran HV, SCHIFANO F, Lader MH: Models of memory dysfunctions? A comparison of the effects of lorazepam and scopolamine on memory, psychomotor performance and mood. *Psychopharmacology*, 10: 83-90, 1991 (\*)
184. SCHIFANO F, Di Costanzo E: Excessive use of anticholinergic drugs in a sub-sample of Italian schizophrenics. *International Journal of Clinical Pharmacology, Therapy and Toxicology*, 29:184-6, 1991 (\*)
185. Di Costanzo E, SCHIFANO F: Lithium alone or in combination with carbamazepine for the treatment of rapid-cycling bipolar affective disorder. *Acta Psychiatrica Scandinavica*, 83: 456-9, 1991 (\*)
186. SCHIFANO F, Di Costanzo E: Rapid cycling bipolar affective disorder and lithium/carbamazepine combination (Il trattamento del disturbo affettivo a cicli rapidi con l'associazione litio-carbamazepina). *Rivista di Psichiatria*, 26: 297-300, 1991 (\*)

187. Marra R, SCHIFANO F, Rinaldo E: Alcohol misuse biological markers, vitamin B12 and folate levels in a DSM-III-R diagnosed population (Relazione tra markers biologici di consumo alcolico e dosaggi sierici di vit. B12 e folati in una popolazione di alcolodipendenti diagnosticati secondo il DSM-III-R). *Giornale di Clinica Medica*, 9: 29-30, 1991 (\*)
188. SCHIFANO F, Garbin A, Renesto V, De Dominicis MG, Trinciarelli G, Silvestri A, Magni G: A double-blind comparison of mianserin and maprotiline in depressed medically ill elderly people. *Acta Psychiatrica Scandinavica*, 81: 289-94, 1990 (\*)
189. SCHIFANO F, Marra R: Naltrexone for heroin addiction: encouraging results from Italy. *International Journal of Clinical Pharmacology, Therapy and Toxicology*, 28: 144-6, 1990 (\*)
190. Marra R, SCHIFANO F, Rinaldo E, Favaro W, Gavioli A: OKT4/OKT8 ratio in asymptomatic heroin addicts. *British Journal of Addiction*, 84: 815-6, 1989 (\*)
191. Marra R, SCHIFANO F, Rinaldo E: Prevalence of HIV infection and changes in CD4/CD8 ratio in asymptomatic heroin addicts. *Giornale di Clinica Medica*, 70: 105-7, 1989 (\*)
192. De Leo D, SCHIFANO F, Magni G: Results of Dexamethasone Suppression Test in early Alzheimer dementia. *European Archives of Psychiatry and Neurological Sciences*, 238: 19-21, 1988 (\*)
193. Magni G, SCHIFANO F, Baiocchi A, Renesto V: Longitudinal evaluation of psychological distress in medical geriatric inpatients. *British Journal of Medical Psychology*, 61: 369-75, 1988 (\*)
194. Magni G, SCHIFANO F, De Dominicis MG, Belloni L: Psychological distress in geriatric and adult medical inpatients. *Archives of Gerontology and Geriatrics*, 7: 151-61. 1988 (\*)
195. Magni G, SCHIFANO F, Renesto V: Identification et appreciation de la souffrance psychologique chez l'agee hospitalisee. *Revue de Epidemiologie et de Santé Publique*, 36: 457-63, 1988 (\*)
196. Magni G, SCHIFANO F, De Leo D, Zangaglia O: Dexamethasone suppression test in dementia. *Italian Journal of Neurological Sciences*, 8: 125-8, 1987 (\*)
197. Magni G, SCHIFANO F, Pastorello M, De Leo D, De Dominicis MG: The use of psychotropic drugs with general geriatric inpatients: Its relation to various parameters of psychological symptoms: Blind assessment. (L'uso dei

farmaci psicotropi nel paziente geriatrico internistico ospedalizzato: sua relazione con vari parametri di sofferenza psicologica (valutati “in cieco”). Rivista Sperimentale di Freniatria, 11 (suppl 2): 476-87, 1987 (\*)

198. Magni G, SCHIFANO F, De Dominicis MG, Renesto V, Garbin A: Syndrome depressif chez les sujets ages hospitalises dans un Service de Medecine Interne. Annales de Medecine Interne, 137: 167-8, 1986 (\*)
199. Magni G, SCHIFANO F, De Leo D, De Dominicis MG, Garbin A, Zangaglia O: The dexamethasone suppression test in depressed and non-depressed geriatric medical inpatients. Acta Psychiatrica Scandinavica, 73: 511-4, 1986 (\*)
200. Magni G, SCHIFANO F, De Leo D: Assessment of depression in an elderly medical population. Journal of Affective Disorders, 11: 121-4, 1986 (\*)
201. Magni G, SCHIFANO F, De Leo D, De Dominicis MG: Depression in elderly inpatients. Annals of Clinical Research, 18: 216, 1986 (\*)
202. Magni G, SCHIFANO F, Pastorello M, De Leo D, De Dominicis MG: The use of psychotropic drugs in general medical geriatric inpatients: its relationship with various parameters of psychological distress. Neuropsychobiology, 16: 181-5, 1986 (\*)
203. Magni G, De Leo D, SCHIFANO F: Depression in geriatric and adult medical inpatients. Journal of Clinical Psychology, 41: 337-44, 1985 (\*)
204. Magni G, SCHIFANO F, De Leo D, De Dominicis MG, Renesto V, Vianello S: Evaluation of use patterns of psychotropic drugs in an Italian geriatric hospital. Neuropsychobiology, 13: 38-43, 1985 (\*)
205. Magni G, SCHIFANO F, De Leo D: Pain as a symptom in elderly depressed patients. European Archives of Psychiatry and Neurological Sciences, 235: 143-5, 1985 (\*)
206. Magni G, De Leo D, SCHIFANO F, De Dominicis MG, Pastorello M: Psychological distress among medical inpatients. Comparison between geriatric patients and adults using the SCL-90. Minerva Psichiatrica, 25: 227-32, 1984 (\*)

#### Review Articles

(\*: peer reviewed journal)

1. Schifano N, Chiappini S, Mosca A, Miuli A, Santovito MC, Pettoroso M, Capogrosso P, Dehó F, Martinotti G, SCHIFANO F. Recreational drug misuse

- and its potential contribution to male fertility levels' decline: a narrative review. *Brain Sciences*, 2022 Nov 19;12(11):1582. (\*)
2. SCHIFANO F, Vento A, Scherbaum N, Guirguis A. Stimulant and hallucinogenic novel psychoactive substances; an update. *Expert Review Clinical Pharmacology*, 2023 Jul-Dec;16(11):1109-1123. (\*)
  3. Corkery JM, SCHIFANO F. First death involving 4-Fluoroethylphenidate (4F-EPH): case-report, user experiences, and review of the related literature. *Academic Forensic Pathology*, 2022 Dec;12(4):149-166. (\*)
  4. SCHIFANO F, Catalani V, Sharif S, Napoletano F, Corkery JM, Arillotta D, Fergus S, Vento A, Guirguis A. Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals. *Drugs*, 2022 Apr 27. doi: 10.1007/s40265-022-01716-0. (\*)
  5. SCHIFANO F, Chiappini S, Corkery JM, Scherbaum N, Guirguis A. The e-psychonaut drugs' psychopharmacology. *Current Opinion in Pharmacology* 2021, 57:165–174 (\*)
  6. Kotzalidis GD, Vento A, de Persis S, De Filippis S, SCHIFANO F, Napoletano F, Corkery JM. Treatment of kratom use disorder with a classical tricyclic antidepressant: A case report and review. *Frontiers in Psychiatry*, 2021 Mar 31;12:640218 (\*)
  7. Chiappini S, Guirguis A, Corkery JM, SCHIFANO F. Misuse of prescription & over-the-counter drugs to obtain illicit highs: how pharmacists can prevent abuse. *The Pharmaceutical Journal*, 2020; doi: 10.1211/PJ.2020.20208538; **top paper of the year 2020 for the Journal**
  8. Martinotti G, De Risio L, Vannini C, SCHIFANO F, Pettoruso M, Di Giannantonio M. Substance Related Exogenous Psychosis: A Post-Modern Syndrome *CNS Spectr.* 2020 Jun 25;1-20. (\*)
  9. SCHIFANO F, Napoletano F, Chiappini S, Orsolini L, Guirguis A, Corkery JM, Bonaccorso S, Ricciardi A, Scherbaum N, Vento A. New psychoactive substances (NPS), psychedelic experiences, and dissociation; clinical and clinical pharmacological issues. *Current Addiction Reports*; 2019; Vol. 6, No. 2, p. 140-152. (\*)
  10. Mullen C, Whalley BJ, SCHIFANO F, Baker J. Anabolic Androgenic Steroid Abuse in the United Kingdom; An Update. *British Journal of Pharmacology*, 2020;177(10):2180-2198. (\*)
  11. Orsolini L, Chiappini S, Papanti GD, De Berardis D, Corkery JM, SCHIFANO F. The bridge between classical and 'synthetic'/chemical psychoses: towards a clinical, psychopathological and therapeutic perspective. *Frontiers in Psychiatry* 2019 Nov 20;10:851. (\*)

12. Bonaccorso S, Metastasio A, Ricciardi A, Stewart N, Jamal L, Rujully N, Theleritis C, Ferracuti S, Ducci G, SCHIFANO F. Synthetic cannabinoid use in a case series of patients with psychosis presenting to acute psychiatric settings: clinical presentation and management issues. *Brain Sciences*, 2018 Jul 14;8(7). pii: E133. doi: 10.3390/brainsci8070133 (\*)
13. SCHIFANO F, Orsolini L, Papanti GD, Corkery J. Post-traumatic stress and substance misuse; neurobiological and clinical pharmacological correlates. *Research Advances in Psychiatry*, in press (\*)
14. Graziano S, Orsolini L, Rotolo MC, Tittarelli R, SCHIFANO F, Pichini S. Herbal highs: review on psychoactive effects and neuropharmacology. *Current Neuropharmacology*, 2017; 15(5):750-761. doi: 10.2174/1570159X14666161031144427 (\*)
15. Gittins R, Guirguis A, SCHIFANO F, Maidment I. Exploration of the use of new psychoactive substances by individuals in treatment for substance misuse in the UK. *Brain Sciences*, 2018, Mar 30;8(4). pii: E58. (\*)
16. Orsolini L, Ciccarese M, Papanti GD, De Berardis D, Guirguis A, Corkery JM, SCHIFANO F. Psychedelic fauna for psychonaut hunters: a mini-review. *Frontiers in Psychiatry*; 2018 May 22;9:153. doi: 10.3389/fpsy.2018.00153. (\*)
17. Gudala K, Bansal D, Vatte R, Ghai B, SCHIFANO F, Boya C. High Prevalence of Neuropathic Pain Component in Patients with Low Back Pain: Evidence from Meta-Analysis. *Pain Physician* 2017; 20: 343-352
18. De Luca MA, Di Chiara G, Cadoni C, Orsolini L, Papanti D, Corkery J, SCHIFANO F. Cannabis; epidemiological, neurobiological and psychopathological issues: an update. *CNS & Neurological Disorders-Drug Targets*, 2017;16(5):598-609. doi: 10.2174/1871527316666170413113246. (\*)
19. Orsolini L, Papanti D, Corkery J, De Luca MA, Cadoni C, Di Chiara G, SCHIFANO F. Is there a teratogenicity risk associated with cannabis and synthetic cannabimimetics' ('Spice') intake? *CNS & Neurological Disorders-Drug Targets*, 2017;16(5):585-591. (\*)
20. SCHIFANO F, Guarino V, Papanti GD, Baccarin J, Orsolini L, Corkery JM. Is there a potential of misuse for *Magnolia officinalis* compounds/metabolites? *Human Psychopharmacology: Clinical and Experimental*, 2017 May;32(3). doi: 10.1002/hup.2595. Epub 2017 May 18. (\*)
21. Guirguis A, Corkery J, Stair J, Kirton S, Zloh M, SCHIFANO F. Intended and unintended use of cathinone mixtures. *Human Psychopharmacology: Clinical and Experimental*, 2017; 32(3). (\*)

22. Scherbaum N, SCHIFANO F, Bonnet U. New Psychoactive Substances (NPS); a Challenge for the Addiction Treatment Services. *Pharmacopsychiatry*, 2017 May;50(3):116-122. (\*)
23. Orsolini L, Papanti GD, Corkery JM, SCHIFANO F. The deep web; why it matters for addiction psychiatry. *Human Psychopharmacology: Clinical and Experimental*, 2017 May;32(3). doi: 10.1002/hup.2573 (\*)
24. Giorgetti R, Tagliabracci A, SCHIFANO F, Zaami S, Marinelli E, Busardò FP. When "chems" meet sex: a rising phenomenon called "ChemSex". *Current Neuropharmacology* 2017;15(5):762-770.
25. SCHIFANO F, Papanti GD, Orsolini L, Corkery JM. Novel Psychoactive Substances: the pharmacology of stimulants and hallucinogens. *Expert Review in Clinical Pharmacology* 4:1-12; 2016  
<http://dx.doi.org/10.1586/17512433.2016.1167597> (\*)
26. SCHIFANO F, Papanti GD, Orsolini L, Corkery JM. The consequences of drug misuse on post-marketing surveillance. *Expert Review Clinical Pharmacology*; editorial; 2016; 9:867-71. (\*)
27. Orsolini L, St John-Smith P, McQueen D, Papanti D, Corkery JM, SCHIFANO F. Evolutionary considerations on the emerging of the new subculture of the e-psychonauts and novel psychoactive substances: a comeback to the shamanism? *Current Neuropharmacology*, 2017;15(5):731-737. doi: 10.2174/1570159X15666161111114838 (\*)
28. Orsolini L, Vecchiotti R, Papanti D, Valchera A, Corkery J, SCHIFANO F. Gli psiconauti: navigatori della mente o sperimentatori chimici? *Medicina delle Dipendenze*, 22: 15-21, 2016 (\*)
29. SCHIFANO F, Orsolini L, Papanti GD, Corkery JM. Le nuove sostanze psicoattive: problematiche cliniche e farmacologiche. *Medicina delle Dipendenze*, 15: 2016 (\*)
30. Davidson C, SCHIFANO F: The potential utility of some legal highs in CNS disorders. *Progress in Neuropsychopharmacology and Biological Psychiatry*, 2016 Jan 4;64:267-74. (\*)
31. Martinotti G, Di Nicola M, Quattrone D, Santacroce R, SCHIFANO F, Murray R, Di Giannantonio M. Novel psychoactive substances and induced phenomena in psychopathology: the lysergic psychoma. *Journal of Psychopathology* 2015; 21:400-405
32. Umaru N, SCHIFANO F, Pezzolesi C, Aldhwaihi K. A systematic review of the nature of dispensing errors in hospital pharmacies. *Integrated Pharmacy Research and Practice Journal*; 5:1-10, 2016 (\*)
33. SCHIFANO F, Orsolini L, Papanti D, Corkery J. Novel psychoactive substances of interest for psychiatry. *World Psychiatry*, 14:15–26, 2015 (\*)

34. Francesconi G, Orsolini L, Papanti GD, Corkery JM, SCHIFANO F. Venlafaxine as the 'baby ecstasy'? Literature overview and analysis of web-based misusers' experiences. *Human Psychopharmacology: Clinical and Experimental*, 30: 255-61, 2015 (\*)
35. Giorgetti R, Marcotulli D, Tagliabracci A, SCHIFANO F. Effects of ketamine on psychomotor, sensory and cognitive functions relevant for driving ability. *Forensic Science International*, 252: 127-142, 2015 (\*)
36. Papaseit E, Farré M, SCHIFANO F, Torrens M. Emerging drugs in Europe. *Current Opinion in Psychiatry*, 27:243-250. 2014 (\*)
37. Orsolini L, Papanti GD, Baccarin J, SCHIFANO F. Legalizzazione della cannabis; cosa suggerisce la scienza? *Medicina dell Dipendenze*, 15: 23-37, 2014 (\*)
38. Corazza O, Valeriani G, Bersani S, Corkery J, Martinotti G, Bersani G, SCHIFANO F. 'Spice', 'Kryptonite', 'Black Mamba': An Overview of Brand Names and Marketing Strategies of Novel Psychoactive Substances on the Web. *Journal of Psychoactive Drugs*, 46: 287-294, 2014 (\*)
39. Siemann H, Scherbaum N, SCHIFANO F. Neuen Drogen/Legal Highs. *Fortschritte der Neurologie und Psychiatrie*, in press (\*)
40. Bersani FS, Corazza O, Albano G, Bruschi S, Minichino A, Vicinanza R, Bersani G, Martinotti G, SCHIFANO F. The "Eyeballing" Technique: an emerging and alerting trend of alcohol misuse. *European Review for Medical and Pharmacological Sciences*, 19: 2311-7, 2015 (\*)
41. Bersani FS, Corazza O, Albano G, Valeriani G, Santacroce R, Cinosi E, Simonato P, Martinotti G, Bersani G, SCHIFANO F, Bolzan F. 25C-NBOMe: preliminary data on pharmacology, psychoactive effects and toxicity of a new potent and dangerous hallucinogenic drug. *BioMed Research International*, Volume 2014, Article ID 734749, 6 pages; <http://dx.doi.org/10.1155/2014/734749> (\*)
42. Papanti GD, Orsolini L, Francesconi G, Schifano F. 'noids; what you (don't) want to know about synthetic cannabinoids. *Advances in Dual Diagnosis*, 7: 1-13, 2014 (\*)
43. SCHIFANO F. Misuse and Abuse of Pregabalin and Gabapentin: Cause for Concern? *CNS Drugs*, published online April 24<sup>th</sup>, 2014; DOI 10.1007/s40263-014-0164-4 (\*)
44. Papanti D, SCHIFANO F, Bonavigo T, Botteon G, Bertossi F, Mannix J, Impagnatiello M, Pascolo-Fabrici E. 'Spicephrenia': a systematic overview of 'Spice'-related psychopathological issues and a case report. *Human Psychopharmacology: Clinical and Experimental*, published online on 25/07/2013 (\*)

45. Jebadurai J, Deluca P, SCHIFANO F. Recreational use of NRG-1; NRG-2; and Benzofury, with review of the available evidence-based literature. *Human Psychopharmacology: Clinical and Experimental*, published online on 25/07/2013 (\*)
46. St John-Smith P, McQueen D, Edwards L, SCHIFANO F. Classical and Novel Psychoactive Substances: Rethinking Drug Misuse from an Evolutionary Psychiatric Perspective. *Human Psychopharmacology: Clinical and Experimental*, published online on 25/07/2013 (\*)
47. Corkery JM, Elliott S, SCHIFANO F, Ghodse AH. MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine; ‘sparkle’; ‘mindy’) toxicity: a brief overview and update. *Human Psychopharmacology: Clinical and Experimental*, 2013 Jul;28(4):345-55. (\*)
48. Corazza O, Assi S, SCHIFANO F: From "Special K" to "Special M"; The Evolution of the Recreational Abuse of Ketamine and Methoxetamine. *CNS Neurosciences and Therapeutics*, Jun;19(6):454-60. (\*)
49. Simonato PL, Corazza O, SCHIFANO F, on behalf of the ReDNet project Rapporto sulla Prima Conferenza Internazionale sulle Nuove Sostanze Psicoattive (Report on the 1st Conference on Novel Psychoactive Substances/NPS): “The Ever-Changing World of Psychoactive Drugs”, Budapest, 12 – 13 March 2012. *Italian Journal of Addictions*, 2: 43-48, 2012 (\*)
50. SCHIFANO F, Di Melchiorre G, Rossi A. Innovation, education and treatment of drug abuse with dual diagnosis (INNUENDO). *Italian Journal of Psychopathology*, 18: 1-3, 2012 (\*)
51. Corkery JM, Durkin EM, Elliott S, SCHIFANO F, Ghodse AH. The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine): a brief review. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 39:253-262, 2012; doi: 10.1016/j.pnpbp.2012.05.022 (\*)
52. Corkery JM, Elliott S, SCHIFANO F, Corazza O, Ghodse AH. 2-DPMP (Desoxypipradrol, 2-Benzhydrylpiperidine, 2-Phenylmethylpiperidine) and D2PM (Diphenyl-2-pyrrolidin-2-yl-methanol, Diphenylprolinol): a preliminary review *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 39: 253–258, 2012; doi: 10.1016/j.pnpbp.2012.05.021 (\*)
53. Gallagher CT, Assi S, Stair J, Fergus S, Corazza O, Corkery J, SCHIFANO F. 5,6-Methylenedioxy-2-aminoindane (MDAI): from laboratory curiosity to “legal high”. *Human Psychopharmacology: Clinical and Experimental*, 27: 106-112, 2012 (\*)
54. Corkery J, SCHIFANO F, Ghodse AH. Phenazepam abuse in the UK: an emerging problem causing serious adverse health problems, including death.

Human Psychopharmacology: Clinical and Experimental, 27:254261, 2012 (\*)

55. Corazza O, Assi S, Corkery J, Trincas G, Simonato PL, Deluca P, Davey Z, Demetrovics Z, Moskalewicz J, Enea A, di Melchiorre G, Mervo' B, Fergus S, di Furia L, Farre' M, Flesland L, Pasinetti M, Pesaresi L, Pezzolesi C, Pisarska A, Scherbaum N, Shapiro H, Siemann H, Skutle A, Stair J, Sferrazza E, Torrens M, van der Kreeft P, Zummo D, SCHIFANO F. Novel Drugs, Novel Solutions: Exploring the potential of technological tools for prevention of drug abuse. *Italian Journal of Addictions*, 1: 25-30, 2011 (\*)
56. SCHIFANO F, Serpelloni G, Bosco O, Bertoncelli S: Aspetti farmacologici e clinici dei vari prodotti a base di cocaina: scheda tecnica riassuntiva (Clinical and pharmacological issues relating to the different cocaine- containing products; a synopsis). *Italian Journal of Addictions*, 1: 60-63, 2011 (\*)
57. Assi S, Fergus S, Stair J, Corazza O, SCHIFANO F. Emergence and identification of new designer drug products from the Internet. *European Pharmaceutical Review*, 16:68-72, 2011 (\*)
58. SCHIFANO F, Albanese A, Fergus S, Stair JL, Deluca P, Corazza O, Davey Z, Corkery J, Siemann H, Scherbaum N, Farre' M, Torrens M, Demetrovics Z, Ghodse AH; Psychonaut Web Mapping; ReDNet Research Groups. Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. *Psychopharmacology (Berl)* 214: 593-602, 2011 (\*)
59. Corkery JM, SCHIFANO F, Oyefeso A, Ghodse AH, Tonia T, Naidoo V, Button J. Overview of literature and information on 'khat-related' mortality: a call for recognition of the issue and further research. *Annali Istituto Superiore di Sanita'/Annals of the Higher Institute of Health*, 47: 445-464, 2011 (\*)
60. Mustata C, Torrens M, Pardo R, Perez C, SCHIFANO F, Corazza O, Deluca P, Davey Z, Di Furia L, Fiesland L, Mannonen M, Pagani S, Peltoniemi T, Pezzolesi C, Scherbaum N, Siemann H, Skutle A, van der Kreeft P, Farre' M. Spice drugs: los cannabinoides como nuevas drogas de diseño (Spice drugs: cannabinoids as a new designer drugs; article in Spanish). *Adicciones*, 21: 3, 181-186, 2009 (\*)
61. SCHIFANO F: Clinica ed epidemiologia delle nuove droghe. *Lo Psichiatra*, January 2008 (\*)
62. SCHIFANO F, Tedeschi D: Synthetic drugs and compulsory treatment in the UK. *International Journal of Mental Health*, 37: 21-56, 2008 (\*)
63. SCHIFANO F: Is urbanization as a risk factor for substance misuse? *Current Opinion in Psychiatry*, 21: 391-397, 2008 (\*)
64. SCHIFANO F: Buprenorphine: clinical pharmacology issues and prescribing guidelines. *Dipendenze Patologiche*, 2: 11-20, 2007 (\*)

65. SCHIFANO F. Recreational drugs involved in aggressive behaviour: a review. *Studies on Aggressiveness and Suicide*, 8: 21-32, 2006 (\*)
66. Sogbein L, SCHIFANO F. Physical exercise addiction. *Dipendenze Patologiche*, 1: 45-48, 2006 (\*)
67. Lunn D, SCHIFANO F. MDMA (ecstasy): clinical pharmacology and fatal consequences of its ingestion. *Dipendenze Patologiche*, 1-2:5-10, 2006 (\*)
68. Corkery J, SCHIFANO F, Ghodse AH, Oyefeso A: Methadone effects and its role in fatalities. *Human Psychopharmacology Clinical and Experimental*, 19:565-576, 2004 (\*)
69. SCHIFANO F, Zamparutti G, Zambello F: Substance misuse in adolescence: theoretical and clinical issues. *Progress in Neurology and Psychiatry*, 8:25-34, 2004 (\*)
70. SCHIFANO F. A bitter pill? Overview of ecstasy (MDMA; MDA) related fatalities. *Psychopharmacology (Berlin)*, 173: 242-248, 2004 (\*)
71. Rudge W, SCHIFANO F: The abuse of stimulants in sports. *Bollettino per le Farmacodipendenze e l'Alcolismo*, 24: 65-69, 2001 (\*)
72. SCHIFANO F: New trends in drug addiction: synthetic drugs. Epidemiological, clinical and preventive issues. *Epidemiologia e Psichiatria Sociale*, 10: 63-70, 2001 (\*)
73. SCHIFANO F. The "nursing role" in the Italian addiction treatment units (ATUs): an interview with Ida Lion, RN. *Journal of Addictions Nursing*, 13: 225-7, 2001. (\*)
74. Bergamo LC, SCHIFANO F, Alati GL: Psychotic disturbances as consequence of neurological disorders' treatments (Disturbi psicotici in corso di terapie neurologiche). *Psichiatria e Psicoterapia Analitica*, 19: 9-21, 2000 (\*)
75. SCHIFANO F: Saturday night stimulants and psychedelics (Eccitanti e psichedelici del sabato sera). *Drug and Alcohol Bulletin (Bollettino per le Farmacodipendenze e l'Alcolismo)*, 21: 9-12, 1998 (\*)
76. SCHIFANO F: Cocaine misuse and dependence. *Current Opinion in Psychiatry*, 9: 225-30, 1996 (\*)
77. SCHIFANO F: Lo stress ed i disturbi di adattamento allo stress. *Giornale di Clinica Medica*, 76: 25-8, 1995 (\*)

78. SCHIFANO F, Di Furia L, Forza G, Levarta E, Bricolo R: Atypical clinical issues and MDMA/ecstasy misuse (Aspetti clinici peculiari dell'abuso di MDMA/ecstasy). *Drug and Alcohol Bulletin (Bollettino per le Farmacodipendenze e l'Alcolismo)*, 18: 53-6, 1995 (\*)
79. SCHIFANO F: Pharmacological strategies for preventing suicidal behaviour. *CNS Drugs*, 1:16-25, 1994 (\*)
80. SCHIFANO F, De Leo D: Psychotropic drugs and suicide (Psicofarmaci e suicidio: una relazione complessa). *Giornale Italiano di Suicidologia*, 2: 5-7, 1992 (\*)
81. SCHIFANO F, De Leo D: Can pharmacological intervention aid in the prevention of suicidal behaviour? *Pharmacopsychiatry*, 24: 113-7, 1991 (\*)
82. SCHIFANO F: Fluoxetina cloridrato. *Giornale di Clinica Medica*, 71: 141-4, 1990 (\*)
83. SCHIFANO F: The pharmacotherapeutic management of rapid-cycling bipolar affective disorder: an update. *Irish Journal of Psychological Medicine*, 7: 71-8, 1990 (\*)
84. SCHIFANO F: Zolpidem tartrate. *Giornale di Clinica Medica*, 71: 299-302, 1990 (\*)
85. Di Costanzo E, SCHIFANO F: Viral hypothesis of schizophrenia. Critical reflections. *Giornale di Clinica Medica*, 61: 361-6, 1990 (\*)
86. SCHIFANO F: La demenza. *Giornale di Clinica Medica*, 70: 139-52, 1989 (\*)
87. Gava R, SCHIFANO F: Oxiracetam. *Giornale di Clinica Medica*, 70: 69-74, 1989 (\*)
88. SCHIFANO F, Marra R, Gava R: Naltrexone. *Giornale di Clinica Medica*, 70: 379-82, 1989 (\*)
89. Di Costanzo E, SCHIFANO F: Pharmacological interactions of lithium. *Giornale di Clinica Medica*, 69: 695-7, 1988 (\*)
90. SCHIFANO F: Il suicidio. *Giornale di Clinica Medica*, 69: 387-95, 1988 (\*)
91. SCHIFANO F: Intorno alle benzodiazepine. *Giornale di Clinica Medica*, 69: 627-33, 1988 (\*)

92. Di Costanzo E, SCHIFANO F: Headache and masked depression.  
Giornale di Clinica Medica, 70:33-6, 1988 (\*)

### Professional Journal Papers

1. Holloway K, SCHIFANO F. Is there a 'game changer' in the treatment of problematic opioid use? The Conversation, 30th November 2023; available from: <https://theconversation.com/buvidal-is-it-really-a-game-changer-in-the-treatment-of-problematic-opioid-use-214895>
2. Carrus D, SCHIFANO F. Alcol e nuove sostanze: dal poliabuso alle strategie di prevenzione web-mediate. Noos, 19: 7-24, 2013
3. Ali M, Schifano F, Robinson P, Phillips G, Dhillon S. Achieving HbA1c targets with patient satisfaction in a community pharmacy. Journal of Diabetes Nursing 16: 215-218, 2012
4. Assi S, Stair J, Fergus S, Corazza O, SCHIFANO F. Happy mate or deadly fate: the real truth behind designer drugs! ReDNet Newsletter, 2011, in press
5. SCHIFANO F. The web and the legal highs; the role of the Recreational Drugs' European Network (ReDNet). SMMGP Newsletter, May 2011
6. SCHIFANO F. GHB, Treatment and management. SCANbites, 7:4-5, 2010
7. Davey Z, Corazza O, Deluca P, SCHIFANO F. Mass-information: mephedrone, myths, and the new generation of legal highs. Drugs and Alcohol Today, 10: 24-28, 2010
8. Corazza O, Davey Z, Deluca P, Demetrovics Z, Drummond C, Enea A, Moskalewicz J, Di Melchiorre G, Di Furia L, Farre' M, Flesland L, Scherbaum N, Siemann H, Skutle A, Torrens M, Pasinetti M, Pezzolesi C, Shapiro H, Sferrazza E, van der Kreeft P, SCHIFANO F. Le nuove potenzialità della prevenzione digitale in materia di nuove droghe: il ruolo del Recreational Drugs European Network. Dipendenze Patologiche/Addictive Behaviors, 43-46, 2010
9. Davey Z, Deluca P, Corazza O, SCHIFANO F. New trends in drug abuse and misuse: the Psychonaut Web Mapping project. SALIS News, Autumn 2009
10. Corazza O, SCHIFANO F, Deluca P, Davey Z. Novel psychoactive drugs on the Internet: the Psychonaut Web Mapping Project. The Italian online psychiatric magazine, February 2010
11. Deluca P, SCHIFANO F, Davey Z, Corazza O. Legal highs and new recreational drugs: the Psychonaut Web Mapping project. SCANbites, Autumn 2009

12. Davey Z, Deluca P, SCHIFANO F, Corazza O. Developing an Internet monitoring system for new drugs: The Psychonaut Web Mapping project. ELISAD Newsletter, November 2009, 7-8
13. SCHIFANO F. Stimulant drugs (cocaine; methamphetamine) and recent pharmacological advances in treatment. SCANbites, Autumn 2009
14. SCHIFANO F, Deluca P: Internet and drugs; overview of the EU-funded Psychonaut 2002 project. SCANbites, Autumn 2005, 11-12.
15. SCHIFANO F: Le nuove droghe: aspetti farmacologici, clinici e terapeutici. Sanita' Iblea (suppl), 1-11, 2004
16. SCHIFANO F, Corkery JM: Drug related mortality data on the website. Substance Misuse Bulletin, 13: 11, 2001
17. SCHIFANO F. Long-term effects of ecstasy consumption. Substance Misuse Bulletin, 14: 6-7, 2001
18. SCHIFANO F: Droghe di sintesi e trattamenti terapeutici: una revisione critica. ADD, 2 :17-24, 2000
19. SCHIFANO F: Le sostanze di abuso del sabato sera. Bollettino Ordine Medici Chirurghi ed Odontojatri di Padova, 3 (supplement): I-VIII, 1999
20. SCHIFANO F, Miconi L, Stivanello A, Di Furia L, Carreri L, Salmaso L, Bricolo R: Infezione da HIV e psicofarmacoterapia. Psichiatria Generale e dell'Età Evolutiva, 34: 435-41, 1997
21. Bricolo R, Carreri L, Miconi L, SCHIFANO F, Stivanello A, Di Furia L, Salmaso L: Le problematiche nella condizione di tossicodipendenza. Psichiatria Generale e dell'Età Evolutiva, 34: 428-34, 1997
22. Miconi L, Stivanello A, Carreri L, Sabbion R, Foscaro R, Salmaso L, SCHIFANO F, Bricolo R: Ruolo dell'assistenza domiciliare nel paziente tossicodipendente sieropositivo. Psichiatria Generale e dell'Età Evolutiva, 34: 423-7, 1997
23. Bagozzi F, Grosso L, SCHIFANO F: Riti e miti delle tribù dell'ecstasy. Animazione Sociale, 109: 29-55, 1997
24. SCHIFANO F: Glossario psichedelico. Animazione Sociale, 109: 41-50, 1997
25. Giannotti CF, Polidori E, SCHIFANO F: Ecstasy and agony. Report on the International Conference on ecstasy in Bologna, Italy. Substance Misuse Bulletin, 9: 6, 1997

26. Marra R, Andrighetti M, Lo Storto MR, SCHIFANO F: Aritmie ventricolari in corso di terapia con fluoxetina: descrizione di un caso clinico. *Le Basi Razionali della Terapia*, 26: 53-5, 1996
27. SCHIFANO F, Di Furia L, Bricolo R: Consumo di ecstasy (MDMA) ed abuso alcolico. *Alcolismi*, 10: 12-4, 1996
28. SCHIFANO F: “Nuove” sostanze d’abuso e “nuova” utenza: i Sert ad una svolta? *Intersert*, 2: 4, 1996
29. Bricolo R, Berto D, SCHIFANO F: New drugs, new clients? *Substance Misuse Bulletin*, 8: 7, 1995
30. SCHIFANO F: Lo stress ed i disturbi di adattamento allo stress. *Giornale di Clinica Medica e Terapia*, 76: 25-8, 1995
31. SCHIFANO F, Guelfi GP: The Italian drug legislation and its reforms: an overview. *Substance Misuse Bulletin*, 8: 6, 1995
32. SCHIFANO F: The pharmacological treatment for cocaine abuse: a puzzling issue. *Substance Misuse Bulletin*, 8: 6-7, 1995
33. Gallimberti I, SCHIFANO F, Minazzato L, Forza G, Miconi L, Schon A, Colombo GC, Gessa GL: Medicina delle farmacotossicodipendenze: riflessioni in tema di eziopatogenesi e trattamento della dipendenza da sostanze psicoattive, con particolare riguardo a quella alcolica. *Il Vaso di Pandora*, 2: 47-90, 1994
34. Orsi M, Bricolo R, SCHIFANO F: Il nuovo scenario della droga. *Salute e Territorio*, 16: 28-62, 1994
35. SCHIFANO F: Il profilo dell’ecstasy. *Salute e Territorio*, 16: 37-40, 1994
36. SCHIFANO F, Magni G: Ansia e depressione nell’ambulatorio di medicina generale. *Medicina Generale*, 1:12-7, 1994
37. SCHIFANO F, Miconi L, Gallimberti L: Considerazioni cliniche sull’assunzione di elevati dosaggi di trimebutina. *Le Basi Razionali della Terapia*, 24: 31-2, 1994
38. Vannucchi T, SCHIFANO F, Villani G: Abuso di sostanze, disturbi dell’umore ed antidepressivi: una miscela esplosiva. *Medicina delle Farmacotossicodipendenze*, 4: 52-3, 1994
39. De Gobbi R, SCHIFANO F: La medicina generale ed i problemi della mente. *Giornale di Clinica Medica e Terapia*, 76: 265-8, 1994

40. De Gobbi R, SCHIFANO F: Il paziente che infastidisce, ovvero come trasformare una situazione di disagio in uno strumento diagnostico-terapeutico. *Giornale di Clinica Medica e Terapia*, 75: 1-3, 1994
41. SCHIFANO F: Ansia e depressione in Ospedale e nel territorio. *Giornale di Clinica Medica e Basi Razionali delle Terapia (Clinica e Terapia)*, 73: 235-43, 1993
42. SCHIFANO F: Padova Centre Report. *ECCAS Bulletin News*, issue 3, October 1993
43. SCHIFANO F, Magni G: Anoressia e bulimia: sindromi diverse o aspetti differenti della stessa patologia? *Medicina Generale*, 3: 19-23, 1993
44. SCHIFANO F, Magni G: Impiego clinico degli antidepressivi di seconda generazione. *Medicina Generale*, 10: 20-7, 1993
45. Vannucchi T, SCHIFANO F: Naltrexone: un “nuovo” effetto collaterale. *Le Basi Razionali della Terapia*, 23: 11-12, 1993
46. Ferrara SD, Snenghi R, Zancaner S, Angelini A, Cibir M, SCHIFANO F, Castagna F, Tedeschi L, Gallimberti L, Marigo M: Droghe e sostanze psicoattive nel Veneto. *Rivista Italiana di Medicina Legale*, 12: 605-25, 1992
47. SCHIFANO F: Psicotropi e comportamento suicidario. *Le Basi Razionali della Terapia*, 22: 17-21, 1992
48. SCHIFANO F: Risultati incoraggianti del trattamento con naltrexone nella dipendenza da oppiacei. *Lettera Terapeutica*, 7: 1-7, 1991
49. SCHIFANO F: Memoria e benzodiazepine. *Le Basi Razionali della Terapia*, 21: 57-8, 1991
50. SCHIFANO F, Magni G, Corfini A: Antidepressivi e apparato cardiovascolare. *Quaderni Italiani di Psichiatria*, 10: 221-44, 1991
51. SCHIFANO F, De Leo D: Esiste il razionale per una prevenzione farmacologica del comportamento suicidario? *Federazione Medica*, 43: 381-4, 1990
52. SCHIFANO F: Aspetti clinici e terapeutici della dipendenza da oppiacei. *Doctor Reports*, June issue: 1-6, 1990
53. SCHIFANO F, Di Costanzo E: Caffaina e caffeinismo. *Le Basi Razionali della Terapia*, 20: 671-6, 1990

54. SCHIFANO F: Alla ricerca di un modello sperimentale farmacologico della demenza di Alzheimer: utilità clinica del modello scopolaminico. *Le Basi Razionali della Terapia*, 19:563-70, 1989
55. SCHIFANO F, Magni G: Il potenziale d'abuso degli agenti anticolinergici. *Le Basi Razionali della Terapia*, 19:169-72, 1989
56. SCHIFANO F, Magni G: La conduzione farmacoterapica del disturbo affettivo a cicli rapidi: un aggiornamento. *Giornale di Neuropsicofarmacologia*, 11: 109-18, 1989
57. Di Costanzo E, SCHIFANO F: L'abuso di farmaci anticolinergici in una popolazione di schizofrenici: rilievi clinici ed epidemiologici. *Giornale di Neuropsicofarmacologia*, 10: 163-6, 1988
58. SCHIFANO F: Un approccio epidemiologico allo studio di una popolazione psichiatrica in età adulto-giovanile. *Rassegna di Studi Psichiatrici*, 77: 1-12, 1988
59. Magni G, De Leo D, SCHIFANO F, De Dominicis MG, Pastorello M: Valutazione della depressione in pazienti dell'Ospedale Geriatrico e Generale. *Rivista di Psichiatria*, 19:18-28, 1984
60. Magni G, SCHIFANO F: Il problema della non-compliance in medicina. *Le Basi Razionali della Terapia*, 14: 605-15, 1984
61. De Leo D, Magni G, SCHIFANO F, Rossi F, Rossetto C: Aspetti psicosomatici della sindrome di Sudeck. *Rivista di Medicina Psicosomatica*, 28: 409-13, 1983
62. Magni G, De Leo D, Canton G, Palazzolo O, Antonielli F, Rossaro P, SCHIFANO F: Valutazione dei patterns d'uso degli psicofarmaci in Ospedale Generale. *Giornale di Neuropsicofarmacologia*, 6: 239-45, 1983
63. Magni G, De Leo D, Corfini A, Capodieci S, Rizzardo R, Forin G, SCHIFANO F, Dal Palù C: Eventi stressanti e cardiopatia ischemica. *Giornale di Gerontologia e Geriatria*, 31: 787-9, 1983
64. Magni G, De Leo D, SCHIFANO F, De Dominicis MG, Pastorello M: Presenza di sintomi depressivi in pazienti dell'Ospedale Geriatrico e Generale. *Giornale di Gerontologia e Geriatria*, 31: 825-7, 1983

#### Official Reports

1. SCHIFANO F, Martinotti G. Analysis of the information available for the ecstasy-like compounds 2-CT2 and 2-CT7 on the web. Report prepared for the Early

Warning System section of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal, pp. 1-4, 2003

2. SCHIFANO F, Deluca P. Analysis of the information available for the Coproxamol-containing compounds on the web. Report prepared for the Patient Safety Renewals and Reclassifications, PLD, Medicines and Healthcare products Regulatory Agency (MHRA), UK, pp.1-5, 2003
3. Gilvarry E, SCHIFANO F: Buprenorphine medical use in the UK. Report prepared for the WHO, pp.1-100, 2002

#### Review of Single Academic Books

(\*: **peer-reviewed journal**)

1. SCHIFANO F. Foreword to the book: Core psychiatric interview skills. Preparing you for the MRCPsych. Moodliar S (ed), 2013
2. SCHIFANO F: Review of the book: 'International Drug Control into the 21st Century; H Ghodse (ed). Ashgate Publishing, July 2008, 242 pages; ISBN: 978-0-7546-7215-9. SCAN website, 2012
3. SCHIFANO F: Review of the book: 'Pass the CASC for the MRCPsych'. Moodliar S (ed), 2012
4. SCHIFANO F: Review of the book: 'The Psychodynamics of Addiction'. Weegman M, Cohen R (eds), Whurr Publishers. Drugs: Education, Prevention and Policy, 10: 395-6, 2003 (\*)
5. SCHIFANO F: Review of the book: 'Comparative treatments of Substance Abuse'. Dowd G, Rugle L (eds), Italian edition. The Mc Graw Hill Publishing Companies, Milan, Italy, 2001
6. SCHIFANO F: Review and translation of the book: 'Uppers, Downers, All Arounders' Inaba D, Cohen S (eds), Italian edition. Piccin Nuova Libreria, Padova, Italy, 1997
7. SCHIFANO F: Review of the book: 'Anxiety and Depression'. The Medical Clinics of North America: 21 (3), Italian edition. Piccin Nuova Libreria, Padova, Italy, 1990

#### Other Publications: Research monographs

1. Corkery J, Claridge H, Loi B, Goodair C, SCHIFANO F. Drug related deaths in the UK; Annual Report 2013. International Centre for Drug Policy, St George's, University of London (UK), 2014; ISBN: 978-1-897778-9-2
2. Ghodse H, Corkery J, Claridge H, Goodair C, SCHIFANO F. Drug related deaths in the UK. Annual Report 2012. International Centre for Drug Policy,

St George's, University of London (UK), 2012 ISBN: 978 1 897778 79 1

3. Mathewson H, James K, SCHIFANO F, Sumnall H, Wing A, Anderson D. Khat: Assessment of Risk to the Individual and Communities in the UK. Advisory Council on the Misuse of Drugs, Report for the Home Secretary, UK, 2013
4. Ghodse H, Corkery J, SCHIFANO F, Piolanti A, Trincas G, Di Melchiorre G. Drug related deaths in the UK. Annual Report 2011. International Centre for Drug Policy, St George's, University of London (UK), 2012 ISBN: 978 1 897778 74 6
5. Ghodse H, Corkery J, Ahmed K, SCHIFANO F. Volatile Substances Abuse Deaths in the UK. Annual Report 2011. International Centre for Drug Policy, St George's, University of London (UK), 2012.
6. Ghodse AH, Corkery J, Ahmed K, Naidoo V, Oyefeso A, SCHIFANO F. Drug related deaths in the UK. Annual Report 2010. International Centre for Drug Policy, St George's, University of London (UK), 2010. ISBN: 978 1 897778 73 9
7. Deluca P, SCHIFANO F, Davey Z, Corazza O, Di Furia L, and the Psychonaut Web Mapping Research Group. Mephedrone Report. Institute of Psychiatry, King's College London, London (UK), 2010. Available from: [www.psychonautproject.eu](http://www.psychonautproject.eu)
8. Ghodse AH, Corkery J, Oyefeso A, SCHIFANO F, Ahmed K, Naidoo V. Drug related deaths in the UK. Annual Report 2009. International Centre for Drug Policy, St George's, University of London (UK), 2009 ISBN: 978 1 897778 68 5
9. Ghodse AH, Corkery J, Oyefeso A, SCHIFANO F. Drug related deaths in the UK. Annual Report 2008. International Centre for Drug Policy, St George's, University of London (UK), 2008 ISBN: 978 1 897778 64 7
10. Ghodse AH, Corkery J, Oyefeso A, SCHIFANO F. Drug related deaths in the UK. January - June 2007, np-SAD Surveillance Report No. 20. International Centre for Drug Policy, St George's, University of London (UK), 2008.
11. Ghodse AH, Corkery J, Oyefeso A, SCHIFANO F, Tonia T. Drug related deaths in the UK. Annual Report 2007. International Centre for Drug Policy, St George's, University of London (UK), 2007 ISBN: 978 1 897778 58 6
12. Ghodse AH, Corkery J, Oyefeso A, SCHIFANO F, Tonia T, Annan J. Drug related deaths in the UK. January - June 2006, np-SAD Surveillance Report No. 18. International Centre for Drug Policy, St George's, University of London (UK), 2007.

13. Ghodse AH, Corkery J, Oyefeso A, SCHIFANO F, Tonia T, Annan J. Drug related deaths in the UK. Annual Report 2006. International Centre for Drug Policy, St George's, University of London (UK), 2006 ISBN: 1 897778 33 3
14. Szendrei K, SCHIFANO F, Carver S, Ghodse AH. Report on the International Expert Group on Herbal Medicine in the treatment of addictions. Report to the Home Office. International Centre for Drug Policy, St George's, University of London (UK), 2006
15. Ghodse AH, Corkery J, SCHIFANO F, Oyefeso A, Tonia T, Annan J. Drug related deaths in the UK, 1999-2004. International Centre for Drug Policy, St George's, University of London (UK), 2006
16. Ghodse AH, Corkery J, SCHIFANO F, Oyefeso A, Bannister D, Annan J. Drug related deaths in the UK. January - June 2005, np-SAD Surveillance Report No. 16. International Centre for Drug Policy, St George's, University of London (UK), 2006
17. Ghodse AH, Corkery J, SCHIFANO F, Oyefeso A, Bannister D, Annan J. Drug related deaths in the UK. Annual Review 2005 and Surveillance Report July-December 2004. International Centre for Drug Policy, St George's, University of London (UK), 2005 ISBN: 1 897778 18 X
18. Ghodse AH, SCHIFANO F, Oyefeso A, Bannister D, Cobain K, Corkery J. Drug related deaths as reported by coroners in England, Wales, Scotland, N Ireland, Guernsey, Jersey and Isle of Man. January-June 2004. np-SAD report no. 14. International Centre for Drug Policy, St George's Hospital Medical School, London (UK), 2005
19. Ghodse AH, SCHIFANO F, Oyefeso A, Bannister D, Cobain K, Dryden R, Corkery J. Drug-related deaths as reported by coroners in England, Wales, Scotland, N Ireland, Guernsey, Jersey and Isle of Man. Annual review 2004 and np-SAD Report no. 13. International Centre for Drug Policy, St George's Hospital Medical School, London (UK), 2004 ISBN: 1 897778 97 X
20. Ghodse AH, SCHIFANO F, Oyefeso A, Cobain K, Corkery J. Drug related deaths as reported by coroners in England, Wales, Scotland, N Ireland and Channel Islands. January-June 2003. np-SAD report no. 12. International Centre for Drug Policy, St George's Hospital Medical School, London (UK), 2004
21. Ghodse AH, SCHIFANO F, Oyefeso A, Jambert -Gray R, Cobain K, Corkery J. Drug-related deaths as reported by coroners in England, Wales, Scotland, N Ireland and Channel Islands. Annual review 2002 and np-SAD Report no. 11. European Centre for Addiction Studies, St George's Hospital Medical School, London (UK), 2003

22. Ghodse AH, SCHIFANO F, Jambert-Gray R, Oyefeso A, Cobain K, Martinotti G, Corkery J: Drug related deaths as reported by coroners in England and Wales. January-June 2002. Np-SAD report no. 10. European Centre for Addiction Studies, St George's Hospital Medical School, London (UK), 2003
23. Ghodse H, Oyefeso A, Webb L, SCHIFANO F, Pollard M. Jambert-Gray R, Corkery J: Drug-related deaths as reported by coroners in England and Wales. Annual review 2001 and np-SAD Report no. 9. European Centre for Addiction Studies, St George's Hospital Medical School, London (UK), 2002

## 2. Other Research Achievement

### Academic dissertations

1. SCHIFANO F: Effetti della somministrazione di dosi singole di lorazepam e scopolamina sulla memoria implicita (Effects of the administration of single doses of lorazepam and scopolamine on implicit memory). Dissertation for the Postgraduate Diploma in Clinical Pharmacology, University of Padova (I) School of Medicine, 1989
2. SCHIFANO F: La depressione nel paziente geriatrico internistico ospedalizzato (Depression in geriatric medical inpatients). Dissertation for the Postgraduate Diploma in Psychiatry, University of Padova (I) School of Medicine, 1985
3. SCHIFANO F: La bouffee delirante acuta. Elementi nosografici e studio catamnestico (Acute psychotic episodes; a retrospective study). MD dissertation, University of Padova (I) School of Medicine, 1981

### Commissioned reports on drug-related mortality

(Note: all of the following have been produced by the National Programme on Substance Abuse Deaths, np-SAD, of which I was first the Co-Principal Investigator, and then the PI)

- (2007) Ghodse AH, Corkery JC, SCHIFANO F, Oyefeso A, Tonia T. Drug-related deaths in the City of Manchester, 1999-2005. International Centre for Drug Policy, 2007.
- (2006) Ghodse, H, Corkery J, SCHIFANO F, Oyefeso A, Tonia T, Annan J. Drug-related deaths in Redbridge, 1999-2005: Special surveillance report for Redbridge Drug and Alcohol Action Team. London: International Centre for Drug Policy. December 2006.
- (2006) Ghodse, H, Corkery J, SCHIFANO F, Oyefeso A, Bannister D, Tonia T, Annan J. Drug-related deaths in Bury, 1999-2003: Special surveillance report for Bury Drug and Alcohol Action Team. London: International Centre for Drug Policy. May 2006.

- (2006) Ghodse, H, Corkery J, SCHIFANO F, Oyefeso A, Tonia T, Annan J. Drug-related deaths in England and Wales, 1999-2004: Special analysis for the Department of Health. London: International Centre for Drug Policy. January 2006.
- (2005) Ghodse, H, Corkery J, SCHIFANO F, Oyefeso A, Bannister D, Annan J. Surveillance report for Oldham Metropolitan Borough. London: International Centre for Drug Policy. December 2005.
- (2005) Ghodse, H, Corkery J, SCHIFANO F, Oyefeso A, Bannister D, Tonia T, Annan J. Drug-related deaths in Brighton and Hove, 1999-2004: Special surveillance report for Brighton & Hove Drug and Alcohol Action Team. London: International Centre for Drug Policy. November 2005.
- (2005) Ghodse, H, Corkery J, SCHIFANO F, Oyefeso A, Bannister D, Annan J. Surveillance report for Derby City Drug and Alcohol Action Team. London: International Centre for Drug Policy. September 2005.
- (2005) Ghodse, H, SCHIFANO F, Oyefeso A, Bannister D, Annan J, Corkery J. Surveillance report for Trafford City Drug and Alcohol Action Team. London: International Centre for Drug Policy. February 2005.
- (2004) Ghodse, H, SCHIFANO F, Oyefeso A, Bannister D, Annan J, Corkery J. Surveillance report for Stockport City Drug and Alcohol Action Team. London: International Centre for Drug Policy. November 2004.
- (2004) Ghodse, H, SCHIFANO F, Oyefeso A, Bannister D, Annan J, Corkery J. Surveillance report for Dudley Drug and Alcohol Action Team. London: International Centre for Drug Policy. November 2004.
- (2004) Ghodse, H, SCHIFANO F, Oyefeso A, Bannister D, Annan J, Corkery J. Surveillance report for Luton Drug and Alcohol Action Team. London: International Centre for Drug Policy. November 2004.
- (2004) Ghodse, H, SCHIFANO F, Oyefeso A, Jambert-Gray R, Dryden R, Cobain K, Annan J, Corkery J. Surveillance report for Hampshire, Southampton, Portsmouth Drug Action Teams. London: International Centre for Drug Policy. August 2004.
- (2004) Ghodse, H, SCHIFANO F, Oyefeso A, Jambert-Gray R, Dryden R, Cobain K, Annan J, Corkery J. Surveillance report for Barnet Primary Care Trust. London: International Centre for Drug Policy. July 2004.
- (2004) Ghodse, H, SCHIFANO F, Oyefeso A, Jambert-Gray R, Dryden R, Cobain K, Annan J, Corkery J. Surveillance report for Lambeth Primary Care Trust. London: International Centre for Drug Policy. June 2004.

- (2003) Ghodse, H, SCHIFANO F, Oyefeso A, Jambert-Gray R, Dryden R, Cobain K, Annan J, Corkery J. Surveillance report for Westminster Drug and Alcohol Action Team: 1998-2002. London: International Centre for Drug Policy. December 2003.
- (2003) Ghodse, H, SCHIFANO F, Oyefeso A, Jambert-Gray R, Cobain K, Annan J, Corkery J. Berkshire Surveillance Report. London: International Centre for Drug Policy. October 2003.
- (2003) Ghodse, H, SCHIFANO F, Oyefeso A, Jambert-Gray R, Cobain K, Annan J, Corkery J. Surveillance Report for Lincolnshire Partnership Trust. London: Centre for Addiction Studies. July 2003.
- (2003) Ghodse, H, SCHIFANO F, Oyefeso A, Jambert-Gray R, Cobain K, Annan J, Corkery J. Surveillance Report for Southend Social Services. London: Centre for Addiction Studies. July 2003.
- (2002) Ghodse, H, Oyefeso A, Webb L, Pollard M, SCHIFANO F, Corkery J. Drug-related deaths in Camden & Islington 1 January 2000 – 31 December 2001: Surveillance Report for Islington Drug & Alcohol Action Team. London: Centre for Addiction Studies. December 2002.
- (2002) Ghodse, H, Oyefeso A, Webb L, Pollard M, SCHIFANO F, Corkery J. Drug-related deaths in Blackpool 1998 - 2001: Surveillance Report for Blackpool Drug Action Team. London: Centre for Addiction Studies. September 2002.
- (2002) Ghodse, H, Oyefeso A, Webb L, Pollard M, SCHIFANO F, Corkery J. Drug-related inquests in Ealing 1 January 2000 – 30 December 2001: Surveillance Report for Ealing Drug & Alcohol Action Team. London: Centre for Addiction Studies. September 2002.
- (2002) Ghodse, H, Oyefeso A, Webb L, Pollard M, Corkery J. Drug-related inquests involving ecstasy and cocaine 1 January 2001 – 30 June 2001: Surveillance Report for Drugscope. London: Centre for Addiction Studies. August 2002.
- (2002) Ghodse, H, Oyefeso A, Webb L, Pollard M, SCHIFANO F, Corkery J. Drug-related inquests in Bournemouth, Poole & East Dorset 1 January 1999 – 31 December 2001: Surveillance Report for Bournemouth GP. London: Centre for Addiction Studies. July 2002.
- (2002) Ghodse, H, Oyefeso A, Webb L, Pollard M, SCHIFANO F, Corkery J. Drug-related inquests in Hackney 1 January 1999 – 31 December 2001: Surveillance Report for Hackney Drug Action Team. London: Centre for Addiction Studies. July 2002.
- (2002) Ghodse, H, Oyefeso A, Webb L, Pollard M, SCHIFANO F, Corkery J. Drug-related inquests in Hampshire 1 January 1999 – 31 December

- 2001: Surveillance Report for Hampshire Drug Action Team. London: Centre for Addiction Studies. July 2002.
- (2002) Ghodse, H, Oyefeso A, Webb L, Pollard M, SCHIFANO F, Corkery J. Drug-related inquests in Worcestershire 1 January 1999 – 31 December 2001: Surveillance Report for Worcestershire Substance Misuse Action Team. London: Centre for Addiction Studies. July 2002.
- (2002) Ghodse, H, Oyefeso A, Webb L, Pollard M, SCHIFANO F, Corkery J. Psychological autopsy for Newham Social Services: 3 inquests in 2000. London: Centre for Addiction Studies. May 2002.
- (2002) Ghodse, H, Oyefeso A, Webb L, Pollard M, SCHIFANO F, Corkery J. Drug-related inquests in Peterborough 1 January 2000 – 31 December 2000 where the verdict was not suicide: Surveillance Report for Peterborough Drug Action Team. London: Centre for Addiction Studies. April 2002.
- (2002) Ghodse, H, Oyefeso A, Webb L, Pollard M, SCHIFANO F, Corkery J. Drug-related inquests in Lancashire 1 January 1998 – 30 June 2001: Surveillance Report for South Lancashire Health Authority. London: Centre for Addiction Studies. April 2002.
- (2002) Ghodse, H, Oyefeso A, Webb L, Pollard M, SCHIFANO F, Corkery J. Drug-related inquests in Shropshire 1 January 1999 – 31 December 1999: Surveillance Report for Shropshire Community Substance Misuse Team. London: Centre for Addiction Studies. March 2002.
- (2002) Ghodse, H, Oyefeso A, Webb L, Pollard M, SCHIFANO F, Corkery J. Drug-related inquests in Southend-on-Sea 1 January 2001 – 30 June 2001: Surveillance Report for Southend Social Services. London: Centre for Addiction Studies. March 2002.
- (2002) Ghodse, H, Oyefeso A, Webb L, Pollard M, SCHIFANO F, Corkery J. Drug-related inquests in Derbyshire 1 July 2000 – 30 June 2001: Surveillance Report for Derbyshire Police for Derbyshire Drug Market Project. London: Centre for Addiction Studies. March 2002.
- (2002) Ghodse, H, Oyefeso A, Webb L, Pollard M, SCHIFANO F, Corkery J. Drug-related inquests in Northumberland 1 January 2000 – 30 June 2001: Surveillance Report for Northumberland Drug Action Team. London: Centre for Addiction Studies. February 2002.
- (2002) Ghodse, H, Oyefeso A, Webb L, Pollard M, SCHIFANO F, Corkery J. Drug-related inquests in Newham, Tower Hamlets & Waltham Forest 1 July 1998 -31 December 2000: Surveillance Report for Newham Social Services. London: Centre for Addiction Studies. January 2002.

### **3. Creative or innovative work**

- Developed and implemented a methodology for assessing the web with respect to the issues related to trafficking, consumption, synthesis of licit and illicit compounds (carried out with the support of the EU for the Psychonaut 2002 project)
- Implemented and analysed the largest database ever of ecstasy (MDMA; MDA)-related fatalities

#### **4. Supervision of research students**

##### *Overseas Academic Visitors*

- One senior scientist from the Higher Institute of Health in Rome (I), funded by the EU Pompidou Group (July 2002)
- Some 50 trainees (e.g. pharmacologists; forensic doctors; clinical psychologists; and psychiatrists) from the Universities of: Ancona, Catania, Cagliari, Trieste, Parma, Verona, Rome, Padova, Udine, Urbino, Palermo (Italy) (since 2002)

#### **Major research seminars or conferences organised**

1. (2014) 3<sup>rd</sup> International Conference on Novel Psychoactive Substances, Rome, March 15-16, 2014
2. (2013) 2<sup>nd</sup> International Conference on Novel Psychoactive Substances Swansea (UK), September 2013
3. (2012) The Ever Changing World of the Novel Psychoactive Substances, Budapest, March 12-13, 2012
4. (2007) The ECCAS Annual General and Scientific meeting, Cambridge (UK)
5. (2006) The ECCAS Annual General and Scientific meeting, Ancona (Italy)
6. (2006) International Expert Group; Herbal Medicine in the Treatment of Addiction, London (UK)
7. (2005) The ECCAS Annual General and Scientific meeting, Sofia (Bulgaria)
8. (2004) The ECCAS Annual General and Scientific meeting, Porto (Portugal)
9. (2003) 2<sup>nd</sup> Psychonaut 2002 scientific meeting on “Licit and illicit compounds on the web; analysis of the web mapping”. Rovigo (Italy)
10. (2003) The 11<sup>th</sup> ECCAS Annual Scientific meeting on “Migration and Substance Abuse“. London (UK)
11. (2002) 1<sup>st</sup> Psychonaut 2002 scientific meeting on “Methodology of web mapping”. London (UK).

12. (2002) The 10<sup>th</sup> ECCAS Annual Scientific meeting on “Drug Use and Criminality”. Malta
13. (2001) The 9<sup>th</sup> ECCAS Annual Scientific meeting on “Dual diagnosis“. Thessaloniki (Greece)
14. (2000) The 8<sup>th</sup> ECCAS Annual Scientific meeting on “Drugs and Driving “. Essen (Germany)
15. (1999) The 7<sup>th</sup> Annual Scientific meeting on “Maternal Health and Addiction: Clinical and Rehabilitative Issues”. Padova, (Italy).
16. (1998) International Seminar on “Neurobiological and psychopathological issues related to ecstasy (MDMA) misuse”. Padova (Italy).
17. (1998) The 6<sup>th</sup> ECCAS Annual Scientific meeting on “Drug abuse-related deaths: Perspectives across Europe”. Oporto, (Portugal).
18. (1997) The 5<sup>th</sup> ECCAS Annual Scientific meeting on “Treatment effectiveness in substance misuse”. Ringkobing (Denmark).
19. (1994) 1<sup>st</sup> National Conference on “L’ecstasy: la cronaca, la clinica”. Padova (Italy).

## **6. Professional advisory or consultancy work**

### **International**

(2010-present) Member of the European Medicines’ Agency Advisory Board (Psychiatry)

(2003-present) Referee/Advisor for the Cochrane Reviews on Drugs and Alcohol (Italy)

(2003) External Advisor of the European Monitoring Centre on Drugs and Drug Abuse (EMCDDA) Early Warning System on New and Synthetic Drugs

(2001-2006) Secretariat of the European Collaborating Centres in Addiction Studies (ECCAS)

(1999-2001) Member, as Scientific/Fundraising Officer, of the Steering Committee of the European Collaborating Centres in Addiction Studies (ECCAS)

(1997-1999) Member of the Steering Committee, as the Membership Officer, of the European Collaborating Centres in Addiction Studies

(1995-1997) Chairman of the Steering Committee of the European Collaborating Centres in Addiction Studies (ECCAS)

(2000-2002) European Commission, Leonardo da Vinci Programme. “Transdrug; Training needs analysis in health and social services; A response to expanding polydrug use”. External Advisor

(1999-2002) Member of the “Designer Drugs” group of the Higher Institute of Health, Ministry of Health, Rome, Italy

(1999-2000) Member of the Drugs and Therapeutics Committee of the Local Health Unit no.16, Padova, Italy

(1999-2000) Member of the “Assessment of the quality of the services offered by the public Addiction Treatment Units of the Veneto Region” group, Venice, Italy

(1999-2000) Member of the “Use of doping compounds in sports” group of the Veneto Region, Venice, Italy

### **National**

(2011-2019) Member of the UK Advisory Council on the Misuse of Drugs (ACMD)

(2013) Contributed drafting the ACMD report on Khat

(2013) Provided written evidence on ketamine to the UK ACMD

(2013) Provided written evidence on zolpidem/zaleplone/zopiclone to the UK ACMD

(2010) Provided written evidence on mephedrone to the UK Advisory Council on the Misuse of Drugs (ACMD)

(2006-2011) Member of the National Institute of Health and Clinical Excellence (NICE) Mental Health Panel

(2006-present) Member of the Executive Board of the Substance Misuse Faculty, Royal College of Psychiatrists, UK

(2006-2010) Chair of the East Anglia/Cambridge Addiction Research Network.

(2008): Provided written and oral evidence to the All Parties Parliamentary Group on Drugs Misuse (inquiry into the Misuse of Prescription and Over the Counter Drugs)

(2006-2009) Chair of the Steering Group of the Tower Hamlets Project: ‘Process and outcome evaluation of the residential opiate dependence treatment programme at Harbour Recovery Centre (the Salvation Army)’

(2005-2010) Member of the Academic Psychiatry Faculty, Royal College of Psychiatrists, UK

(2002) Member of the Psychopharmacology Special Interest Group, Royal College of Psychiatrists, UK

(2002-2010) Member of the Substance Misuse Faculty, Royal College of Psychiatrists, UK

(2001-2011) Member of the British Association of Psychopharmacology

### **Regional**

(2000-present) Member of the London Drug Consultants Group

### **Local**

(2006-2012) Member of the Drugs and Therapeutics Committee; Hertfordshire Partnership NHS Foundation Trust

## **7. Clinical responsibilities**

Serving currently as Consultant Psychiatrist responsible for specialist assessment and treatment of severe problem substance (drug and alcohol) misuse and comorbid psychiatric disorders in the Hertfordshire Drug and Alcohol Recovery Services.

**Awarded, in April 2009, with 9 points of the Clinical Excellence Awards NHS Consultants' scheme**

My clinical responsibilities cover 5 (daytime) weekly sessions plus 1:9 out-of-hours consultant on-call rota duties, and include:

Patient assessment  
Clinical management  
Case review  
Provision of second opinions on difficult cases  
Provision of clinical reports  
Provision of forensic psychiatric court reports

## **8. Service as an external examiner**

(2006) PhD examiner; SOAS University of London, London

(2005) PhD examiner; University of East London, London

(1989-1999) Serving as Principal Examiner (Clinical Psychopharmacology), Postgraduate Specialisation School of Clinical Pharmacology, University of Padova (I) School of Medicine and Surgery

## **9. Service as a referee**

### **a. Journal referee**

- ◆ The Lancet
- ◆ British Medical Journal
- ◆ The Lancet Neurology
- ◆ Neuropsychopharmacology
- ◆ Psychotherapy and Psychosomatics
- ◆ Addiction
- ◆ Drug and Alcohol Dependence
- ◆ Psychopharmacology (Berlin)
- ◆ Journal of Psychopharmacology
- ◆ PLoS Medicine
- ◆ Current Opinion in Psychiatry
- ◆ Pharmacology, Biochemistry and Behavior
- ◆ International Psychiatry
- ◆ Human Psychopharmacology, Clinical and Experimental
- ◆ Frontiers in Addictive Disorders
- ◆ American Journal of Cardiovascular Drugs
- ◆ Vaccine
- ◆ Alcohol
- ◆ Acta Neuropsychiatrica
- ◆ Neuropsychobiology
- ◆ Cochrane Database System Review
- ◆ Canadian Medical Association Journal
- ◆ Medical Science Monitor
- ◆ BioMed Central Psychiatry
- ◆ Advances in Psychiatric Treatment
- ◆ Epidemiologia e Psichiatria Sociale
- ◆ Annals of Higher Institute of Health, Rome (Annali Istituto Superiore di Sanita')
- ◆ Drug and Alcohol Bulletin (Bollettino per le Farmacodipendenze e l'Alcolismo)
- ◆ Psichiatria e Psicoterapia Analitica
- ◆ Giornale di Clinica Medica
- ◆ Giornale Italiano di Suicidologia

#### **b. Research proposal referee**

- ◆ MRC; Neurosciences and Mental Health Board (2004)
- ◆ Economic & Social Research Council/UK (2009)
- ◆ EU Commission; Sixth and Seventh Research Framework Programme (since 2004)
- ◆ National Treatment Agency (NTA), UK (2005)
- ◆ Health Department, Scottish Executive, Chief Scientist Office Biomedical and Therapeutic Research Committee (2006)
- ◆ Programmes for the clinical management of drug addiction, Veneto Region, Italy (1998-2000)

#### **c. Book proposal referee**

- Oxford University Press
- The McGraw Hill Publishing Companies, Italy
- Piccin Nuova Libreria, Italy

**10. The holding of an office in a learned society or professional body**

(2006-2010) Member of the Executive Board of the Substance Misuse Faculty, Royal College of Psychiatrists, UK

(2001-2006): Secretariat and Scientific Officer of the European Collaborating Centres in Addiction Studies (ECCAS)

(1997-1999): Chairman of the European Collaborating Centres in Addiction Studies (ECCAS)

**11. Other public service in a professional capacity (e.g., service by invitation as expert on advisory bodies)**

(2006-2011) Member of the National Institute of Health and Clinical Excellence (NICE) Mental Health Panel

(2008) Given evidence to the UK Advisory Council on the Misuse of Drugs (ACMD) on issues related to possible reclassification of MDMA/ecstasy.

(2006) Scientific Advisor to the Tower Hamlets (London) Drug Action Team

(2003-2005) Scientific Advisor to the Drug Related Deaths panel of the Buckinghamshire Mental Health PCT NHS Trust

(2003-2005) Scientific Advisor to the Drug Related Deaths panel of the Reading and Berkshire PCT NHS Trust

**12. Academic invitations received for the presentation of external lectures and papers, contributions to conference proceedings etc**

(§: indicates an *invitation as key note speaker* on an ‘all expenses paid’ basis; the following list provides just an indication, being by no means exhaustive)

(2007) Invited speaker at the Science, Practice and Policy Symposium Program (SPPS). Talk given: Drugs of Abuse: effects on mental health and mental illness. 20<sup>th</sup> June 2007; Hatfield, Fielder Centre (UK) (§)

(2007) Invited speaker at the Dual diagnosis (La doppia diagnosi) meeting. Montecchio Maggiore, Vicenza (I): June 14<sup>th</sup>, 2007 (§)

(2007) Invited speaker at ‘The severe psychotic client’ (Il paziente grave. Dalla psicosi alla doppia diagnosi; percorso psicopatologico e trattamento farmacologico). Piacenza (I), 13<sup>th</sup> June 2007 (§)

- (2007) Invited speaker at the SCAN Annual Addiction Psychiatry Meeting. Talk given: Drug related deaths. Bath (UK), 7-8 June 2007 (§)
- (2007) Invited speaker at the ‘Cannabis, alcohol and psychotic disorders’ (Cannabis, alcol e disturbi psicotici) meetings. Held in: Padova, Pescara, Trieste, Ancona, Napoli (14<sup>th</sup>, 15<sup>th</sup>, 29<sup>th</sup>, 30<sup>th</sup>, 31<sup>st</sup> May 2007) (§)
- (2007) Invited speaker at the ‘Addictions: new scenarios and new approaches’ (Dipendenze; nuovi scenari e nuovi approcci) meeting. Verona (I), 31st May-1<sup>st</sup> June 2007 (§)
- (2007) Invited speaker at the ‘Dual diagnosis’ (La doppia diagnosi: un ponte tra la farmacologia e la clinica) meeting. Vicenza (I), 12<sup>th</sup> June 2007 (§)
- (2006) Invited speaker at the Stevenage (UK) Pain Management Study Day. Talk given: ‘Treatment of intravenous drug users in the hospital and pain management’; Stevenage (UK) November (§)
- (2006) Invited speaker at the Teolo (Italy) National Conference on ‘Bipolar Disorder’. Talk given: ‘Substance misuse and bipolar disorder’; Teolo (Italy) October (§)
- (2006) Invited speaker at the Ancona (Italy) International ECCAS Conference on ‘Cocaine, crack and dual diagnosis in the UK’. Ancona (Italy) October (§)
- (2006) Invited speaker at the Manchester (UK) SCAN National Conference. Talk given: ‘Ecstasy and ecstasy-like drugs’; Manchester, UK, September (§)
- (2006) Invited speaker at the Perugia (Italy) National Conference on ‘Cocaine, crack and dual diagnosis; clinical and epidemiological issues’. Talk given: ‘Cocaine and crack cocaine in the UK; epidemiological issues and psychopathological consequences’; Perugia (Italy) June (§)
- (2006) Invited speaker at the Milano (Italy) National Conference on ‘Psychosis and drug addiction’. Talk given: ‘Old and novel drugs of abuse; the role of statutory services in the London area’; Milano (Italy) June (§)
- (2006) Invited speaker at the Catania (Italy) National Psychiatric Conference; talk given: ‘Hypomanic disorders and substance abuse’; Catania (Italy) June (§)
- (2006) Invited speaker at the Verona (Italy) National Conference on Cocaine. Talk given: ‘Fatalities and other key cocaine/crack cocaine indicators for the United Kingdom, 1990-2004’; Verona (Italy) June (§)
- (2006) Invited speaker/trainer at the Verona (Italy) Regional training for professionals; lecture given: ‘Drug and alcohol addiction, and update’. Verona (Italy) May (§)
- (2006) Invited speaker/trainer at the Castelfranco (Italy) National Conference on Pathological Gambling, on ‘Compulsivity and impulse control disorders; neurobiological issues’ Castelfranco (Italy) May (§)

(2006) Invited speaker/trainer at the Roma (Italy) National Conference on Psychiatric Stigma, on 'Dual diagnosis and psychiatric emergencies' Rome (Italy) May (§)

(2006) Invited speaker/trainer at the Roma (Italy) training meeting for psychiatrists, on 'Synthetic drugs' misuse and psychiatric emergencies' Rome (Italy) April (§)

(2006) Invited speaker at the Vicenza (Italy) Conference on 'PK Dick and the hallucinogens' Vicenza (Italy) March (§)

(2005) Invited speaker/trainer at the Bolzano (Italy) training meeting for psychiatrists, on 'Atypical antipsychotics and dual diagnosis' Bolzano (Italy) December (§)

(2005) Invited speaker/trainer at the Rome (Italy) training meeting for psychiatrists, GPs and paediatricians on 'Novel recreational drugs' intake' Rome (Italy) November (§)

(2005) Invited speaker/trainer at the Modena (Italy) scientific meeting on 'Drug addictions issues; historical and genetics' issues' intake' Modena (Italy) November (§)

(2005) Invited speaker/trainer at the Rimini (Italy) scientific meeting on 'Psychosis and recreational drugs' intake' Rimini (Italy) November (§)

(2005) Invited speaker at the Mestre (Venezia; Italy) scientific meeting on 'Personality disorders and dual diagnosis'; Mestre (Venezia; Italy) October (§)

(2005) Invited speaker at the Edinburgh (UK) Royal College of Psychiatrists annual meeting June (§)

(2005) Invited speaker at the Thiene (Vicenza; Italy) scientific meeting on 'Psychiatry and related areas; Drug Addiction'; Thiene (Vicenza; Italy) June (§)

(2005) Invited speaker at the Siracusa (I) scientific meeting on 'Ethos and Pathos'; Siracusa (I), June (§)

(2005) Invited speaker at the Parma (I) scientific meeting on 'Dual diagnosis'; Parma (I), May (§)

(2005) Invited speaker at the Merano (Bolzano, Italy) scientific meeting on 'Drug abuse and related psychopathological issues'; Merano (I), March (§)

(2005) Invited speaker at the bilateral UK/I Meeting on 'Psychiatric emergencies in metropolitan areas; Rome and London', Rome (I), January (§)

(2004) Invited speaker at the 'Drug-Related Deaths Conference', Manchester, November (§)

(2004) Invited speaker at the Scientific meeting on 'Psychobiological issues and behaviour', Cesena (I), November (§)

(2004) Invited speaker at the Scientific meeting on 'Alcohol and substance misuse: symptom or disease?', Modena (I), October (§)

(2004) Invited speaker at the British Association of Psychopharmacology Annual Conference, Harrogate, (UK), July (§)

(2004) Invited speaker at the Scientific meeting on 'Aggression: neurobiological, pharmacological and clinical issues', Udine (I), June (§)

(2004) Invited speaker at the Scientific meeting on 'Dual Diagnosis', Adria, Rovigo (I), June (§)

(2004) Invited speaker at the National Psychiatric Conference, Siracusa (I), June (§)

(2004) Invited speaker at the Scientific meeting on 'Hypomania and substance misuse', Loiano, Bologna (I), June (§)

(2004) Invited speaker at the Research and Development Conference: "Delivering Research for Better Services" London, May (§)

(2004) Invited speaker at the Conference on 'Depression and Personality Disorders', Teolo, Padova (I), May (§)

(2004) Invited speaker at the Royal College of Psychiatrists Faculty of Substance Misuse, Glasgow (UK), May (§)

(2004) Invited speaker at the Symposium on Aggressive Behaviours, Italian Society of Psychopathology National Conference, Rome (I), February (§)

(2003) Invited speaker at the EMCDDA/European Parliament Conference on 'Substance misuse in the youth', Malaga (E), October (§)

(2003): Invited speaker at the National Research Council Conference on 'Atypical antipsychotics', Cagliari (I), June (§)

(2003) Invited speaker at the Psychostimulants Conference, Dundee (Scotland), June (§)

(2003) Invited Chair at the Medical Council on Alcohol Seminar, London, May

(2002) Invited workshop speaker the Royal College of Psychiatry/Society of Substance Abuse Annual Symposium, Leeds, November (§)

(2001) Invited speaker at the meeting for European experts on drug addiction in the EU offices, Bruxelles (B), December (§)

(2001) Invited speaker at the European debate on Drug Prevention Issues, Milan (I), June (§)

- (2001) Invited speaker at the Medical Council on Alcohol Seminar, London, May
- (2001) Invited speaker at the Transdrug European meeting, Helsinki (SF), February (§)
- (2000) Invited speaker at the National Institute of Health meeting on 'Dance Drugs', Rome (I), January (§)
- (1999) Invited speaker at the Symposium: 'Tra rischio e piacere: I giovani e le relazioni pericolose'. Liguria Region (I), February (§)
- (1998) Invited speaker at the Regional meeting: 'Disagio femminile e dipendenza da sostanze psicoattive', Venice (I), March (§)
- (1996) Invited speaker at the National meeting on 'Ecstasy e sostanze psichedeliche', Bologna (I), November (§)
- (1993) Invited speaker at the Seminar on 'Gamma-hydroxybutirate prescription in the treatment of alcohol dependence', Minneapolis Medical School, Minnesota (USA), May (§)
- (1992) Invited speaker at the EU meeting on 'Methadone programmes in the member states', Luxembourg, May (§)

### **13. Previous conferences and seminars attended**

(please note that this list is not exhaustive and is meant to give only an indication of the range of conference attended)

- (1994) 7<sup>th</sup> European College of Neuropsychopharmacology, Jerusalem (Israel), October
- (1994) 10<sup>th</sup> International thematic meeting on 'Risques depressifs et depressions a risques', Paris (F), June
- (1994) International Council on Alcohol and the Addictions, Prague (CZ), July
- (1993) 6<sup>th</sup> European Congress of the European College of Neuropsychopharmacology (ECNP), Budapest (Hungary), October
- (1993) American Society of Addiction Medicine Annual General meeting, Los Angeles (USA), April
- (1992) International Congress on Alcohol and the Addictions, Glasgow (UK), August
- (1991) 5<sup>th</sup> International Congress of the Biological Psychiatry Society, Florence (I), June
- (1990) International Congress of Psychiatric Epidemiology, Montreal (Can), June

(1985) 3<sup>rd</sup> International Congress of Psychiatric Epidemiology, Bruxelles (B), September

#### **14. Major academic visits and collaborations in the UK and abroad**

##### *Academic visits*

King's College, Institute of Psychiatry, Department of Psychopharmacology, University of London, UK (September 1988- March 1989)

Department of Psychiatry, Minneapolis Medical School, Minnesota (USA) (May 1993)

##### *Current collaborations*

##### **UK**

University of Wales Swansea, Medical School  
Institute of Psychiatry, London

##### **Spain**

Institute of Neuropsychiatry and Addictions-Hospital del Mar in Barcelona.  
Hospital Universitari Germans Trias i Pujol, Department of Clinical Pharmacology.

##### **Germany**

LVR-Hospital Essen, Department of Addictive Behaviour and Addiction Medicine,  
Medical Faculty, University of Duisburg-Essen, Essen

##### **Italy**

Department of Neurosciences and Imaging; University of Chieti-Pescara  
University of Cagliari, Department of Pharmacology  
School of Pharmacy, University of Padova

##### **Greece**

Aristotle University of Thessaloniki, Department of Clinical Pharmacology